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 i 
Abstract.  
Oxygen is a requirement for almost all living organisms and adaptations to oxygen 
shortage are essential for surviving periods of oxygen deprivation, known as 
hypoxia. Cells have evolved a range of mechanisms which increase the supply of 
oxygen and facilitate metabolic alterations that enable the cell and the organism to 
maintain functionality under hypoxic conditions. Hypoxia is a hallmark of solid 
tumours and is associated with increased malignancy and mortality in hepatocellular 
carcinoma (HCC). Transarterial chemoembolisation therapy (TACE) using 
doxorubicin is the current standard of care for intermediate HCC, although response 
rates are poor. Drug eluting bead transarterial chemoembolisation (DEB-TACE) 
shows improved response rates over TACE. More recently, rapamycin has come 
under scrutiny as an effective therapy against HCC. Embolisation therapies have 
been shown to induce hypoxia in HCC, leading to the escape of hypoxia-adapted 
cancer cells from therapy. The principal transcription factor which orchestrates 
responses to hypoxia is hypoxia inducible factor 1 (HIF-1). Laboratory and clinical 
evidence support the hypothesis that HIF-1 activity contributes to cancer progression 
and increased mortality. Targeting HIF-1 therefore presents an opportunity for 
improving outcomes of cancer therapy.  
A hypoxic model of HCC was established, and used to characterise the responses of 
the cell line HepG2 to chemotherapeutic agents in both normoxic and hypoxic 
conditions. Firstly, the time and concentration dependent effects of doxorubicin, 
rapamycin and both drugs in combination on the viability of HepG2 cells cultured 
under both normoxic and hypoxic conditions were investigated. SDS-PAGE and 
Western Blotting was then used to evaluate the responses of HIF-1α, NFkB, S6K and 
Akt expression to doxorubicin, rapamycin and both drugs in combination in cells 
cultured under both normoxic and hypoxic conditions. Finally, the anti-tumour 
effects of doxorubicin, rapamycin and both drugs in combination were investigated 
in vivo using an ectopic xenograft murine model of HCC.  
The in vitro evidence presented in this thesis demonstrates that a concentration of 
doxorubicin relevant to clinical concentrations following DEB-TACE effectively 
inhibits the viability of both normoxic and hypoxic liver cancer cells. Also presented 
is in vitro evidence that low dose rapamycin inhibits the viability of both normoxic, 
and to a lesser extent, hypoxic liver cancer cells. The addition of low dose rapamycin 
to doxorubicin was consistently observed to have an additive effect on the inhibition 
of cell viability. Protein analysis demonstrated that low dose rapamycin inhibits the 
hypoxia stimulated accumulation of HIF-1α, as does high dose doxorubicin. 
However, inhibition of HIF-1α was attenuated when the two drugs were used in 
combination. Cytotoxic effects are not, therefore, wholly dependent on inhibition of 
HIF-1α. Inhibition of HIF-1α by each drug alone appears to be due to different 
mechanisms. This study also showed in vivo that combinations of doxorubicin DEB-
TACE with either rapamycin DEB-TACE or oral rapamycin are more effective than 
either treatment alone at reducing tumour burden in a mouse model of HCC. Two 
clinical trials are now underway to investigate the combination of doxorubicin DEB-
TACE and low dose oral rapamycin to treat HCC.  
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Chapter 1  
 
Introduction. 
 
1.1 Liver Cancer. 
1.1.1 Epidemiology, Etiology, Diagnosis and Treatment. 
Hepatocellular carcinoma (HCC), or primary liver cancer, is the sixth most common 
cancer worldwide, and the third most common cause of cancer death. More than half 
a million new cases are diagnosed each year. The prognosis is generally poor, with 
survival rates of between 3 and 5%, and the number of deaths per year is almost 
equal to the number of new cases. The major risk factors for HCC are infection with 
the hepatitis B or hepatitis C virus (HBV, HCV). Indeed, 75% of all cases are a result 
of hepatitis infection. The incidence of HCC is highest in Asian and African 
countries, where chronic HBV infection is the predominant risk factor, and the 
incidence of HCC mirrors the prevalence of HBV infection (Parkin et al., 2005, Zhu 
et al., 2011). In Europe, North America and Japan chronic HCV infection and 
alcoholic cirrhosis are the predominant risk factors, and HCC is the leading cause of 
death for cirrhotic patients (Parkin et al., 2005, Bruix et al., 2006, Di Bisceglie, 
1995). 
Exposure to the aflatoxin is a risk factor in sub-Saharan Africa, Southeast Asia, and 
China (Liu and Wu, 2010). Aflatoxin is a deoxyribonucleic acid (DNA) damaging 
agent produced by the fungus Aspergillus, which grows on food stored in warm and 
damp conditions (Sanyal et al., 2010). 
The diverse etiologies of HCC mean that determining the prognosis and treatment 
plan for patients is not straightforward. The extent of underlying liver disease, as 
well as the tumour stage, needs to be taken into account when deciding on treatment 
modalities, and clinical staging systems are used for patient assessment. The staging 
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systems most commonly used for HCC are the Okuda, the tumour node metastasis 
(TNM), the Cancer of the Liver Italian Program (CLIP) score and the Barcelona 
Clinic Liver Cancer staging systems (BCLC). The Child-Pugh score, as summarised 
in Table 1.1, is used to measure liver function. 
Score 1 2 3 
Ascites Absent Slight Moderate 
Hepatic encephalopathy Absent Mild/transient Hepatic coma 
Bilirubin (µM/L) < 34 34 - 51 >51 
Albumin (g/L) >35 35 - 28 < 28 
Prothrombin (sec)* < 4 4 – 6 >6 
Child A: score 5-6 (well compensated). 1 yr survival = 100%, 2 yr survival = 85%. 
Child B: score 7-9 (functional compromise). 1 yr survival = 81%, 2 yr survival = 57%. 
Child C: score 10-15 (decompensated). 1 yr survival = 45%, 2 yr survival = 35%. 
*Difference between patient and control. 
 
Table 1.1 Child Pugh Classification of Liver Function.  
The Child Pugh classification assesses five clinical measures of liver disease. Each 
measure is scored from 1 to 3, with 3 indicating the most pathological. Liver disease 
is then classified into Child-Pugh class A to C, according to the added score from the 
assessment of liver damage. 
The BCLC links the patient’s general state of health, Child Pugh classification, and 
extent of tumour spread with a treatment algorithm, and this staging system has now 
become the international standard (Bruix et al., 2006, Pons et al., 2005). Figure 1.1 
illustrates the staging system algorithm. Surveillance of patients with cirrhosis or 
hepatitis is crucial if patients are to be diagnosed early enough for curative treatments 
(Wong et al., 2008, Wong et al., 2000, Mok et al., 2005). The European Association 
for the Study of the Liver (EASL) recommends surveillance using ultrasound and 
serum alpha-fetoprotein (AFP) every 6 months. 
If HCC is detected early enough, the treatment options are surgical resection, liver 
transplantation, and percutaneous ablation. Percutaneous ablation is the destruction 
of neoplastic cells by ethanol or acetic acid or by temperature (radiofrequency, laser, 
 3 
microwave, and cryoablation). The 5-year survival rates for early stage treatments 
are 70 - 90% (Rampone et al., 2009, Granito and Bolondi, 2009).  
 
 
Figure 1.1 The Barcelona Clinic Liver Cancer (BCLC) Staging Classification 
and Treatment Schedule.  
The BCLC links the stage of the disease to a specific treatment strategy.PS, 
performance status; OLT, orthotopic liver transplantation; PEI, perctaneous ethanol 
injection; PVI, portal vein invasion; PVT, portal vein thrombosis; RFA, 
radiofrequency ablation. 
The treatment option that has shown best patient outcome and survival benefit for 
intermediate stage HCC is transarterial chemoembolisation (TACE) (Biselli et al., 
2005, Takayasu et al., 2006, Lee et al., 2006, Kaibori et al., 2006, Molinari et al., 
2006, Bruix et al., 2006, Llovet and Bruix, 2003). TACE is the current standard-of-
care for intermediate stage HCC, and shows 1, 2 and 3 year survival rates of 80%, 
65% and 50% respectively (Bruix et al., 2006, Bruix et al., 2004, Raoul et al., 2011). 
For advanced stage patients, sorafenib is the new standard of care (Keating and 
Santoro, 2009). Sorafenib is a small molecule multi-kinase inhibitor and has been 
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shown to improve survival times, but by months rather than years. Survival rates at 
one, two and three years are 29%, 16% and 8% respectively (Llovet et al., 2008, 
Cheng et al., 2009). End stage patients are treated symptomatically and have a life 
expectancy of less than 6 months (Granito and Bolondi, 2009). 
The introduction of screening programmes for those at risk of developing HCC has 
resulted in more cases being diagnosed at an early stage, when curative treatments 
are possible (Sangiovanni et al., 2004). However, the majority of cases are not 
diagnosed until intermediate or advanced stage, by which time the treatment options 
are limited and the prognosis is poor (Colombo and Sangiovanni, 2003). 
1.1.2 Transarterial Chemoembolisation (TACE). 
Transarterial embolisation (TAE) is a technique used to treat HCC, and exploits both 
the fact that the liver tumour is fed by the hepatic artery whilst the normal liver tissue 
is fed by the portal vein (Breedis and Young, 1954), and that HCCs are typically 
highly vascularised (Ackerman, 1972).  
TACE was first pioneered by Yamada in the 1980s (Yamada et al., 1980, Yamada et 
al., 1983) in an attempt to improve the dismal treatment outcomes associated with 
systemic chemotherapies. TACE combines tumour embolisation with delivery of 
chemotherapeutic agent(s) directly to the blood vessels feeding the tumour, thus 
increasing the intratumoural concentration and of the drug(s) whilst decreasing 
systemic concentration (Biolato et al., 2010). The embolic blocks the flow of blood 
to the tumour, starving tumour cells of oxygen and nutrients. There is minimal 
damage to paranchymal liver tissue since this tissue receives 75% of its blood supply 
via the portal vein, whereas the tumour derives 95% of its blood supply from the 
hepatic artery (Bruix et al., 2004). Typically, the protocol for conventional TACE 
(cTACE) consists of the catheter-based intra-arterial injection of a chemotherapeutic 
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iodised oil emulsion followed by injection of an embolic material (Liapi and 
Geschwind, 2010). TACE therapy allows a complete local tumour control of 25-35% 
and improved survival in patients with intermediate HCC, according to BCLC 
classification, when compared to systemic therapies. As an adjunctive therapy prior 
to liver resection TACE allows 70% tumour control (Vogl et al., 2009). TACE using 
the anthracycline antibiotic doxorubicin is the standard of care for the treatment of 
unresectable HCC (Biolato et al., 2010; Bruix et al., 2004).  
1.1.3 Drug-eluting Bead Chemoembolisation (DEB-TACE). 
Drug-eluting bead transarterial chemoembolisation (DEB-TACE) is a refinement of 
TACE, and provides a one-step procedure for both embolisation and drug delivery. 
The most successful embolic microsphere developed to date in terms of doxorubicin 
loading and release is the DC Bead (Biocompatibles UK). For HCC, the bead is 
available pre-loaded with doxorubicin (DEBDOX™). DEB-TACE allows a 
controlled, localised and sustained release of the drug to the tumour bed, with 
reduced systemic doxorubicin and an improved safety profile compared to cTACE 
(Varela et al., 2007, Lewis and Holden, 2011, Lewis et al., 2007). DEB-TACE also 
addresses some of the issues with regard to a lack of standardisation in the treatment 
of intermediate stage HCC. The only other commercially available DEB is the 
HepaSphere™, from Merit Medical Systems Inc.  
The DC Bead actively sequesters doxorubicin from a non-ionic solution, due to an 
active ion-exchange process between the negatively charged sulfonate moieties on 
the microspheres with the positively charged amine region of the doxorubicin 
molecule. Drug elution is dependent on ion exchange with blood plasma ions after 
delivery of the microspheres (Lewis and Holden, 2011). 
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Figure 1.2 Schematic Outlining the Procedure for DEB-TACE. 
A catheter is inserted into the femoral artery and directed to the liver using contrast 
media and X- ray equipment.  Drug eluting beads are then injected into the 
capillaries feeding the tumour via the catheter. The procedure is normally carried out 
under local anaesthetic. Image adapted with permission from Biocompatibles UK 
Ltd. 
 
 
 
 
Figure 1.3 In Vivo Images of DEB-TACE. 
A) An X-ray image of a chemoembolisation procedure. B) and C) histological 
analysis of DC Beads 14 days after DEB-TACE, in a rabbit Vx-2 model of hepatic 
arterial embolisation (Hong et al., 2006). 
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To deliver the beads to the tumour bed, a catheter is inserted into the femoral artery 
and directed to the liver. The beads are then injected via the catheter into the 
capillaries feeding the tumour. The procedure, outlined in Figures 1.2 and 1.3(A), is  
normally carried out under local anaesthetic, without the need for overnight 
hospitalisation. Figure 1.3 (B) and (C) show in vivo imaging of beads after DEB-
TACE in a rabbit model. 
Results so far from clinical trials, including the results of a randomised phase II trial 
(PRECISION V), show that DEB-TACE using DEBDOX shows a significant 
survival advantage, higher rates of complete response, and significant differences in 
objective response and disease control in patients with advanced HCC when 
compared with cTACE (Dhanasekaran et al., 2010, Liapi and Geschwind, 2011, 
Lammer et al., 2010, Reyes et al., 2009). The incidence of doxorubicin-related 
adverse events was significantly lower with DEBDOX compared to cTACE 
(Lammer et al., 2010). TACE using DEBDOX also demonstrated improved local 
response, fewer recurrences, and a longer time to progression when compared with 
bland embolisation using unloaded DC Beads (Malagari et al., 2010). DEB-TACE is 
a minimally invasive treatment that is becoming more widely used as a treatment for 
unresectable HCC, as an adjunctive therapy prior to resection and as a bridge therapy 
to maintain patients on transplant waiting lists (Carter and Martin Ii, 2009, Liapi and 
Geschwind, 2011, Lewis and Holden, 2011). The results of ongoing clinical trials 
will, in the future, contribute to the optimisation of treatment strategies. 
1.2 Cellular Oxygen Supply and Hypoxia. 
 
Adequate supplies of oxygen are essential for the normal functioning of all 
multicellular organisms/metazoan species. The principle energy source for the 
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majority of cellular processes is adenosine triphosphate (ATP). Oxidative 
phosphorylation is the process by which cells generate ATP from the catabolism of 
glucose and fatty acids, and the oxygen molecule is the metabolic substrate for this 
cellular respiration, acting as the terminal electron acceptor. 
Low cellular oxygen concentrations, known as hypoxia, can compromise cell 
function and lead to cell death and tissue damage. However, oxygen molecules are 
potentially toxic, since they can cause oxidative damage to macromolecules within 
the cell. The control of oxygen homeostasis is thus essential for maintaining cellular 
and therefore whole organism viability. 
The physiological oxygen tension within healthy human tissue varies according to 
the organ, but generally lies within the range 20 – 120 mmHg (Vaupel et al., 1989). 
Cells in different tissues experience different oxygen tensions, and cells within one 
tissue experience a range of oxygen tensions, depending on both distance from the 
nearest blood supply - the diffusion distance of oxygen through tissue is estimated to 
be around 150 µm (Coleman et al., 2002) - and the oxygenation status of that blood 
supply. For instance, the pressure of O2  of the blood supply to the liver ranges from 
95–105 mmHg in the hepatic artery, 50-65 mmHg in the portal vein, 35-45 mmHg in 
the sinusoids and 30– 40 mmHg in the central vein (Lee et al., 2007). The different 
oxygen tensions that each cell experiences in a healthy liver are all perceived as 
normal – indeed, the oxygen gradient along the sinusoid is the regulatory factor 
which creates the zonation of metabolic functioning within the sinusoid (Vollmar and 
Menger, 2009). Sensitive and adaptive mechanisms for sensing intracellular oxygen 
concentrations and responding to change are vital in order to maintain oxygen 
homeostasis. Adaptations to fluctuating oxygen levels need to be flexible and 
capable of responding to subtle changes. 
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Hypoxia occurs when oxygen tensions are ≤ 7 mmHg, usually as a result of 
decreased partial pressure of oxygen in the blood (hypoxeamia) or a decrease in the 
oxygen carrying capacity of the blood (anaemia) (Vaupel and Harrison, 2004). 
Molecular responses to hypoxia result in the increased expression of genes involved 
in adaptations to hypoxia, and the promotion of a range of physiological responses 
and adaptations that allow cells to survive in a hypoxic environment. These target 
genes play critical roles in angiogenesis, metabolism, cell proliferation and cell 
survival. The master regulator of adaptations to hypoxia is the transcription factor 
hypoxia-inducible factor (HIF) (Wang and Semenza, 1993). 
1.2.1 Hypoxia-inducible Factor 1 (HIF-1). 
HIF-1 was first identified by Gregg Semenza in 1992 whilst he was studying 
erythropoietin gene expression (Semenza and Wang, 1992). HIF is a highly 
conserved DNA binding protein (Iyer et al., 1998) that activates the expression of 
genes containing a hypoxia response element (HRE) (Wang and Semenza, 1993). 
HIF is a heterodimer comprising of two sub-units, α and β. Both sub-units belong to 
the Per-Arnt-Sim (PAS) family of helix-loop-helix (HLH) proteins (Wang and 
Semenza, 1995). HIF activity is regulated by the abundance of the HIF-α sub-unit. 
To date, three HIF-α isoforms have been described, with HIF-1α being the best 
characterised. In this study, we have concerned ourselves with the activity of HIF-1α. 
HIF-1α is constitutively expressed, but under normoxic conditions is subject to 
oxygen-dependent hydroxylation and ubiquitination that determines proteasomal 
degradation (Huang et al., 1998). Under hypoxic conditions the HIF-1α sub-unit 
stabilises, accumulates within the cell and translocates to the nucleus. Here it 
heterodimerises with HIF-1β, recruits the co-activators p300/cAMP binding protein 
(CBP) and becomes transcriptionally active (Wang and Semenza, 1993). This 
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response is rapid and its intensity correlates to the severity of hypoxia (Jiang et al., 
1996). HIF-1β (also known as aryl hydrocarbon receptor nuclear translocator ARNT) 
is also constitutively expressed, and its stability is independent of oxygen tension. 
HIF-1β is involved in a wider range of cellular processes than HIF-1α via interaction 
with other proteins (Maxwell et al., 2001, Semenza et al., 1997, Swanson et al., 
1995). 
In addition to mediating cellular responses to oxygen shortage, there is increasing 
evidence that HIF-1 may be involved in preventing premature cell senescence, and in 
innate host defence mechanisms (Welford et al., 2006, Zarember and Malech, 2005, 
Lukashev et al., 2006). HIF-1 also plays an essential role in embryonic development 
(Huang et al., 2010). 
1.2.2 HIF-α Isoforms. 
In mammals, three isoforms of HIF-α have been identified – HIF-1α, HIF-2α (also 
known as Endothelial PAS domain
 
protein or EPAS) and HIF-3α (also known as 
inhibitory Per Arnt Sim or IPAS). These are encoded by the genes HIF1A, EPAS1, 
HIF3A respectively. The HIF-1α, HIF-2α isoforms are structurally similar in their 
DNA binding and dimerisation domains, and regulation of gene expression by HIF-
2α is similar to that of HIF-1α (Wiesener et al., 1998, O'Rourke et al., 1999). They 
differ in their transactivation domains, implying that they may have unique target 
genes (Heidbreder et al., 2003, Wiesener et al., 2003, Tian et al., 1997). HIF-3α 
lacks the transactivation domain found in factors containing either the 1α or 2α 
subunits and appears to inhibit transcriptional activation induced by hypoxia (Hirota 
and Semenza, 2006). HIF-1α is ubiquitously expressed, whereas expression of HIF-
2α is cell specific (Loboda et al., 2010). In this study we have focussed on the 
abundance of HIF-1α in response to hypoxia. 
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1.2.3 The Structure of HIF-1α. 
HIF-1α and HIF-1β belong to the Per Arnt Sim (PAS) sub-family of the HLH family 
of transcription factors. Both contain basic HLH motifs and a PAS domain, which 
are involved in DNA binding and dimerisation. The α sub-unit contains an oxygen 
degradation domain (ODD) and two transactivation domains – the N-terminal 
transactivation domain (NAD) and the C-terminal transactivation domain (CAD) 
(Figure 1.4) (Wang and Semenza, 1995, Chapman-Smith et al., 2004). 
 
 
 
Figure 1.4 Schematic Showing Simplified Structure of HIF-1α and 
Hydroxylation Sites.  
bHLH, basic helix-loop helix domain; CAD, C-terminal transactivation domain; 
NAD, N-terminal transactivation domain; ODD, oxygen degradation domain; PAS, 
Per Arnt Sim domain. Pro402, Pro 564 are the prolyl hydroxylation sites. Asn803 is 
the asparaginyl hydroxylation site. 
1.2.4 Prolyl Hydroxylation Promotes the Degradation of HIF-1α. 
In normoxic conditions HIF-1α is identified for ubiquitination and degradation via 
enzymatic hydroxylation of proline residues. The region of HIF-1α in which this 
takes place is known as the ODD. The ODD extends from amino acids 401 – 603 and 
contains proline residues at positions 402 and 564 (Bruick and McKnight, 2001, 
Huang et al., 1998) (Figure 1.5). Three HIF prolyl-hydroxylases (PHDs) have been 
identified (Jaakkola et al., 2001, Ivan et al., 2001). The hydroxylation promotes 
interaction with the von Hippel-Lindau (VHL) ubiquitylation complex (Ivan et al., 
2001). The pVHL binds to the ODD and HIF-1α is ubiquinated by the VCB E3 
ubiquitin-ligase complex. This labels the protein complex for proteasomal 
bHLH PAS CADNAD
Asn803Pro402 Pro564
ODD
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degradation (Masson et al., 2001, Kamura et al., 2000, Iwai et al., 1999). Either or 
both of the residues can be hydroxylated, but hydroxylation of both residues is 
required for efficient degradation (Masson et al., 2001). The hydroxylation reaction 
requires oxygen, 2-oxogluterate and Fe (II). In hypoxic conditions (oxygen 
concentration < 6%), prolyl hydroxylation decreases and HIF-1α stabilises and 
accumulates (Ivan et al., 2001, Maxwell et al., 1999). 
 
 
 
Figure 1.5 Schematic Outlining the Regulation of HIF-1α in Hypoxia.  
Under normoxic conditions PHDs 1-3 and FIH hydroxylate HIF-1α on proline and 
asparagine residues respectively. The hydroxylation of the proline residue promotes 
interaction with the VHL/E3 ubiquitin ligase complex and consequent proteosomal 
degradation. Hydroxylation of the asparagine residue prevents recruitment of 
p300/CBP. Under hypoxic conditions the enzymes are inactive, and the α sub-unit 
stabilises and dimerises with the β sub-unit. p300/CBP is recruited and HIF-1 binds 
to HREs in the promoter region of target genes. 
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1.2.5 Asparagine Hydroxylation Inhibits Transcriptional Activation of HIF-1. 
The C-terminus of HIF-1α contains a CAD and an NAD. The CAD contains a 
conserved asparagine residue at position 803 (Kaelin and Ratcliffe, 2008) (Figure 
1.5). This is the region where recruitment of the transcriptional co-activator 
p300/CBP takes place, facilitating the binding of HIF-1 to the HRE in the promoter 
of hypoxia-response genes. In normoxic conditions factor-inhibiting HIF-1α (FIH-1) 
catalyses the hydroxylation of the asparagine (Asp) residue (McNeill et al., 2002, 
Lando et al., 2002). This hydroxylation prevents the recruitment of the co-activator 
and inhibits C-TAD activation (Mahon et al., 2001).  The reaction requires 2-OG and 
Fe (II) (Lando et al., 2002), so that in hypoxia the hydroxylation does not occur and 
the CAD is activated. FIH-1 is abundant and ubiquitous in all cell types (Stolze et al., 
2004). 
1.2.6 HIF Prolyl-hydroxylases (PHDs). 
 
The PHDs are highly conserved iron and 2-oxoglutarate dependant dioxygenases. 
Three PHD enzymes have been identified – PHD1, PHD2 and PHD3 (Jaakkola et al., 
2001, Ivan et al., 2001). They have similar sequence and structure, with a catalytic 
core that brings the binding sites for Fe (II) and 2-OG together. PHD1 and PHD2 
both have a C-terminal catalytic domain and an N terminal extension. PHD2 has a 
zinc finger in the N terminal. PHD3 lacks the N terminal extension (Choi et al., 
2005). All three PHDs can hydroxylate Pro564, but only PHD1 and PHD2 
hydroxylate Pro402 (Epstein et al., 2001). Several facts suggest that PHD2 is the 
most important of the three isoforms. Firstly, the activity of each PHD is dependent 
on its concentration within the cell, and PHD2 is the most abundant form. Secondly, 
PHD2 is ubiquitously expressed, whereas PHD1 and PHD3 are more tissue specific. 
For instance, PHD1 is highly expressed in the testes and PHD3 is highly expressed in 
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the heart (Lieb et al., 2002). Suppression of PHD2 using small interfering ribonucleic 
acid (siRNA) increases levels of HIF-1α in normoxic cells (Berra et al., 2003). 
Thirdly, PHD2 knockout mice are embryonically lethal, whilst PHD1 and PHD3 
knockout mice are viable (Takeda et al., 2006). Finally, PHD2 seems to regulate 
HIF-1α more than HIF-2α, and PHD3 seems to regulate HIF-2α more than HIF-1α 
(Aprelikova et al., 2004). Since HIF-1α is ubiquitous and HIF-2α is tissue-specific, 
we can conclude that PHD2 has broader activity. 
There are a number of negative feedback mechanisms regulating PHD activity. 
Hypoxia induces the expression of PHD2 and PHD3 in a HIF-1 dependant manner 
(Berra et al., 2003), perhaps to cap the levels of stabilised HIF-1 within the cell, or to 
protect against damage caused by reoxygenation (D'Angelo et al., 2003). Hypoxic 
preconditioning is known to protect cells against reoxygenation damage (D'Angelo et 
al., 2003). On the other hand, PHDs are degraded by Sian 1 and 2, and this 
degradation is enhanced by hypoxia because transcription of Sian 1 and 2 is 
increased in hypoxia in a HIF-1 independent manner (Nakayama and Ronai, 2004). 
1.2.7 HIF-1 Activates the Transcription of Hypoxia Response Genes. 
HIF-1 binds to hypoxia-responsive elements containing the recognition sequence 5’–
RCGTC – 3’ on target genes (Semenza et al., 1991, Semenza et al., 1994), initiating 
or upregulating (and in some cases downregulating) their expression (Semenza et al., 
1997, Greijer et al., 2005). The target genes are physiologically relevant to 
overcoming hypoxia, operate at systemic, local and intracellular levels and include 
genes whose products are involved in cell proliferation, cell survival, cell motility, 
cell adhesion, apoptosis, angiogenesis, erythropoeisis, potential of hydrogen (pH) 
regulation and glucose metabolism (Greijer et al., 2005, Hirota and Semenza, 2006). 
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Microarray analyses have shown that there are hundreds of genes that respond to 
hypoxia, more than 50% of which are HIF-1 dependant (Elvidge et al., 2006). 
1.3 Hypoxia and Cancer. 
 
Tumour hypoxia is a positive factor for the growth of solid tumours, and is 
associated with malignant progression and a poor prognosis (Semenza, 2007a, Bos et 
al., 2003). Cells undergoing hypoxia escape necrosis and undergo a range of 
phenotypic adaptations. These adaptations not only allow the cells to survive the 
hypoxic environment, but may also increase the potential malignancy of the residual 
tumour cells. Intratumoural hypoxia and the hypoxic phenotype are implicated in 
drug resistance and tumour progression, and chemoresistance to doxorubicin can be 
attributed in part to the upregulation of hypoxia response genes (Semenza, 2007a, 
Semenza, 2000b, Vaupel and Harrison, 2004, Tomida and Tsuruo, 1999). Increased 
understanding of the pathophysiological responses to hypoxia will contribute to 
improved treatment regimes and treatment outcomes. 
1.3.1 Hypoxia and Adaptations to Hypoxia in Solid Tumours. 
When a solid tumour grows to 1 – 2 mm in diameter, the core becomes hypoxic, 
HIF-1 is activated and neo-vascularisation occurs. This tumour-driven angiogenesis 
is a requirement for continued cell proliferation and tumour growth (Kerbel, 2000). 
However, the vascularisation is poor, comprising of leaky and malformed blood 
vessels which are unable to supply the rapidly proliferating tumour mass with 
sufficient oxygen and nutrients. Whilst the central core of a tumour becomes anoxic 
and consequently necrotic, micro-regions of hypoxia persist within the tumour and 
HIF-1 continues to stabilise. The activity of HIF-1 increases as the oxygen 
concentration decreases. Hypoxia-inducible genes controlling cell proliferation and 
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survival, cell metabolism, cell invasiveness, metastatic potential and angiogenesis are 
all activated. Consequently, hypoxic tumours may have a more malignant phenotype 
(Harris, 2002). The metabolic alterations to cancer cells in hypoxia result in an 
increasingly acidic extracellular milieu (Vaupel et al., 1989). The relationship 
between oxygen pressure and local pH is represented in Figure 1.6. 
 
 
Figure 1.6 Graph showing intratumoural oxygen concentration and pH in 
relation to the nearest tumour blood vessel.  
Oxygen concentration decreases and acidity increases as distance from the nearest 
blood vessel increases. Adapted from Vaupel (Vaupel et al., 1989). 
Hypoxia is associated with resistance to both chemotherapies and radiotherapy, and 
hypoxia is positively correlated with a poor prognosis in many cancers (Hockel and 
Vaupel, 2001, Lee et al., 2006). HIF-1α knock-out studies have demonstrated that 
HIF-1 is a positive factor in tumour growth and proliferation (Zhang et al 2004; 
Helton et al 2005; Dang et al 2006; Li et al 2006; Luo et al 2006). HIF-1α 
overexpression is associated with angiogenesis, metastases, resistance to radio- and 
chemotherapies, malignant progression and a poor prognosis (Hockel and Vaupel, 
2001, Semenza, 2000b).  
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Intrinsic and acquired drug resistance present major challenges for the treatment of 
cancers. Both tumour microenvironment and the cellular phenotype contribute to 
chemoresistance. HIF-1α expression is upregulated in many cancer cell lines even 
under normoxic conditions, either as a result of clonal selection, gain-of-function 
mutations, loss-of-function tumour suppressors or the influence of growth factors and 
cytokines and hypoxia and HIF-1α have been shown to contribute to 
chemoresistance in a range of cancers and cancer cell lines (Sullivan et al., 2008, 
Unruh et al., 2003, Rohwer et al., 2010, Daskalow et al., 2010, Jung et al., 2010, 
Nardinocchi et al., 2009a). 
1.3.2 Hypoxia as a Consequence of Embolisation Therapy. 
A negative, but inevitable, consequence of embolisation therapy is the creation of 
hypoxic regions within the tumour. Tumour hypoxia is associated with tumour 
growth, malignant progression, and resistance to therapies, and the escape of tumour 
cells from TACE therapy can potentially increase the aggressiveness of the tumour 
(Guo et al., 2004, Guo et al., 2002, Gupta et al., 2006, Kim et al., 2001, Liao et al., 
2003, Liao et al., 2004, Shao et al., 2002). Both animal and human studies have 
reported increased HIF-1α levels in plasma and in liver tumour tissue samples post-
TACE, and this increase is thought to be a result of hypoxia induced by the 
procedure (Liang et al., 2009, Liang et al., 2010b, Virmani et al., 2008, Rhee et al., 
2007). Anti-sense HIF-1α has been shown to increase chemosensitivity and reduce 
hypoxia-stimulated cell migration (Song et al., 2006, Sun et al., 2009). 
One of the effectors of HIF-1 is the endothelial cell mitogen vascular endothelial 
growth factor (VEGF) (Semenza et al., 2006). VEGF initiates a sequence of 
molecular events resulting in angiogenesis, which is a requirement for tumour 
growth. Increased proliferation of vascular endothelial cells post-TACE has been 
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reported (Kim et al., 2001), and increased VEGF has been reported within liver 
tumours and in plasma samples post-TACE (Li et al., 2003, Li et al., 2004, Wang et 
al., 2008a, Liang et al., 2010b, Liang et al., 2010a). High plasma VEGF levels post-
TACE are associated with the development of metastases (Xiong et al., 2004), a poor 
treatment response and shorter survival times (Sergio et al., 2008, Poon et al., 2004, 
Shim et al., 2008). 
In short, hypoxia is a major cause of tumour resistance to chemotherapy and is a 
positive factor for tumour progression. There is a growing body of evidence to 
support the hypothesis that embolisation therapies cause hypoxia and the activation 
of HIF-1; and that inhibition of HIF-1 and/or its effectors may improve treatment 
outcome. There is, therefore, a need to develop therapies which address both 
normoxic and hypoxic regions within a tumour. Targeting hypoxic tumour cells is a 
logical next step to improving treatment outcome. 
1.4 Doxorubicin. 
 
Doxorubicin is an anthracycline antibiotic that is widely used as a chemotherapeutic 
agent for the treatment of a range of cancers, including breast cancer, soft tissue 
sarcomas, childhood solid tumours and lymphomas. TACE using doxorubicin is the 
standard of care for HCC. The use of doxorubicin-eluting embolic beads is a new 
development of the TACE procedure (Lewis and Holden, 2011). 
Anthracyclines are antibiotics derived from the bacterial species Streptomyces and 
are highly toxic to mammalian cells, displaying both anti-proliferative and cytotoxic 
effects. Doxorubicin (also known as Adriamycin™) is a metabolite of a mutated 
strain of the wild-type bacterium S. peucetius.  During the 1950’s S. peucetius was 
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cultured from a soil sample taken from the grounds of a 13
th
 century castle in Italy 
(Figure 1.7). The bacterium produces a red pigmented antibiotic, daunorubicin,  
 
 
 
 
Figure 1.7 Castel del Monte, Puglia, Italy. 
The bacterium Streptomyces  peucetius was cultured from a soil sample taken from 
the grounds of Castel del Monte in the 1950s. Stock photograph from TPGIMAGES. 
which was found to have strong antitumoural activity in mice. By 1967, the 
cardiotoxic effects of daunomycin had been recognised (Tan et al., 1967). Mutating  
the bacterial species to S. peucetius var. caesius resulted in the accumulation of a 
slightly different antibiotic which proved to have a higher therapeutic index than 
daunorubicin (Bonadonna et al., 1969), although the cardiotoxic effects were still 
apparent. This toxicity limits both the single and cumulative doses of the drug 
(Young et al., 1981). 
The chemical structure of doxorubicin comprises a four ring aglycone region linked 
to an amino sugar daunosamine by a glycosidic bridge (Figure 1.8). 
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Figure 1.8 The Chemical Structure of Doxorubicin. 
The chemical formula for doxorubicin is C27H29NO11HCl, and the molecular weight 
is 579.98. Doxorubicin consists of a water insoluble tetracycline aglycone and a 
water soluble daunosamine sugar. Ring C is a quinone group, which activates to a 
semiquinone radical after reduction. Ring B is a hydroquinone and can be activated 
to a semiquinone radical after oxidation. During anaerobic reduction, the sugar group 
is split off and C7-deoxyaglycone is formed. 
1.4.1 Mode of Action of Doxorubicin. 
There are a number of different mechanisms by which doxorubicin is cytotoxic to 
eukaryotic cells. Different mechanisms of action are apparently activated at different 
drug concentrations, and the presence or absence of oxygen may also influence the 
mechanisms and degree of cytotoxicity. The interaction of doxorubicin with cells is 
complex, and is outlined below. 
1.4.1.1 Doxorubicin Intercalation with Deoxyribonucleic Acid. 
 
DNA contains the genetic information for the development and functioning of, with 
the exception of viruses, all living organisms. The genetic information in DNA is 
stored as a code made up of four chemical bases: the purines adenine (A) and 
guanine (G), and the pyrimidines cytosine (C) and thymine (T). The DNA bases pair 
up with each other, A with T and C with G, to form units called base pairs. Each base 
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is also attached to a 5 carbon sugar. The sugars are linked by phosphate groups that 
form a phosphodiester bond between carbons 3 and 5 of adjacent sugars. Together, a 
base, sugar, and phosphate are called a nucleotide. The sugar and phosphate residues 
form the backbone of a DNA strand. DNA strands exist in a double helix formation, 
with two anti parallel DNA strands being stabilised by hydrogen bonding between 
the complimentary base pairs.  
Doxorubicin complexes with double stranded DNA by intercalation (Pigram et al., 
1972). Rings B and C of the doxorubicin core (Figure 1.8) intercalate between G-C 
and C-G DNA base pairs, causing the base pairs above and below the drug molecule 
to buckle. Doxorubicin is stabilised within the DNA by the interactions between the 
electron-deficient quinone rings and the electron-rich purine-pyrimidine bases 
(Quigley et al., 1980, Patel et al., 1981). The daunosamine sugar and the carbonyl 
side chain linked to Ring D remain in the minor groove. The positively charged 
daunosamine interacts with the phosphate backbone of the DNA and Ring A 
protrudes into the major groove of the double helix. This distorts the tertiary 
structure of the DNA helix (Cullinane and Phillips, 1990). Intercalation inhibits the 
action of DNA and RNA polymerases and nucleotide replication, and protein 
synthesis and cell proliferation are inhibited (Neidle, 1979). The inhibition of RNA 
synthesis is a potential mechanism of anthracycline toxicity to non-dividing cells. It 
has been well established that doxorubicin inhibits DNA and RNA synthesis in cells, 
although the extent of the effects are cell specific (Gewirtz, 1999). Whether or not 
this inhibition translates to a cytotoxic or cytostatic outcome is less straightforward. 
1.4.1.2 Doxorubicin Cross-linking of DNA. 
 
Doxorubicin forms covalent adducts with cellular DNA, and this has been reported at 
drug concentrations of 50 µM (Sinha and Chignell, 1979). DNA cross-linking can 
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occur as a consequence of adduct formation, and this inhibits DNA replication. The 
ability of doxorubicin to form adducts with DNA correlates strongly to its 
cytotoxicity in certain cell lines, and fewer cross-links are found in drug-resistant 
cells compared to drug sensitive cells even when the intracellular drug concentrations 
are the same (Swift et al., 2006). 
1.4.1.3 Doxorubicin is a Topoisomerase II Poison. 
 
The primary mechanism for the cytotoxicity of doxorubicin at clinical concentrations 
is likely to be due to interference with the ubiquitous enzyme topoisomerase II 
(TOP2). This enzyme belongs to the topoisomerase family of enzymes, which are 
required for DNA replication, DNA transcription and chromosome segregation and 
therefore essential for cell survival (Wang, 2002, Nitiss, 2009). 
1.4.1.3.1 The Role of Topoisomerase II in the Cell. 
In order to be packaged into cells, DNA has to be supercoiled. DNA molecules are 
negatively supercoiled, since complimentary strands of negatively coiled DNA are 
more easily separated than those of positively coiled DNA (Boles et al., 1990). 
During replication, as the replication fork moves along the DNA, positive 
supercoiling of the DNA occurs ahead of the replication machinery. Similar 
problems arise during transcription, when RNA polymerases move along the 
separated DNA strand. The accumulation of positive supercoils makes strand 
separation more difficult and interferes with the processes of replication and 
translation (Wang, 2002). 
Topoisomerases are responsible for maintaining the correct topological arrangement 
of DNA molecules, and regulate positive and negative supercoiling as well as 
knotting and tangling of DNA. Topoisomerase I (TOP1) enzymes generate a 
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transient break in one strand of a DNA duplex, and then either pass the other strand 
through the break (a single stranded passage reaction), or rotate it around the break, 
thus relieving twists in duplex DNA (McClendon and Osheroff, 2007). TOP2 
enzymes generate a break in both strands of the DNA duplex, and then pass another 
intact DNA duplex through the gap. This is known as a double stranded passage 
reaction (Berger and Wang, 1996). TOP2 enzymes relieve over- or under-winding of 
the DNA helix ahead of or behind the replication fork, and resolve tangles and knots 
(known as catananes) between DNA duplex molecules (Osheroff, 1989, Osheroff et 
al., 1991). 
1.4.1.3.2 The Catalytic Cycle of Topoisomerase II. 
TOP2 enzymes are homodimeric, and an active tyrosyl residue in each subunit 
cleaves the phosphate backbone of opposite DNA strands of a DNA molecule, 
leaving a 4-base 5’ overhang on each strand. TOP2 forms a covalent bond between 
the tyrosyl residue and the newly cut 5’ end of the DNA phosphodiester backbone 
(Sander and Hsieh, 1983). This cleaved DNA is known as the G (gate) segment. The 
energy of the phosphate bond is retained within the phosphotyrosine bond, and is 
available for religation (Nitiss, 2009). TOP2 binds ATP and undergoes a 
conformational change such that the intact DNA helix, known as the T (transporter) 
segment, is passed through the cleaved DNA helix. ATP hydrolysis enables the 
release of the nucleic acids, and the cut ends religate (Lindsley and Wang, 1993, 
Lindsley and Wang, 1991). 
1.4.1.3.3 Doxorubicin Interaction with Topoisomerase II. 
TOP2 mediated strand breaks are transient intermediates in the catalytic cycle, and 
low levels are well tolerated. Doxorubicin is a TOP2 poison – that is, it increases the 
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concentration of TOP2 cleavage complexes within the cell to levels that are toxic. 
Intercalating TOP2 poisons have a high binding affinity for DNA. It is the ability of 
doxorubicin to intercalate DNA that enables the drug to stabilise the TOP2-DNA 
complex. Doxorubicin interacts with TOP2 at the protein-DNA interface by non-
covalent bonding and inhibits the ability of TOP2 to religate the cleaved DNA 
strands (Wilstermann and Osheroff, 2003).  In the presence of doxorubicin, TOP2 
remains locked to the 5’ cut ends of the DNA molecule (Tewey et al., 1984). This 
then increases the concentration of DNA cleavage complexes within the cell. 
Cleavage complexes are recognised by DNA surveillance and tracking machinery 
such as replication and transcription complexes. When a nucleic acid tracking system 
encounters a cleavage complex, it converts the transient break to a permanent one, 
and this then activates a range of repair pathways. The repair process involves the 
removal of the cleavage complex, and this results in a permanent double strand 
break. If the number of permanent double strand breaks is such that the cell is 
overwhelmed, apoptotic cell death pathways are triggered (Fortune and Osheroff, 
2000). The repair of double strand breaks is by homologous recombination and non-
homologous end joining. These repair processes are imperfect and can generate 
chromosomal translocations and other DNA aberrations (Aratani et al., 1996). Such 
aberrations can lead to the development of therapy related secondary leukaemias, 
most notably acute myeloid leukaemia (Kantidze and Razin, 2007, Felix, 1998). 
The concentration of TOP2 is higher in rapidly proliferating cells than in quiescent 
cells, with levels peaking in G2/M phase, hence the efficacy of doxorubicin against 
neoplastic cells (Sullivan et al., 1987, Sinha, 1995). Drug sensitivity correlates with 
cellular TOP2 levels and drug resistant cancer cells have been shown to have reduced 
activity and/or decreased levels of TOP2 and a reduction in the number of strand 
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breaks (Beck et al., 1993, Pommier et al., 2010). Suppressing the expression of 
TOP2α using RNA interference has confirmed that reduction in TOP2 levels 
increases the resistance of cells to doxorubicin (Burgess et al., 2008). 
1.4.1.4 Doxorubicin and Free Radical Formation. 
 
Doxorubicin has a quinone ring (Figure 1.8), and this acts as an electron acceptor. As 
a result the quinones are converted to semiquinone free radicals which can induce 
DNA damage themselves as well as interacting with molecular oxygen to yield 
superoxides, hydroxyl radicals and peroxides. The formation of these reactive 
oxygen species (ROS) causes oxidative damage to cell components, cell membranes 
and DNA. The redox-cycling of doxorubicin has been observed in the cytoplasm, 
mitochondria, endoplasmic reticulum and nucleus of cells, and clearly influences the 
cytotoxicity of the drug (Doroshow, 1983, Goodman and Hochstein, 1977, Berlin 
and Haseltine, 1981, Rowley and Halliwell, 1983). 
The ROS-dependent cytotoxicity of doxorubicin is reliant on the tumour cell being 
able to carry out the reductive reactions which activate ROS production, and this 
requires the presence of molecular oxygen (Teicher et al., 1981). However, under 
hypoxic conditions, doxorubicin does have the ability to generate aglycone free 
radicals. The redox-cycling of doxorubicin is slower under hypoxic conditions, but 
the aglycone free radicals that are generated can potently alkylate cellular DNA, and 
create DNA strand breaks. Under hypoxic conditions, the semiquinone free radical 
loses its sugar moiety and converts to the inactive metabolite C7-deoxyaglycone. 
This tautomerises to C7-quinone methide which is a DNA-alkylating species 
(Averbuch et al., 1985). 
In the presence of oxygen, the reduced form of doxorubicin is known to cause lipid 
peroxidation of cell and mitochondrial membranes (Mimnaugh et al., 1985a, 
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Mimnaugh et al., 1985b). However, the evidence for doxorubicin-induced lipid 
peroxidation as a contributing factor to tumour cytotoxicity is inconclusive (Gewirtz, 
1999). 
1.4.1.5 Doxorubicin Damages the Cell Membrane. 
 
Doxorubicin interacts directly with cell surface proteins and disrupts membrane 
structure and signal transduction pathways. Doxorubicin binding to cell surfaces can 
have a direct or an indirect effect on cell survival (Tritton, 1991). 
1.4.1.6 Doxorubicin Interferes with HIF-1 Signalling. 
 
Topoisomerase poisons other than doxorubicin (topotecan, etoposide, NSC 644221) 
have been reported to attenuate responses to hypoxia by decreasing levels of HIF-1α 
or by inhibiting its transcriptional activity (Creighton-Gutteridge et al., 2007, Choi et 
al., 2009). Since the investigations reported in this thesis began, doxorubicin has 
been shown to prevent the binding of HIF-1 to the promoter regions of hypoxia 
response genes (Lee et al., 2009a). 
1.5 Rapamycin. 
 
Rapamycin (also known as sirolimus) is a macrolide compound belonging to the 
class of secondary metabolites known as polyketides. Rapamycin is produced by the 
bacterium Streptomyces hygroscopicus. This organism was first isolated from a soil 
sample collected from the Polynesian island Rapa Nui (also known as Easter Island) 
in 1970, hence the name rapamycin (Figure 1.9) (Neuhaus et al., 2001). 
Colleagues have previously shown that rapamycin can successfully be loaded onto 
poly vinyl alcohol (PVA) microspheres, either alone or in combination with 
doxorubicin (Forster 2009), and this provides the rationale for our choice of drugs in 
this investigation. Rapamycin (Figure 1.10) is a mammalian target of rapamycin  
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Figure 1.9 Huge statues, known locally as Moai, on Rapa Nui.  
The bacterium Streptomyces hygroscopius was first isolated from a soil sample from 
the Polynesian island of Rapa Nui in 1970. Photograph Copyright free. 
(mTOR) inhibitor which has antifungal, immunosuppressant and antineoplastic 
properties. It has been used as an immunosuppressant for more than ten years, and, in 
the majority of cases, is well tolerated. The immunosuppressant activity of 
rapamycin results from the inhibition of T cell activation. It is widely used to prevent 
the rejection of kidney and liver transplants. Rapamycin inhibits the proliferation of 
vascular smooth muscle cells, and for this reason it is used as an antirestenosis drug 
in coronary artery stents (Namur et al., 2010). mTOR has been implicated in the 
pathology of a range of diseases, including cancers, cardiovascular disease, 
neurological disorders and diabetes, and is thought to play an important role in the 
regulation of aging and lifespan (Tsang et al., 2007). 
A number of clinically active rapamycin analogues – known as rapalogues – are now 
available. Rapalogues have improved pharmacological properties, and include 
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everolimus, temsirolimus, deferolimus, biolimus, picrolimus and zotarolimus. The 
structure of rapamycin is shown below (Figure 1.10). 
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Figure 1.10 The Chemical Structure of Rapamycin.  
The chemical formula for rapamycin is C51H79NO13, and the molecular weight is 
914.18. Rapamycin is a macrocyclic lactone antibiotic. 
1.5.1 The PI3K/Akt/mTOR Pathway. 
In order to understand the mechanism of action of rapamycin, it is necessary to have 
an understanding of the PI3K/Akt/mTOR pathway, which is outlined in Figure 1.11. 
The PI3K/Akt/mTOR pathway is a cell survival pathway that orchestrates cellular 
responses to nutrients, growth factors, cytokines, mitogens, hormones and stress. 
Activation of the pathway results in increased cell growth and proliferation and an 
inhibition of apoptosis. 
At the top of the signalling cascade are members of the phosphoinositide 3-kinase 
family (PI3K), which are activated by the binding of the relevant ligands to their 
membrane-bound receptors. PI3K localises to the membrane and catalyses the 
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Figure 1.11 The PI3K/Akt/mTOR Pathway. 
PI3K is activated by the binding of the relevant ligands to membrane-bound 
receptors. PI3K localises to the membrane and catalyses the conversion of PIP2 to 
PIP3. PIP3 binds to Akt, and Akt subsequently translocates to the cell membrane, 
whereupon it is phosphorylated and activated by PDK-1. Akt activates mTOR via 
phosphorylation of the protein at ser2448. mTOR binds to Raptor to form mTORC1 
The downstream effectors of mTORC1 are S6 kinase (S6K), the ribosomal protein 
S6 and the eukaryotic initiation factor 4E binding protein 1 (4EBP-1). Both regulate 
the translation of mRNAs encoding proteins involved in cell growth. PTEN 
negatively regulates the PI3K pathway via dephosphorylation of PIP2 and PIP3. 
TSC1/TSC2 negatively regulates mTOR via Rheb. Akt can also activate mTOR via 
the inactivation of TSC. 
conversion of phosphotidylinositol (4, 5)-biphosphate PIP2 to phosphotidylinositol 
(3, 4, 5)-biphosphate PIP3. PIP3 binds to Akt, and Akt subsequently translocates to 
the cell membrane, whereupon it is phosphorylated at Thr
308
 by 3’-phosphoinositide-
dependant kinase 1 (PDK-1). Akt takes centre stage in the PI3K/Akt/mTOR 
pathway, with a vast array of effectors under its control. The outcomes of Akt 
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activation all result in anti-apoptotic and pro-proliferative cell survival strategies 
(Jiang and Liu, 2008b, Dancey, 2006, Foster and Fingar, 2010). 
1.5.1.1 Phosphotase and Tensin Homolog Deleted on Chromosome 10 (PTEN). 
 
PTEN is a tumour suppressor protein and antagonist of the PI3K pathway (Maehama 
and Dixon, 1999). PTEN dephosphorylates PIP2 and PIP3, thereby negatively 
regulating the activation of Akt. PTEN prevents uncontrolled cell growth by 
inducing cell cycle arrest and apoptosis, and is thought to interfere with cell 
migration, cell adhesion and angiogenesis. Mutations to PTEN result in 
constitutively active Akt (Maehama and Dixon, 1998, Maehama and Dixon, 1999, 
Chu and Tarnawski, 2004, Jiang and Liu, 2008a). PTEN mutations are frequently 
found in liver cancers, and are critically involved in the progression of HCC (Chen et 
al., 2009a, Dong-Dong et al., 2003, Hu et al., 2003, Ma et al., 2005, Mi et al., 2006, 
Peyrou et al., 2010, Sieghart et al., 2007, Tian et al., 2010a, Tian et al., 2010b, Wan 
et al., 2003, Zhou et al., 2009). Loss of PTEN facilitates the expression of HIF-1 
gene expression via activation of Akt (Zundel et al., 2000) and increases the 
transcriptional activity of HIF-1 (Emerling et al., 2008).  
1.5.1.2 Involvement of the Tuberous Sclerosis Tumour Suppressor Complex 
TSC1/TSC2. 
 
TSC1/TSC2 is a tumour suppressor protein which is a negative regulator of 
mTORC1. Hypoxia activates TSC1/TSC2 by two separate pathways, one of which is 
HIF-dependent. HIF-dependent activation of TSC1/TSC2 depends on REDD1 
mediated shuttling of the protein 14-3-3. 14-3-3 is an inhibitory protein which binds 
to phosphorylated TSC2. Activation of Akt causes phosphorylation of TSC2. This 
promotes the association of TSC2 with 14-3-3, and inhibits TSC1/TSC2 function. 
Under hypoxic conditions, HIF-1 induces the expression of REDD1. REDD1 
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preferentially binds to 14-3-3, thereby activating the TSC1/TSC2 complex, which 
then inhibits mTORC1. Hypoxia-induced negative regulation of mTORC1 results in 
a decrease in mRNA translation and protein synthesis, and suppression of cell growth 
and proliferation (Brugarolas et al., 2004, DeYoung et al., 2008, Sofer et al., 2005). 
1.5.1.3 Akt Signalling to mTOR. 
 
Akt can activate mTOR directly by phosphorylating the protein at Ser
2448
 or 
indirectly via the inactivation of the tuberous sclerosis protein complex TSC (Jiang 
and Liu, 2008a). The consequences of hyperactive mTOR signalling are 
demonstrated in the disease tuberous sclerosis complex, which is characterised by 
mutations to one of the two genes tsc1 or tsc2. As previously mentioned, 
TSC1/TSC2 are negative regulators of mTORC1. The loss of function of either 
TSC1 or TSC2 results in the formation of multiple benign tumours and possibly the 
development of early-onset renal cell carcinoma (Nass and Crino, 2008). 
1.5.2 Structure of mTOR. 
mTOR (Figure 1.12) is a 289 kDa serine/threonine kinase which belongs to the 
PI3K-related protein kinase family and regulates levels of protein translation in 
response to nutrients, growth factors, energy and stress. mTOR has a catalytic C 
terminal kinase domain, a FK506-binding protein 12 (FKBP12) rapamycin binding 
domain, a C terminal repressor domain and FAT-C-terminus domain. The kinase 
domain phosphorylates serine (Ser) or threonine (Thr) residues in protein substrates. 
The FKBP12-rapamycin binding domain is specific to TOR and not other members 
of the PIKK family, hence the specificity of rapamycin (Choi et al., 1996, Chen and 
Fang, 2002).  
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Upon activation, mTOR is known to form at least two complexes – mTOR complex 
1 (mTORC1) and mTOR complex 2 (mTORC2). In the mTORC1 complex mTOR is 
bound to regulatory associated protein of mTOR (Raptor) and the mTOR-interacting 
protein mLST8. In the mTORC2 complex mTOR is bound to Raptor independent 
companion of mTOR (Rictor), mLST8 and at least two other accessory proteins. 
 
 
 
 
Figure 1.12 Schematic showing the basic structure of mTOR. 
HEAT repeats, N terminus FAT region, FKBP12-rapamycin binding domain, C 
terminal kinase domain, C terminal repressor domain and FAT-C-terminus domain. 
mTORC1 responds to nutrients and growth factors and ultimately results in increased 
cell proliferation. mTORC2 only responds to growth factors and appears to be 
involved in actin organisation (Houghton and Huang, 2004, Huang and Houghton, 
2003). mTORC2 positively feeds back to Akt via phosphorylation of Akt at Ser
473 
(Sarbassov et al., 2005). 
1.5.3 Downstream Effectors of mTORC1. 
The downstream effectors of mTORC1 are S6 kinase (S6K), the ribosomal protein 
S6 and the eukaryotic initiation factor 4E binding protein 1 (4EBP-1). Both regulate 
the translation of mRNAs encoding proteins involved in cell growth. 
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Phosphorylation of S6K at Thr
389
 by mTORC1 activates the ribosomal protein S6 
and increases the translation of mRNAs that have a 5’ tract of oligopyramidine 
(5’TOP) motif and increases the synthesis of ribosomal proteins and translation 
factors. mTORC1 also phosphorylates the elongation factor 4E (elF4F) inhibitor 
4EBP-1. Upon phosphorylation, 4EBP-1 dissociates from elF4E and allows elF4E to 
associate with the 5’-CAP of RNAs and so promotes cap-dependant protein synthesis 
(Dufner et al., 1999, Dufner and Thomas, 1999).  
When nutrients and growth factors are present, mTOR is activated and protein 
translation is upregulated. The cell mass increases and the cell cycle moves from the 
G1 phase to the S phase, thus increasing the rate of cell proliferation. In the absence 
of these ligands, protein translation is downregulated and energy is conserved. Cells 
are arrested at the G1 phase and apoptosis increases (Houghton and Huang, 2004). 
1.5.4 Mode of Action of Rapamycin. 
The biological activity of rapamycin is a consequence of the fact that it contains an 
mTOR-binding region and a FKBP12-binding region. When rapamycin enters the 
cytosol, FKBP12 binds to rapamycin with high affinity. The resulting FKBP12-
rapamycin complex binds specifically and irreversibly to mTOR and prevents 
downstream signalling (Huang et al., 2003). 
mTORC1 is inhibited by FKBP12-rapamycin. Components which are specific to 
mTORC2 are thought to prevent the FKBP12-rapamycin complex from binding to 
mTOR. If exposure to rapamycin is prolonged, however, the complex binds to newly 
synthesised mTOR before it assembles into mTORC2 (Houghton and Huang, 2004, 
Huang and Houghton, 2003), and recent reports suggest that rapamycin inhibits 
mTORC2 under certain conditions and in specific cell types (Barilli et al., 2008, 
Sarbassov et al., 2006). Rapamycin thus inhibits protein synthesis by blocking 
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mTORC1 signalling via S6K and 4E-BP1. Without a sufficient increase in cell size 
and mass, the cell cycle arrests at the G1 stage and apoptosis is increased (Mita et al., 
2003). 
1.5.5 Rapamycin and HIF-1. 
Oxygen concentration is the primary determinant of HIF-1 activation. However, the 
extent of HIF-1 activation is partly modulated through the PI3/Akt/mTOR pathway, 
and hyperactive Akt is a positive factor for HIF-1 dependent signalling pathways. 
Rapamycin has been observed to interfere with HIF-mediated cell signalling 
pathways (Jiang and Liu, 2008b, Guba et al., 2002, Hudson et al., 2002, Zhong et al., 
2000). 
1.5.6 The PI3K/Akt/mTOR Pathway and Cancer Cells. 
The anticancer activity of rapamycin was first recognised by the National Cancer 
Institute in the 1970s but was not extensively investigated until the late 90s. The 
PI3K/Akt/mTOR pathway is deregulated in many cancers and hyperactivity is 
implicated in tumourigenesis. The mechanisms of deregulation are numerous, and 
include loss of PTEN, amplification or gain of function mutations to PI3K, Akt or 
growth factor receptors, and exposure to carcinogens (LoPiccolo et al., 2008). The 
net result is an increase in cell proliferation and an increased resistance to apoptosis. 
Hyperactive Akt signalling may also result in increased HIF-1 activation. For 
instance, PTEN deficient cells display an exaggerated HIF-1 response to hypoxia, 
and this may contribute to the aggressiveness of PTEN deficient tumours (Zundel et 
al., 2000). 
If cancer cells are dependent on mTOR signalling for survival, there is a potential 
role for mTOR inhibitors in the treatment of cancers with mutations to the 
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PI3K/Akt/mTOR pathway (Tsang et al., 2007). A number of preclinical and clinical 
trials of rapamycin and rapalogs against cancers including renal cell carcinoma, 
mantle cell lymphoma, and breast and endometrial cancers have had some 
encouraging results, particularly against some cancers with mutations to PTEN and 
Akt (O'Donnell et al., 2008, Okamoto et al., 2010, Hudes et al., 2009, Slomovitz et 
al., 2010, Yao et al., 2008, Hess, 2009, Motzer et al., 2010, Lu et al., 2008). Other 
trials however, have shown only modest or short lived responses with no significant 
improvements (Huang et al., 2003, LoPiccolo et al., 2008). 
1.5.7 Protein Phosphatase and Tensin Homolog (PTEN). 
Mutations or deletions to the tumour suppressor PTEN lead to hyperactivation of the 
PI3K/Akt/mTOR pathway. PTEN is a tumour suppressor protein and antagonist of 
the PI3K pathway (Maehama and Dixon, 1999). PTEN modifies other proteins by 
removing phosphate groups. It functions as a tumour suppressor by negatively 
regulating the Akt signalling pathway, and mutations to PTEN result in constitutively 
active Akt. PTEN prevents uncontrolled cell growth by inducing cell cycle arrest and 
apoptosis, and is thought to interfere with cell migration, cell adhesion and 
angiogenesis (Maehama and Dixon, 1998, Maehama and Dixon, 1999, Chu and 
Tarnawski, 2004, Jiang and Liu, 2008a). 
PTEN mutations are frequently found in liver cancers, and are critically involved in 
the progression of HCC (Chen et al., 2009a, Dong-Dong et al., 2003, Hu et al., 2003, 
Ma et al., 2005, Mi et al., 2006, Peyrou et al., 2010, Sieghart et al., 2007, Tian et al., 
2010a, Tian et al., 2010b, Wan et al., 2003, Zhou et al., 2009). The loss of PTEN 
facilitates the expression of HIF-1 gene expression via activation of Akt (Zundel et 
al., 2000) and increases the transcriptional activity of HIF-1 (Emerling et al., 2008). 
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We know that in HepG2 cells PTEN is barely detectable (Ma et al., 2005, Zhang et 
al., 2004) and that this results in increased synthesis of HIF-1α (Zundel et al., 2000, 
Zhong et al., 2000). Overexpressing PTEN in HepG2 cells decreases the activation 
of HIF-1 and suppresses angiogenesis, migration and invasiveness (Tian et al., 
2010a, Tian et al., 2010b, Sze et al., 2011). The loss of PTEN therefore contributes 
to tumour cell survival under hypoxic conditions. Decreased PTEN in tumour biopsy 
specimens correlated with tumour progression and a poor prognosis in HCC (Hu et 
al., 2003, Chen et al., 2009a, Dong-Dong et al., 2003, Sze et al., 2011, Mi et al., 
2006). Recently, an association has been found between PTEN haplotypes and 
susceptibility to HCC (Ding et al., 2011). 
1.6 Combination Therapies for the Treatment of HCC. 
 
The combination of standard chemotherapeutic agents with one (or more) of the 
recently identified molecular targeted therapies in the treatment of HCC presents 
opportunities to improve patient outcome. The rationale for combination 
chemotherapy is to use drugs that have different mechanisms of action, and reduce 
chemoresistance. For instance, the targeted drug may restore the apoptotic pathway 
in cells, thus allowing the traditional chemotherapeutic to cause apoptosis. 
Recent research indicates that rapamycin will be most effective when used in 
combination with other chemotherapeutics or other molecular inhibitors (Huynh et 
al., 2009, LoPiccolo et al., 2008, Wang et al., 2008c, Piguet et al., 2008). 
1.7 Nuclear Factor Kappa-light-chain-enhancer of Activated B Cells (NF-kB). 
 
Nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) is a family of 
transcription factors which mediate cell proliferation, apoptosis and immune 
responses. It also mediates cellular responses to hypoxia, and the involvement of 
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NFkB in responses to hypoxia is now starting to be investigated. NFkB consists of a 
family of seven transcription factors, divided into two subfamilies – the Rel proteins 
and the NFkB proteins. The Rel protein subfamily includes p65 (aka RelA), and the 
NFkB protein subfamily includes the p105/p50 (aka NFkB1) and the p100/p52 (aka 
NFkB2) isoforms. NFkB subfamily proteins have long C-terminal domains which 
inhibit their activity, and are only able to bind to DNA in their shorter forms (e.g. 
p105 to p50). Members of the NFkB subfamily only activate transcription when they 
dimerise with one of the Rel subfamily. The p50-RelA heterodimer is the major 
NFkB dimer in many cells (Gilmore, 2006). 
Two pathways have been described for NFkB activation – the canonical (or classical) 
pathway and the non-canonical (or alternative) pathway. The non-canonical pathway 
activates NFkB complexes during B- and T-cell development, and will not be 
considered in this study. In the canonical pathway, NFkB signalling is regulated by 
inhibitor kB (IkB) proteins. Inactive NFkB dimers, such as p50/RelA, are bound to 
IkB, and maintained in the cytosol. In response to a range of extracellular signals, 
IkB kinase (IKK) complexes phosphorylate IkB and induce its degradation. This then 
frees the NFkB dimer, which translocates to the nucleus and activates expression of 
its target genes. A third pathway is thought to involve translocation of homodimers 
of p50 to the nucleus (Gilmore, 2006). 
Due to the number of different NFkB isoforms and IkBs, the complexity of their 
regulatory pathways, and the influence of post-translational modifications, the 
phenotypic effects of NFkB activation are not well understood (Perkins, 2006). 
NFkB is upregulated in HCC, and is associated with both pathogenesis and 
chemoresistance (Arsura and Cavin, 2005, He and Karin, 2011, Luedde and 
Schwabe, 2011). 
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1.8 Apoptosis. 
 
Apoptosis can be defined as ‘programmed cell death’. It is an energy requiring 
process and occurs in response to severe cell damage or cellular stress, including the 
formation of radical oxygen species, which can also initiate apoptosis (Kim and Park, 
2003). Apoptosis is regulated by a caspase cascade, and is characterised by 
chromatin condensation, membrane blebbing, cytoplasmic shrinking, the formation 
of apoptotic bodies and DNA fragmentation. Caspases are cysteine proteases which 
are activated when cleaved. Both initiator and effector caspases determine the fate of 
the cell, and apoptosis is tightly regulated. The principal anti-apoptotic proteins are 
Bcl-2 and Bcl-xL and the principal pro-apoptotic proteins are Bax, Bad, Bak and Bid 
(Piret et al., 2002b). 
1.8.1 Hypoxia and Apoptosis. 
Hypoxia can induce both pro and antiapoptotic responses, depending on the severity 
and duration of oxygen depletion. Severe hypoxia < 0.5% oxygen concentration 
results in pro-apoptotic responses due to the stabilisation of p53 (Santore et al., 2002) 
whereas moderate/mild hypoxia results in anti-apoptotic cellular survival responses 
such as angiogenesis and in some cases cell proliferation (Carmeliet et al., 1998). 
Severe hypoxia causes genetic instability and a high mutation rate, and apoptosis 
prevents the accumulation of cells carrying such mutations (Reynolds et al., 1996). 
Anoxic cells lack the energy required for apoptosis and undergo necrotic cell death. 
The apoptotic cascade in hypoxia is to some extent directly regulated by HIF-1 (Erler 
et al., 2004, Sowter et al., 2001). Pro-apoptotic proteins upregulated by HIF-1 
include BNIP3 and NIX, which are both Bcl-2 binding proteins, and therefore inhibit 
the antiapoptotic activity of Bcl-2 (Goda et al., 2003). Conversely, hypoxia also 
induces expression of antiapoptotic proteins such as IAP-2 (via the transcription 
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factor NFkB) and downregulates the expression of the pro-apoptotic protein Bax 
(Dong et al., 2003). Disturbances to the inner mitochondrial membrane in hypoxia 
can also result in apoptosis. Oxygen depletion decreases the membrane potential at 
the inner membrane of the mitochondria. This activates Bax and Bak and initiates the 
caspase cascade (Saikumar et al., 1998). 
As already discussed, solid tumours contain regions of both chronic and intermittent 
hypoxia. Some of these cells may be resistant to apoptosis, and are selected for. In 
addition to being resistant to hypoxia-induced apoptosis, these cells are also less 
sensitive to apoptosis induced by chemotherapeutics causing DNA damage, and 
apoptosis-resistant cells are a hallmark of solid of tumours (Chresta et al., 1996). 
1.9 Tumour Suppressor Protein p53. 
 
The tumour suppressor p53 is a pro-apoptotic protein and transcription factor that is 
activated in response to cellular stress, such as hypoxia, DNA damage and osmotic 
shock. Nuclear accumulation of p53 occurs in response to DNA damage. p53 
activates the transcription of proteins that are involved in damage repair or apoptosis. 
When intracellular levels of p53 are low to moderate, the cell cycle is arrested at the 
G1 phase and DNA damage repair takes place. However, if levels of p53 are high, 
apoptotic cell death pathways are triggered. p53 is implicated in oncogenic 
transformation, and cancer cells which have mutated p53 are resistant to chemo- and 
radio-therapies (Bold et al., 1997). Fifty percent of tumours have been shown to have 
mutated or deleted p53 (Hammond and Giaccia, 2002), which protects from drug-
induced apoptosis. Doxorubicin induces apoptosis as a consequence of DNA damage 
via p53 dependant mechanisms (Lee et al., 2002). 
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1.9.1 Regulation of p53. 
In unstressed cells, p53 is bound to its negative regulator, the protein Mdm2. This 
binding promotes ubiquitination of p53 and the protein complex undergoes 
proteosomal degradation. In stressed cells the N-terminal end of p53 is 
phosphorylated by protein kinases and Mdm2 binding is disrupted, and p53 
accumulates. Transcriptional co-activators p300/CRB are recruited, allowing the 
DNA binding domain of p53 to interact with the promoters and/or repressors of 
downstream genes (Piret et al., 2002b). 
1.9.2 p53 and HIF-1. 
The relationship between p53 and HIF-1 is complicated. There is a direct physical 
interaction between HIF-1α and p53. p53 only accumulates in response to hypoxia 
when hypoxia is severe and prolonged and appears to play a role in the regulation of 
HIF-1α.  Two p53 binding sites have been identified within the ODD of HIF-1α. p53 
stabilises HIF-1α and this promotes Mdm2-dependant degradation of HIF-1α (Chen 
et al., 2003, Sanchez-Puig et al., 2005). HIF-1 induces apoptosis by directly 
interacting with and stabilising wild-type p53. p53 activates the proapoptotic proteins 
Bax and Bak (Greijer and van der Wall, 2004). 
Both HIF-1 and p53 require recruitment of the co-activator p300 in order to be 
transcriptionally active, and it has been suggested that competition for p300 
attenuates transcriptional activity of HIF-1 (Blagosklonny et al., 1998). p53 induced 
by hypoxia is reported to be transcriptionally inactive, although it can still induce 
apoptosis, probably by associating with co-repressors (Koumenis et al., 2001). The 
inactivity could be explained by losing the competition with HIF-1 for co-activator 
p300. However, since severe hypoxia also causes DNA damage, which causes 
further stabilisation of p53, it is possible that with increasing severity of hypoxia the 
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competitive balance shifts in favour of p53, and p53 becomes transcriptionally active 
and HIF-1 attenuated (Kaluzova et al., 2004). 
1.10 Cell Respiration. 
 
Cell respiration is the process by which cells harvest energy from organic 
compounds and store it in the chemical bonds of adenine tri-phosphate (ATP). ATP 
is then used by the cell to provide the energy required for cellular processes to take 
place. 
1.10.1 ATP. 
ATP is a nucleic acid which has a ribose sugar attached to the nitrogenous base 
adenine. This sugar has three phosphate groups attached, each of which has a 
negative charge. Because of the proximity of these negative charges to each other, 
strong bonds are needed to hold the phosphate groups in place. If these bonds are 
broken, phosphate groups are uncoupled from the molecule and the bond energy is 
released. The cell uses hydrolysis to dephosphorylate ATP, resulting in the release of 
usable energy and the conversion of ATP to either adenine di-phosphate (ADP) 
(when only one phosphate group is removed) or adenosine monophosphate (AMP) 
(when two phosphate groups are removed). 
1.10.2 Glucose Metabolism in the Presence of Molecular Oxygen. 
In the presence of oxygen, mammalian cells generate ATP by the complete oxidation 
of glucose to water and carbon dioxide. This catabolic pathway comprises of a series 
of oxidation and reduction reactions that take place within the cytosol and the 
mitochondria. There are three major steps to aerobic cell respiration – glycolysis, the 
Krebs Cycle and the electron transport chain (ETC). The theoretical net energy gain 
is 38 molecules of ATP for each molecule of glucose. 
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1.10.3 Glycolysis. 
Glycolysis takes place in the cytosol. In glycolysis one 6-carbon molecule of glucose 
is phosphorylated and converted to two 3-carbon molecules of pyruvate. The 
phosphorylation of glucose is catalysed by hexokinase enzymes. Splitting the glucose 
molecule is catalysed by a series of glycolytic enzymes. The pyruvate is then shunted 
towards the mitochondria for entry into the Krebs Cycle and the ETC. 
1.10.4 Glucose Metabolism in the Absence of Molecular Oxygen. 
In the absence of oxygen, ATP production comprises two stages – glycolysis and 
fermentation. Both of these take place in the cytosol. The end product is lactic acid. 
ATP levels are maintained and cells can continue to survive and proliferate in the 
absence of oxygen. Anaerobic respiration is much less efficient than aerobic 
respiration with a net gain of only 2 ATP molecules for every molecule of glucose. 
The pyruvate molecules generated in glycolysis are reduced to lactic acid. The 
increased conversion of pyruvate to lactic acid in hypoxic cells is known as the 
Pasteur Effect (Krebs, 1972). 
Hypoxic cells increase the uptake of glucose molecules by upregulating the 
expression of glucose transporters and glycolytic enzymes in a HIF-1 dependant 
manner (Semenza, 2003). The glycolytic enzymes rapidly convert the glucose into 
pyruvate. HIF-1 also upregulates lactate dehydrogenase A (LDH-A) which shunts the 
pyruvate towards anaerobic glycolysis and conversion to lactic acid in the cytoplasm 
(Papandreou et al., 2006). Aerobic metabolism of pyruvate requires pyruvate 
dehydrogenase (PDH) and HIF-1 upregulates the expression of PDK1 which inhibits 
PDH (Kim and Dang, 2006). 
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1.10.5 Glucose Metabolism in Tumour Cells. 
Cancer cells metabolise glucose through a cytoplasmic glycolytic pathway, even 
when molecular oxygen is available to the cell. This phenomenon is known as the 
Warburg Effect (Kim and Dang, 2006). Anaerobic metabolism is far less efficient 
than aerobic metabolism, and requires a much higher flux of glucose molecules. This 
increase in energy consumption explains why cancer patients suffer from cachexia 
(Dills, 1993). HIF-1 facilitates anaerobic glycolysis by upregulating enzymes as 
described in 1.10.4, and ATP production in cancer cells is HIF-dependent (Brahimi-
Horn and Pouyssegur, 2006). 
1.11 Using Hypoxic Culture Conditions for In Vitro Research. 
 
It is now a well established fact that hypoxia influences tumour biology and 
intracellular pathways, including those that control proliferation, cell cycling and 
apoptosis. These changes will clearly have an impact on the effects of 
chemotherapeutic agents. The importance of pre-clinical in vitro research on cells 
cultured within a hypoxic environment is now apparent. Indeed, some of the 
disparities between in vitro and in vivo responses to cancer treatments may be due to 
the fact that much of the in vitro work has been carried out at an oxygen 
concentration of 21%. 
 
1.12 Summary. 
 
As discussed above, solid tumours contain regions of hypoxia, and this is associated 
with chemo- and radiotherapy-resistance, and a shift to a more malignant phenotype. 
HCCs have hypoxic regions, and this is associated with a poor outlook. TACE is the 
standard of care for intermediate HCC, although response rates are not good. There is 
a concern that, as well as creating regions of anoxia leading to tumour necrosis, the 
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escape from embolisation therapies of tumour cells in hypoxic regions could result in 
a residual population of aggressive cancer cells which are then clonally selected for.  
Cellular responses to hypoxia are regulated principally by the transcription factor 
HIF-1. Targeting HIF-1 thus provides a therapeutic opportunity. Recent research has 
shown that doxorubicin interferes with HIF signalling pathways. Rapamycin is also 
thought to interfere with HIF signalling, by inhibiting the rate of synthesis of HIF-1α. 
The use of systemic low dose rapamycin to treat HCC is presently under clinical 
investigation. 
The use of doxorubicin loaded DEBs for the treatment of HCC facilitates the 
sustained delivery of high concentrations of drug straight to the tumour bed, with 
minimal systemic exposure. Rapamycin can also be loaded onto DEBs, both on its 
own or in addition to doxorubicin. 
1.13 Aims of the Thesis. 
 
In this thesis we have investigated the response of the human HCC cell line HepG2 
to doxorubicin and rapamycin, both as single agents and in combination. In vitro 
assessment of cytotoxicity was carried out in cells cultured under both normoxic and 
hypoxic conditions. Western Blotting was then employed in order to elucidate the 
mechanisms of action of the two drugs, and highlight differences in the expression of 
relevant proteins in normoxic and hypoxic cells. In vivo assessment of the anti-
tumour activity of the drugs was carried out using an ectopic human HCC xenograft 
mouse model. 
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In summary, the aims of this thesis were as follows: 
•  to develop a hypoxic in vitro model of liver cancer 
 to assess the cytotoxicity of doxorubicin and rapamycin, both as single 
agents and in combination, towards the human HCC cell line HepG2 
cultivated in vitro under both 21% and 1% oxygen concentrations;   
 to analyse changes in expression of relevant proteins in these cells; 
•  to investigate the anti-tumour activity of the drugs in vivo, using an ectopic   
     human HCC xenograft mouse model. 
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Chapter 2  
Materials and Methods. 
 
2.1 Cell Culture. 
 
Cell culture is a well established laboratory technique and one of the major tools at 
the disposal of cell and molecular biologists. Cells isolated from tissues are 
proliferated ex vivo, and this provides a model system for the study of cell 
physiology and biochemistry; and for investigating the effects of drugs and toxic 
compounds.  
2.1.1 Cell Line. 
The cell line used in all experiments was the human hepatocellular liver carcinoma 
cell line HepG2. The cells are derived from the liver tissue of a fifteen year old 
Caucasian male with a well differentiated HCC, and are extensively used for in vitro 
investigations of liver cancer. The cells have an epithelial morphology, and are 
anchorage-dependent. The cells were purchased frozen from ATCC Cell Biology 
Collection (ATCC, HB-8065, UK). 
2.1.2 Culture Conditions.  
Specific culture conditions vary with cell type. However, all cells in culture require a 
substrate that supplies the essential nutrients that are required for growth and 
proliferation; the presence of growth factors; and regulation of temperature and 
gases. Cells in culture should be passaged during the log phase of growth, before 
they reach confluence. 
Here, cell culture in normoxic conditions was carried out under aseptic conditions 
inside a laminar flow cell culture hood (HERA Safe, Heraeus). All equipment was 
sterilised before use, and the hood was swabbed down with 70% industrial 
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methylated spirits. HepG2 cells were cultured in Minimum Essential Medium 
(MEM) + Earle’s salts + L-Glutamine (PAA Laboratories, GmBH) supplemented 
with 10% Foetal Bovine Serum Heat Inactivated (PAA Laboratories, GmBH,) and 
1% Non-essential Amino Acids (PAA Laboratories, GmBH), all of which were 
warmed to 37°C before use. The cells were seeded onto T75 tissue culture coated 
flasks (NUNC™, Denmark) and incubated at 37°C, 95% air and 5% CO2. Cells were 
passaged when confluence reached 70%, using a sub-cultivation ratio of 1:6. All 
experiments used cells between passage numbers 96 and 125.  
2.1.3 Passage Protocol. 
The media was aspirated from the flask, and 5 ml of trypsin-EDTA (0.05% / 0.02% 
in PBS) (PAA Laboratories, GmBH) was added in order to detach the cells. The 
flask was incubated for 10 minutes at 37°C. Microscopy was used to confirm that the 
cells had detached from the surface of the flask. 10 ml of complete media was then 
added to the flask in order to neutralise the trypsin and the cell suspension was 
removed to a centrifuge tube. The cell suspension was centrifuged at 300 g for 5 
minutes (Heraeus, Multifuge 3S). The supernatant was removed and discarded, and 
the pellet was resuspended in 1 ml of media. 10 µl of cell suspension was removed 
and added to 90 µl of PBS, providing a 1:10 dilution of the cell suspension to 
determine the cell count. 15 µl of the 1:10 dilution was pipetted onto a 
haemocytometer slide and the cells were counted. The appropriate fraction of cell 
suspension was then added to a new T75 flask, and fresh media was added to a total 
volume of 20 ml. Microscopy was used to confirm the presence of cells in the flask, 
and the flask was placed in the incubator.  
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2.2 Hypoxic Incubations. 
 
In vitro experiments attempt to mimic the in vivo environment as closely as possible. 
However, most cell culture is carried out at 21% oxygen, which in most cases does 
not mirror the physiological oxygen concentration within the relevant tissue.  
In this study a hypoxic glove box was used for hypoxic cell culture in order to 
investigate the responses of cells that may be refractory to embolisation therapy. The 
glove box allows the oxygen environment to be tightly regulated, and cell culture and 
manipulation of cells can be carried out under maintained oxygen concentrations. An  
 
 
 
 
Figure 2.1 The COY Hypoxic Glove Box.  
The glove box allows cell culture and manipulation of samples in an oxygen 
controlled environment, with temperature, humidity and CO2 control. Oxygen, 
nitrogen and carbon dioxide cylinders supply gas feeds to the glove box. HEPA 
atmosphere filtration ensures sterility, and an internal fan ensures uniform gas 
distribution. The oxygen concentration is maintained using an oxygen sensor and 
controller, with an automatic purge control. Samples are introduced through a 
transfer chamber airlock which is purged to equilibrate to the O2 level within the 
glove box. An internal humidified incubation box prevents media from drying out 
during long incubation periods. Manipulation of samples is carried out through 
sealed arm ports so that the internal atmosphere is not compromised. 
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oxygen concentration of 1% was selected because it represents  
a) an oxygen concentration at which HepG2 cells adapt to hypoxic conditions. At 
concentrations lower than 0.5%, the cells undergo apoptosis, and at 
concentrations less than 0.1% the cells undergo necrosis 
and 
b) an oxygen concentration that represents an in vivo niche, where cells that 
experience embolisation-induced hypoxia are exposed to doxorubicin as it elutes 
from the bead (Namur et al., 2010).  
For hypoxic incubations the cells were cultured inside a hypoxic glove box (COY 
Laboratory Products Inc. MI. USA) (Figure 2.1) set to 1% oxygen, 5% carbon 
dioxide, 94% nitrogen. Any media used in the hypoxic condition was placed inside 
the chamber for 24 hours before use in order that the liquid phase could equilibrate to 
the gas phase.  
2.3 Verification of Stabilisation of HIF-1α in Hypoxic Culture Conditions. 
 
Two methods were utilised to confirm that HIF-1α had stabilised and translocated to 
the nucleus in HepG2 cells exposed to 1% oxygen – SDS-PAGE and Western 
Blotting (see 2.5 for method and Chapter 6 for results); and immunohistochemistry.  
2.3.1 Immunohistochemistry. 
Specific proteins in cultured cells can be labelled using antibodies conjugated to 
fluorophore reporter systems. The presence or absence of these proteins can then be 
investigated using fluorescence microscopy. A nuclear counter stain allows 
visualisation of all the cells in the sample. Here, levels of HIF-1α in normoxic and 
hypoxic HepG2 cells were compared. 
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HepG2 cells were seeded onto chamber slides (Fisher Scientific, UK) at a seeding 
density of 2 x 10
5
 per well and incubated in normoxic conditions until confluence 
was 60%. The cells were then incubated at either 21% oxygen or 1% oxygen for 24 
hours. The cells were fixed with 3.7% formalin at room temperature for 20 minutes, 
and washed in PBS. Cells were blocked for 15 minutes using blocking buffer (0.7% 
glycerol, 0.2% Tween-20, 2% BSA, in PBS). Blocking buffer was removed and HIF-
1α antibody diluted 1:750 in blocking buffer was added to the chamber slides. The 
slides were incubated overnight at 4°C, and then washed with wash buffer (0.7% 
glycerol, 0.4% Tween-20, 2% BSA, in PBS). A tetramethylrhodamine-5-(and 6)-
isothiocyanate fluorescein isothiocyanate (TRITC) conjugated secondary antibody 
(Sigma, UK), diluted 1:200 in blocking buffer, was added to the chamber slides. The 
slides were protected from light, and subjected to agitation for 1 hour at room 
temperature. Secondary antibody was removed and cells washed in wash buffer at 
room temperature for 1 hour. Cells were counter-stained with 4', 6-diamidino-2-
phenylindole (DAPI) (Gibco, UK), and viewed by confocal microscopy at  x 100 
magnification. 
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Figure 2.2 Immunohistochemistry Staining for HIF-1 in Normoxic and Hypoxic HepG2 cells.  
Cells were seeded onto chamber slides HepG2 cells were seeded onto chamber slides and incubated under normoxic conditions until 
confluence was 60%. The cells were then incubated under normoxic or hypoxic conditions for 24 hours. The cells were incubated 
overnight with antibodies to HIF-1α, and then incubated with TRITC conjugated secondary antibody. DAPI staining was used to 
visualise the nucleus. Images are taken at x100 magnification. HIF-1α is absent in normoxic cells and present in hypoxic cells. 
DAPI HIF-1α Overlay
Normoxic
Hypoxic
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2.4 The 3 - (4, 5  dimethylthiazol - 2 - yl) - 5 - (3 - carboxymethoxyphenyl) - 2 - (4 
sulfophenyl) 2H - tetrazolium, inner salt (MTS) Cytotoxicity Assay. 
 
The MTS assay is a cell-based assay, the end point measure of which indicates the 
number of viable cells in culture (Cory et al., 1991). MTS assays are widely used for 
pharmacological studies to investigate the effects of cytotoxic compounds on cell 
viability and cell proliferation. The assay relies on the assumption that the number of 
viable cells is directly proportional to the coloured formazan product. 
Here the CellTiter 96
® 
Aqueous One Solution Proliferation Assay (Promega, UK) 
was used to determine the chemosensitivity of HepG2 cells to treatment with 
doxorubicin, rapamycin and both in combination under both normoxic and hypoxic 
culture conditions. The CellTiter 96
® 
Aqueous One Solution Proliferation Assay is a 
colorimetric assay which depends on the cellular reduction of the tetrazolium 
compound MTS to the coloured product formazan. The reagent contains the 
tetrazolium compound MTS together with an electron coupling reagent (phenazine 
ethosulfate; PES), which combine to form a stable solution.  The conversion of MTS 
to formazan is due to the activity of mitochondrial dehydrogenase enzymes within 
metabolically active cells.  
Metabolic activity in cells produces reducing agents nicotinamide adenine 
dinucleotide (NADH) and nicotinamide adenine dinucleotide phosphate (NADPH). 
These reducing compounds donate their electrons to the electron coupling reagent 
PES, and this then reduces the MTS to formazan. The formazan product is soluble in 
tissue culture medium. The quantity of formazan product is measured by the amount 
of absorbance at 490 nm, and this measure is directly proportional to the number of 
living cells in culture (Cory et al., 1991). The sensitivity of the assay is 
approximately 1 x 10
3
 cells/well in a 96-well plate (Promega Protocols and 
Applications Guide). 
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Cell titrations were carried out under both normoxic and hypoxic conditions to 
validate the assay. The optimal seeding density and optimal MTS reagent incubation 
period, such that absorbance readings across the time course of the experiment fell 
within the linear range of the assay, was found to be 1 x 10
4 
cells/well and the 
optimal and 2 hours respectively (data not shown). These values were used in all 
experiments.  
Control wells containing media and cytotoxic compound(s) but no cells were 
included in the experimental design. The mean control absorbance was subtracted 
from each of the absorbance readings to yield a corrected absorbance.  
2.4.1 Determining the Effect of Doxorubicin, Rapamycin or a Combination of 
Both on Cell Viability. 
2.4.1.1 Seeding the 96-well Plates. 
 
HepG2 cells were grown to 70% confluence in a T75 flask, and harvested and 
counted as previously described. The cells were resuspended in media to a 
concentration of 5 x 10
4 
cells/ml. Cells were seeded onto six 96-well tissue culture 
coated plates in 200 µl aliquots to provide a cell seeding density of 1 x 10
4 
cells/well. 
The plates were incubated under normoxic conditions for 24 hours to allow the cells 
to equilibrate. 
2.4.1.2 Exposure of Cells to Doxorubicin, Rapamycin or a Combination of Both. 
 
Three 96-well plates were removed to hypoxic conditions and three 96-well plates 
remained in normoxic conditions. The media was aspirated from the plates and 
replaced with 200 µl of the appropriate concentration of drug(s) in solution. Six 
replicate wells were prepared for each drug concentration. Two control wells, 
containing no cells, were prepared for each drug concentration. The plates were 
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incubated for either 24, 48 and 72 hours, under either normoxic or hypoxic 
conditions as appropriate (Figure 2.4). 
2.4.1.3 Measuring Cell Viability using the MTS Assay. 
 
After the required incubation period, 40 µl of MTS assay reagent was added to each 
of the wells. This was carried out under normoxic or hypoxic conditions, as 
appropriate. The plates were incubated for a further two hours. 
 
 
 
 
Figure 2.3 Schematic showing timeline for the cytotoxicity assay.  
HepG2 cells were seeded onto 96-well plates and incubated for 24 hours to 
equilibrate. Plates were removed to either normoxic or hypoxic conditions. Cells 
were exposed to cytotoxic compounds and incubated for 24, 48 and 72 hours. MTS 
assay reagent was added and the cells were incubated for a further 2 hours. The 
absorbance at 490 nm was recorded. 
 
The absorbance at 490 nm was read using a multiwell plate reader (BioTek, UK). 
The mean control absorbance was calculated for each experimental condition. The 
mean control absorbance for each experimental condition was then subtracted from 
each of the six absorbance readings for the same experimental condition. The mean 
absorbance for each experimental condition was then calculated. The effect of the 
drug(s) for each experimental condition was calculated as percentage change in mean 
absorbance compared to the untreated control. 
 
Removal to either normoxic 
or hypoxic condition 
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Figure 2.4 Schematic showing the layout of the 96 well plates for MTS assay.  
A) doxorubicin alone B) rapamycin alone and C) doxorubicin and rapamycin 
combinations. The last two wells in each column do not contain cells, and provide 
control absorbance readings. 
0    0.1    1     5     10    25   50   µM doxorubicin
With cells
Without cells
0      1     10    50   100  500         nM rapamycin  
With cells
Without cells
0    0.1     1     10    25    50     0     0.1     1     10     25    50          µM doxorubicin
0      0      0       0      0      0     10     10    10    10    10    10           nM rapamycin
With cells
Without cells
B) 
C) 
nM rapamycin 
µM doxorubicin 
A) 
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2.5 Preparation of Drug Solutions. 
 
2.5.1 Preparation of Doxorubicin Solutions. 
Doxorubicin hydrochloride (> 98% purity; Zhejiang Hisun Pharmaceuticals, China) 
was supplied dissolved in sterile H2O at a concentration of 50 mg/ml. The stock 
solution was stored at 4˚ C in a glass vial. Doxorubicin hydrochloride can be stored 
for 6 - 12 months at 4˚ C without loss of potency (Hoffman et al., 1979). 
For each experiment dilutions of doxorubicin hydrochloride in media were made up 
fresh from the stock solution, under sterile conditions, in either normoxic or hypoxic 
conditions as appropriate. 
2.5.2 Preparation of Rapamycin Solutions. 
Rapamycin (> 99% purity, LC Laboratories, Massachusetts, USA) was supplied at 
60 mg/ml in the solvent dimethyl sulfoxide (DMSO). Since the drug is poorly 
soluble in media, a 10 mM solution of rapamycin was prepared in DMSO. A cell 
proliferation assay had previously been carried out using the highest concentration of 
DMSO seen by the cells in order to demonstrate that there were no cytotoxic effects 
from the diluent itself (data not shown). 
Fresh dilutions of rapamycin were made up for each experiment. Rapamycin as 
supplied was stored long term at − 20˚C. Rapamycin/DMSO was stored at 4˚ C 
protected from light for up to 4 weeks. 
2.5.3 Preparation of Doxorubicin/Rapamycin Combination Solutions. 
Solutions of doxorubicin were prepared as described in 2.3.1. A 10 µM solution of 
rapamycin in media was made up from the 10 mM rapamycin/DMSO stock 
described in 2.3.2. Appropriate amounts of the 10 µM solution were used to spike the 
doxorubicin solutions to a final rapamycin concentration of 10 nM. 
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2.6 Preparation of Nuclear and Cytoplasmic Cell Extracts for SDS-PAGE and 
Western Blotting. 
2.6.1 Treating the Cells. 
HepG2 cells were seeded onto T75 flasks and incubated under normoxic conditions 
until confluence reached 60%. The flasks were then removed to either normoxic or 
hypoxic conditions. The media was aspirated off, and replaced with concentrations of 
drug as described in the figure legends. The cells were incubated for 24 hours under 
either normoxic or hypoxic conditions, as appropriate. 
2.6.2 Harvesting the Cells. 
The media was aspirated from cells under normoxic or hypoxic conditions as 
appropriate. Cells were washed twice using 2 mls of phosphate-buffered saline (PBS) 
(Sigma Aldrich, UK). PBS (1.5 ml) was added to the flask and the cells were 
dislodged from the flask using a cell scraper. The cell suspension was removed to a 
microcentrifuge tube (Eppendorf UK) using a Gilson pipette and centrifuged at 
13,000 rpm for three minutes. The supernatant was discarded. 
2.6.3 Preparation of Nuclear and Cytoplasmic extracts. 
The cell pellet was resuspended in 400 µl of Buffer A (10mM Hepes pH 7.9, 10mM 
potassium chloride, 0.1mM EDTA pH 8.0, 0.1mM EGTA pH 8.0, 1mM DTT, 1x 
protease inhibitor cocktail (Roche, UK) and incubated on ice for fifteen minutes. 25 
µl of 10% NP-40 was added. The mixture was vortexed for 30 seconds and 
centrifuged for 45 seconds. Aliquots of the cytoplasmic extract supernatant were 
removed to Eppendorf tubes and snap frozen in liquid nitrogen. The pellet was 
resuspended in 50 µl of Buffer C (20mM Hepes pH 7.9, 400mM sodium chloride, 
1mM EDTA pH 8.0, 1mM EGTA pH 8.0, 1mM DTT, 5% glycerol, 1x protease 
inhibitor cocktail) and incubated for 1 hour at 4°C with vigorous shaking. The 
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mixture was then centrifuged at 13,000 rpm for thirty seconds. Aliquots of the 
nuclear extract were removed to Eppendorf tubes and snap frozen in liquid nitrogen. 
Nuclear and cytoplasmic extracts were stored at − 20°C. When probing for 
phosphorylated proteins, phosphotase inhibitor cocktail (10 mM sodium flouride, 10 
mM sodium molybdate, 10 mM β-glycerophosphate, 10 mM sodium vanadate and 
10 mM p nitrophenyl phosphate) was added to buffer A. 
2.6.4 Determining the Protein Concentration of Cell Extracts using the 
Bradford Assay. 
A protein assay is used to measure the protein concentration of a solubilised protein. 
This measure is then used to ensure that equal amounts of protein are analysed when 
performing quantitative comparisons of protein expression between different 
experimental conditions, for instance in Western Blotting. The dye-binding assay 
used here is based on the method of Bradford (Bradford, 1976), and depends on the 
fact that a differential colour change occurs in response to varying protein 
concentrations. The intensity of the colour can be quantified by measuring the 
absorbance at 595 nm using a spectrophotometer. Comparison with a standard curve 
allows the protein concentration to be determined. 
A stock solution of protein assay dye reagent was prepared by diluting one part Bio-
Rad assay dye (BioRad, UK) with four parts distilled deionised water. A standard 
curve was prepared by measuring the absorbance at 595 nm of known concentrations 
of bovine serum albumin (BSA) (BioRad, UK). An aliquot (3 µl) of cell extract was 
added to 1 ml of stock solution and briefly vortexed. The mixture was incubated at 
room temperature for fifteen minutes and transferred to a cuvette. The absorbance of 
the cell extract was determined spectrophotometrically at 595 nm. The protein 
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concentration of the cell extract was calculated by comparison with the standard 
curve.  
2.7 Sodium Dodecyl Sulphate-polyacrylamide Gel Electrophoresis and Western 
Blotting. 
 
Protein expression in HepG2 cells was analysed using sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) and Western Blotting. Briefly, 
protein samples were denatured and coated with negative charge. The samples were 
loaded onto wells in a polyacrylamide gel. The gel was placed into the SDS-PAGE 
apparatus, the wells were positioned at the negative electrode side. Application of a 
voltage pulls the samples towards the positively charged electrodes. Since smaller 
proteins move more easily through the gel (have a greater electrophoretic mobility), 
the proteins were size-fractionated. A molecular ladder was run alongside the 
samples to determine size (kDa). The proteins fixed as bands in the gel matrix were 
transferred to a membrane. The membrane was then probed using a primary antibody 
raised against the protein of interest. The antibody-antigen complex was detected 
using a secondary antibody-enzyme conjugate. The membrane was then incubated in 
a substrate solution, and the conjugated enzyme catalyzed the conversion of the 
substrate into a visible product that precipitated at the blot site.  The intensity of the 
signal in different samples was compared using densitometry analysis, and changes 
in protein expression between different experimental conditions were quantified.  
2.7.1 Preparation of Samples for SDS-PAGE. 
Before the cell extracts were applied to the gel they were incubated with SDS sample 
buffer. This contains SDS which breaks up hydrophobic interactions to denature the 
proteins, and coats the proteins with negative charge; and β-mercaptoethanol which 
further denatures the proteins by reducing the disulfide bonds. 
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Using the results from the protein assay, the volume of cell extract equivalent to     
20 µg of protein was calculated using Excel. This was mixed with sterile water to a 
total volume of 10 µl. An equal volume of SDS sample buffer (95% Laemmli sample 
buffer (BioRad Laboratories Inc. UK), 5% β-mercaptoethanol (BioRad Laboratories 
Inc. UK) was added. The samples were mixed by gently pipetting and incubated at 
room temperature for 10 minutes.  
2.7.2 Separation of the Proteins by Gel Electrophoresis. 
The proteins were separated by running on a 10% SDS-PAGE gel (resolving gel; 
10% acrylamide/Bis mix, 0.38 M Tris-HCl pH 8.8, 0.0001% SDS, 0.0001% APS, 
0.00005% TEMED in H2O. Stacking gel; 5% acrylamide/Bis mix, 0.125 M Tris-HCl 
pH 6.8, 0.0001% sodium dodecyl sulphate (SDS), 0.0001% ammonium persulphate 
(APS), 0.0001% TEMED in H2O) for 60 minutes at 150 V/50 mA in SDS running 
buffer (3g/l Tris Base, 14.4 g/l glycine, 1 g/l SDS) (Bio-Rad Mini Protean 3 Cell, 
Bio-Rad UK). A molecular marker was run alongside the protein samples (Bio-Rad 
Precision Plus Protein Kaleidoscope standards, Bio-Rad, UK). 
2.7.3 Transferring the Protein to a Polyvinylidene Fluoride Membrane. 
The proteins were transferred from the gel onto a polyvinylidene fluoride (PVDF) 
membrane (Immobilon-P membrane, Millipore Corp.) using a semi-dry electro-
blotting apparatus (TRANS-BLOT
®
,
 
Bio-Rad, UK). 
The apparatus was wiped down with distilled water then methanol before use. Filter 
paper was pre-soaked in transfer buffer (3.0 g/l Tris base, 14.4 g/l glycine). The 
PVDF membrane was pre-soaked in methanol for 30 seconds, water for two minutes 
and transfer buffer for five minutes. A sandwich of thick filter paper (BioRad 
Laboratories Inc. UK), gel, PVDF membrane and another layer of thick filter paper 
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were placed onto the anode plate of the electro-blotting apparatus. A roller was used 
to remove air bubbles. The top of the apparatus (the cathode plate) was put on, and 
the apparatus was run at 60 mV for 30 minutes (45 minutes for two gels). When the 
current was applied, the proteins were electrophoresed out of the gel and onto the 
membrane. 
2.7.4 Blocking the Membrane. 
In order to prevent non-specific binding of the primary antibody to membrane 
proteins, the membrane was blocked using a dilute protein solution. The proteins in 
the solution attach to the membrane proteins, where cell proteins have not attached. 
During optimisation of Western Blotting, different blocking agents at varying 
concentrations were tested, and the blocking protocol varies somewhat for the 
different proteins that were investigated. See Table 2.1 for details. Membranes were 
incubated in blocking buffer for 1 hour at room temperature with gentle agitation. 
Following blocking, the membranes were washed 3 times for 5 minutes in wash 
buffer (200 mM Tris-HCl pH 7.6, 29.2 g/l NaCl, 0.05% Tween 20). 
2.7.5 Incubation of the Membrane with Primary and Secondary Antibody. 
Primary antibodies bind to specific antigens with high affinity. Secondary antibodies 
bind to a primary antibody, according to the host species in which the primary was 
raised. Secondary antibodies can be conjugated to reporter enzymes to allow 
detection and quantification of protein in a sample. 
The membrane was placed in a Falcon tube, with the protein side facing inwards. 
Primary antibody solution in wash buffer (5 ml) was added, and the membrane was 
incubated overnight with rotation at 4°C.  The membrane was then washed twice 
quickly, once for fifteen minutes and twice for five minutes in large volumes of wash 
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buffer. The primary antibodies, the antibody dilutions and the diluent used are 
detailed in Table 2.1. 
The membrane was placed in a Falcon tube, with the protein side facing inwards. An  
aliquot of secondary antibody solution (5 ml) was added, and the membrane was 
incubated for one hour at room temperature. The membrane was then washed twice 
quickly, once for fifteen minutes and twice for five minutes in large volumes of wash 
buffer. The secondary antibodies, the antibody dilutions and the diluent used are 
detailed in Table 2.1. 
2.7.6 Visualising the protein. 
Enhanced chemiluminescence (ECL) was used to visualise the protein bands 
(Amersham ECL Plus™ Western Blotting Detection Reagents, GE Healthcare, UK). 
Combined horseradish peroxidise (HRP) and peroxide catalysed oxidation of the 
Lumigen PS-3 substrate produces a chemiluminescent signal, which can be captured 
when the membrane is exposed to autoradiography film (HyperfilmTM ECL, GE 
Healthcare, UK).  
The detection reagents were equilibrated to room temperature before use, and made 
up as specified by the manufacturers to a volume of 1 ml solution/10 cm
2 
membrane. 
Any excess wash buffer was drained off the PVDF membrane. Detection mix was 
pipetted onto the membrane to thoroughly soak. After five minutes, the detection mix 
was wicked from the membrane, and the membrane was wrapped in saran wrap. The 
membrane was placed inside a Kodak cassette. Under darkroom conditions, the 
membrane was exposed to autoradiography film. The film was developed using an 
automatic developer (XoGraph Healthcare Ltd., UK). 
 
 63 
2.7.7 Stripping and Reprobing the Membrane. 
PVDF membranes can be stripped of signal, primary and secondary antibodies and 
the same blot can be reprobed for a different protein. In order to quantitatively 
evaluate protein expression between samples, the chemiluminescent signal from the 
target protein was compared to that of a structural protein on the same blot. The 
amount of structural protein is not expected to change between samples. This 
provides an internal standard and allows normalisation and standardisation of sample 
load. In addition, membranes probed for a specific phosphorylated protein were 
stripped and reprobed for total levels of the same protein, in order that the ratio of 
phosphorylated to total protein could be determined. 
The blot was washed three times for five minutes, and incubated in stripping buffer 
(Restore Western Blot Stripping Buffer, Thermo Fisher Scientific Inc.) for fifteen 
minutes with shaking at 37°C. The wash was repeated. Checks were carried out to 
ensure complete removal of primary and secondary antibodies, after which the next 
antibody detection was carried out (as from 2.6.4). 
2.7.8 Densitometry Analysis. 
The blot was analysed using densitometry. This technique measures the intensity of 
the band, and thus the amount of protein transferred, in terms of optical density. 
Densitometry analysis was carried out on both the target protein and the structural 
protein, using FlouroChem software (Alpha Innotech, USA) and the amount of target 
protein was normalised to the amount of structural protein. This corrects for any 
difference in protein loading or protein transfer between the samples. Quantitative 
comparisons can then be made between different experimental samples. 
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* Non-fat dried milk powder diluted in wash buffer. 
† Bovine serum albumin diluted in wash buffer. 
 
Table 2.1 Primary and Secondary Antibodies used for Western Blotting. 
This table details the blocking and antibody protocols for all Western Blotting.
 
Protein of 
interest 
 
Intracellular 
location 
 
Blocking  
protocol 
 
 
1° antibody and antibody dilution  
 
 
2° antibody and antibody dilution  
 
HIF-1α 
 
Nuclear 
 
10% milk*  
CS #3716 (Cell Signaling Tech., MA) 
1:250 in wash buffer 
CS#7074 Anti-rabbit IgG, HRP-linked (Cell Signaling Tech., MA) 
1:1000  in 1% milk*  
 
NFkB 
 
Nuclear 
 
10% milk*  
ab7971   (abcam®, UK) 
1:400  in wash buffer 
CS#7074 Anti-rabbit IgG, HRP-linked (Cell Signaling Tech., MA) 
1:1000  in 1% milk* 
 
Lamin B1 
 
Nuclear 
 
10% milk*  
ab16048 (abcam®, UK) 
1:5000  in wash buffer 
CS#7074 Anti-rabbit IgG, HRP-linked (Cell Signaling Tech., MA) 
1:5000  in 1% milk* 
 
S6k 
 
Cytoplasmic 
 
5% BSA†  
ab24490 (abcam®, UK) 
1:400  in wash buffer 
CS#7074 Anti-rabbit IgG, HRP-linked (Cell Signaling Tech., MA) 
1:5000  in 1% BSA† 
 
phospho S6k 
 
Cytoplasmic 
 
5% BSA† 
ab2571 (abcam®, UK) 
1:250 in 5% BSA† 
CS#7074 Anti-rabbit IgG, HRP-linked (Cell Signaling Tech., MA) 
1:1000 in 1% BSA 
 
Akt 
 
Cytoplasmic 
 
10% milk 
CS#9272 (Cell Signaling Tech., MA) 
1:1000 
CS#7074 Anti-rabbit IgG, HRP-linked (Cell Signaling Tech., MA) 
1:1000 in 1% milk 
 
phospho Akt 
 
Cytoplasmic 
 
5% BSA† 
CS#4058 (Cell Signaling Tech., MA) 
1:1000 in 5% BSA† 
CS#7074 Anti-rabbit IgG, HRP-linked (Cell Signaling Tech., MA) 
1:1000 in 1% BSA 
 
B actin 
 
Cytoplasmic 
 
5% BSA†  
ab8226 (abcam®, UK) 
1:2500  
ab6789 Anti-mouse IgG, HRP-linked 
1:5000 in 1% BSA† 
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2.8 In Vivo Animal Study. 
 
The first step in in vivo pre-clinical testing of anti-cancer compounds typically 
involves the subcutaneous injection of human cancer cells into immunocompromised 
mice, thereby creating an ectopic xenograft tumour model. Assessment of tumour 
growth can be carried out externally using a caliper, and tumours can be excised post 
mortem for immunohistochemical analysis. 
In this study the anti-cancer activity of doxorubicin-eluting beads, rapamycin eluting 
beads, rapadox eluting beads, oral rapamycin and combinations thereof was 
investigated in an ectopic xenograft human HCC mouse model. The experiments were 
carried out by EPO-GmbH under approved conditions. 
2.8.1 Animal Species. 
National Medical Research Institute (NMRI) nu/nu mice (Taconic M & B, Ry, DK), 
adult females weighing 20 g. These animals lack a thymus, and are unable to produce 
T-cells, so are immunodeficient. All experiments were approved by LAGeSo (State 
Office of Health and Social Affairs), Berlin. 
2.8.2 HCC Xenograft Model. 
The HCC cell line used was the HepG2 cell line. Cells were cultivated in vitro and 
harvested prior to implantation. 
2.8.3 Preparation of Beads for Injection. 
DC Bead microspheres (Biocompatibles UK) were loaded to a doxorubicin 
concentration of 25 mg/ml, a rapamycin concentration of 20 mg/ml, and a combination 
of both.  The beads were then lyophilised and gamma sterilised (Isotron PLC, UK) and 
stored in vials containing 1 ml of bead. 
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A 3 ml aliquot of alginate solution (0.6% w/v, CellMed) was added to the vial, and 
mixed on a whirlimixer to hydrate the beads. The alginate acts as a viscosity 
modulator and stabilises the beads in situ post injection. 
2.8.4 Preparation of Rapamycin for Gavage. 
Rapamycin powder was fully dissolved in ethanol to a concentration of 10 mg/ml. This 
was then diluted to 0.01 mg/ml in drinking water. A dose of 1 mg/kg/day was 
administered by gavage. 
2.8.5 Treatment Protocol. 
Mice were randomly assigned to one of 7 treatment groups A – G, n = 3 per group. 1 x 
10
7 
HepG2 cells from culture were transplanted subcutaneously at day 0. Treatment 
started when the tumours were of palpable size, = day 23. 100 µl of bead/alginate mix 
was applied adjacent to the tumour by direct injection. Oral rapamycin was 
administered daily by gavage. See Table 2.2. 
2.8.6 Assessment of Tumour Growth. 
Tumour growth was measured twice per week in two perpendicular diameters using 
a caliper. Tumour volume was calculated using the ellipsoid volume formula where 
tumour volume = π/6 x length x width2. This method has previously been shown to 
be the most accurate method for assessing the volume of subcutaneous tumours in 
nude mice (Tomayko and Reynolds, 1989). 
2.8.7 Assessment of Toxic Effects. 
The mice were inspected regarding signs of toxicity and behavioural changes 
immediately after application of the beads, and then twice daily. Body weight change 
was used as a parameter for toxicity. Mouse body weight was determined twice per  
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Table 2.2 Treatment Protocol for In Vivo Study.  
This table summarises the treatment schedules for each experimental condition.
 
 
Group 
 
 
n 
 
 
DEB 
 
Oral 
rapamycin 
 
Volume of  injected 
alginate/DEB mix (ul) 
 
Amount of drug 
(mg/ml bead) 
 
Predicted maximum 
dose (mg) 
 
A 
 
3 
 
- 
 
- 
 
- 
 
- 
 
- 
 
B 
 
3 
 
Bland bead 
 
- 
 
100 
 
- 
 
0 
 
C 
 
3 
 
Doxorubicin 
 
- 
 
100 
 
25 
 
0.8 
 
D 
 
3 
 
Rapamycin 
 
- 
 
100 
 
20 
 
0.67 
 
E 
 
3 
 
Rapadox 
 
- 
 
100 
 
 
25 (dox), 20 (rapa) 
 
 
0.8 (dox), 0.67 (rapa) 
 
F 
 
3 
 
- 
 
1 mg/kg/day 
 
- 
 
- 
 
- 
 
G 
 
3 
 
Doxorubicin 
 
1 mg/kg/day 
 
100 
 
25 
 
0.8 
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week. Mice were euthanized at a moribund stage, or if the tumour was larger than 10% 
of total body weight. 
2.8.8 Autopsies. 
The tumours were removed and weighed. The tumours were shock frozen for future 
immunohistochemistry. 
2.9 Statistical Analysis. 
 
Statistical analysis was carried out using Excel and Minitab. For comparisons where 
data was normally distributed, T tests were applied. Where data was not normally 
distributed, the non-parametric equivalent, the Wilcoxon Signed-Rank test, was used. 
Where more than one comparison was carried out on a data set, the Bonferroni 
correction was applied, whereby the α level is divided by the number of comparisons 
made.  
The α level defines the probability of making a Type I (false positive) error – i.e. 
rejecting the null hypothesis if it is true. Conventionally, α is set at 0.05, so that there 
is only a 5% chance of wrongly rejecting the null hypothesis. If more than one 
comparison is made within a data set the chance of making a Type I error increases. 
The Bonferroni correction is used when more than one statistical test is being 
performed simultaneously. The level of α is divided by the number of comparisons 
being made. If the p-value is less than or equal to α/n then the null hypothesis can be 
rejected. This maintains the family wise error rate within the data set, and the 
experiment wide critical value remains equal to α. The Bonferroni correction is fairly 
conservative, and decreases the chance of making a Type I error, but increases the 
chance of making a Type II error. 
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For analysing the data generated from the in vivo experiments (Chapter 7), where all 
the data was normally distributed, analysis of variance was used. Post hoc Bonferroni 
pairwise comparisons were used to directly compare different treatments. 
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Chapter 3  
 
The Effects of Doxorubicin on HepG2 Cells Cultured In Vitro Under Normoxic 
and Hypoxic Conditions.  
 
3.1 Introduction. 
 
Tumour hypoxia is a positive factor for the growth of solid tumours, and is 
associated with malignant progression and a poor prognosis (Semenza, 2007a, Bos et 
al., 2003). The hypoxic phenotype is implicated in drug resistance and tumour 
progression (Semenza, 2007a, Semenza, 2000b, Vaupel and Harrison, 2004, Tomida 
and Tsuruo, 1999). TACE using the chemotherapeutic doxorubicin is the current 
standard of care for unresectable HCC. Doxorubicin-loaded DEB-TACE offers a 
survival advantage over cTACE and is becoming more widely used. There is, 
however, a concern that hypoxia which occurs as a result of embolisation therapy 
allows the escape of tumour cells from necrosis, and results in clonal selection for 
hypoxia-resistant cells and cells with a more aggressive phenotype. Recent reports 
suggest that doxorubicin can, to some extent, block hypoxia-induced survival 
pathways. 
3.1.1 Doxorubicin. 
Doxorubicin is an anthracycline antibiotic which, despite the lack of a clear survival 
benefit, has become the standard of care for inoperable HCC.  
The cytotoxicity of doxorubicin against cancer cells is attributed to a number of 
different mechanisms, including - the intercalation of the drug in the DNA of 
dividing cells and the consequent inhibition of DNA and RNA synthesis; the activity 
of doxorubicin as a topoisomerase II poison; the generation of free oxygen radicals 
which damage DNA and cell membranes; and direct interaction with cell surface 
proteins (Aubel-Sadron and Londos-Gagliardi, 1984, Keizer et al., 1990, Zunino and 
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Capranico, 1990, Tritton, 1991, Pommier et al., 2010). The cytotoxicity of 
doxorubicin towards HepG2 cells has been demonstrated numerous times and 
continues to be demonstrated (Boulin et al., 2011). 
3.1.2 Doxorubicin and HIF-1. 
There have been reports that doxorubicin inhibits angiogenesis in HCC (Piguet et al., 
2008) and in other cancers (Drevs et al., 2004, Quesada et al., 2005). The 
transcription factor HIF-1 induces angiogenesis as a response to hypoxia. Inhibition 
of HIF-1 signalling by Topoisomerase I poisons (Rapisarda et al., 2004a, Beppu et 
al., 2005, Puppo et al., 2008, Sapra et al., 2011a, Choi et al., 2009) and 
Topoisomerase II poisons (Yamazaki et al., 2006, Creighton-Gutteridge et al., 2007, 
Dai et al., 2010, Choi et al., 2009, Chang et al., 2003, Xie et al., 2007) has been 
reported in a number of different cell lines.  
Since we started this investigation, one publication has shown that doxorubicin 
inhibits the transcription of HIF-mediated genes by blocking the binding of HIF-1 to 
the promoter region of hypoxia response genes in Hep3B cells and reduces tumour-
derived angiogenesis and tumour vascularisation in xenograft murine tumour models 
(Lee et al., 2009a).  
This concurs with findings that doxorubicin results in the downregulation of VEGF 
but not HIF-1α in HepG2 tumour models (Liu et al., 2008a). Doxorubicin was also 
found to inhibit both HIF-1 activity and VEGF expression in human ovarian cancer 
cells (Duyndam et al., 2007). The anthracyclines cinerubin and aclarubicin inhibit 
hypoxic induction of VEGF in HepG2 cells (Yamazaki et al., 2006). However, the 
same study reported no effect from doxorubicin on either HIF-1 transcriptional 
activity or VEGF expression (Yamazaki et al., 2006).  
 72 
These findings provide a rationale for the anti-angiogenic effects of anthracycline 
therapy that have previously been reported and suggest that doxorubicin can, to some 
extent, block the cell survival pathways activated by hypoxia. Since chemoresistance 
to doxorubicin can be attributed in part to the phenotypic alterations that occur in 
response to hypoxia, there is a need to investigate the cytotoxicity of doxorubicin to 
tumour cells cultured under hypoxic conditions in vitro, and the effect of doxorubicin 
treatment on cell survival pathways induced by hypoxia. 
3.1.3 Hypoxia, Doxorubicin and NFkB. 
Cellular stresses such as hypoxia and doxorubicin-induced DNA damage have been 
reported to activate the transcription factor NFkB (REFS). NFkB regulates the 
transcription of HIF-1α.  
3.1.4 Phosphorylation of S6K and Akt.  
The PI3K/Akt/mTOR pathway regulates cellular responses to nutrients, growth 
factors and stress. Activation of the pathway results in increased cell proliferation 
and inhibition of apoptosis. Phosphorylation of Akt via PI3K is at thr
308
, and Akt 
directly phosphorylates mTORC1 at ser
2448
. Akt lies upstream of mTOR, and is 
negatively regulated by PTEN. Akt is positively regulated by mTORC2 via 
phosphorylation at ser
473
. In order to conserve cellular energy, hypoxia 
downregulates mTORC1 activation via a different pathway involving the 
upregulation of REDD1 (Brugarolas et al., 2004). In cells with mutations to PTEN 
this mechanism may be dysregulated.  
Activated mTORC1 phosphorylates S6K at thr
389
. This then increases the number of 
ribosomal components involved in protein translation, and thus affects the rate of 
global protein synthesis. 
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3.2 Aims. 
 
• To study the effects of doxorubicin in a time and concentration dependent manner 
on the viability of HepG2 cells under normoxic and hypoxic conditions.  
• To evaluate the response of HIF-1α, NFkB, S6K and Akt expression in HepG2 
cells under normoxic and hypoxic conditions.  
3.3 Objectives. 
 
Here the chemosensitivity of HepG2 cells cultured under normoxic and hypoxic 
conditions to the application of clinically relevant concentrations of doxorubicin 
hydrochloride was investigated. Cell viability was estimated using the CellTiter 96
® 
Aqueous One Solution Proliferation Assay. Hypoxic culture conditions (oxygen = 
1%) were established using the Coy Hypoxic Glove box, as described in the Methods 
section. 
SDS-PAGE and Western Blotting were used to quantify the nuclear accumulation of 
HIF-1α and p50 NFkB; and the phosphorylation status of p70 S6K and Akt. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 74 
3.4. Results. 
3.4.1 Cell Viability at 24 Hours. 
The only doxorubicin treatment that had a significant effect at 24 hours was the  
25 µM doxorubicin treatment, which significantly decreased the viability of cells 
cultured under normoxic conditions (p = 0.009, α/n = 0.01) (Figure 3.1, Table 3.3). 
Cells cultured under hypoxic conditions were resistant to all doxorubicin 
concentrations at the 24 hour time point (Figure 3.1, Table 3.3 and 3.4). 
3.4.2 Cell Viability at 48 Hours. 
After 48 hours, 10 µM doxorubicin significantly decreased cell viability in cells 
cultured under normoxic conditions and in cells cultured under hypoxic conditions 
when compared to untreated controls (p = <0.001 and p = <0.001 respectively, α/n = 
0.01). Furthermore, the 25 µM doxorubicin treatment significantly decreased cell 
viability in normoxic cells and in hypoxic cells control (p = <0.001 and p = 0.008 
respectively, α/n = 0.01). However, whilst the 50 µM doxorubicin treatment 
significantly decreased cell viability in normoxic cells (p = <0.001, α/n = 0.01), it 
had no significant effect on cell viability of hypoxic cells (Figure 3.2 and Tables 3.5 
and 3.6). Under hypoxic conditions, 10 µM doxorubicin was more effective at 
decreasing cell viability than 25 µM (p = <0.001, α/n = 0.01) (Table 3.6).  
Both 10 µM and 25 µM doxorubicin treatments were more effective at decreasing 
cell viability in normoxic cells than in hypoxic cells (p = 0.019 and p = 0.005 
respectively, α/n = 0.025) (Table 3.7). 
3.4.3 Cell Viability at 72 Hours.  
After 72 hours, 5 µM doxorubicin significantly decreased cell viability in cells 
cultured under normoxic conditions when compared to untreated controls (p = 
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<0.001, α/n = 0.01). 10 µM doxorubicin significantly decreased cell viability in cells 
cultured under normoxic conditions and in cells cultured under hypoxic conditions 
when compared to untreated controls (p = <0.001 and p = <0.001 respectively, α/n = 
0.01). The 25 µM doxorubicin treatment significantly decreased cell viability in 
normoxic cells (p = <0.001, α/n = 0.01) but had no significant effect on cell viability 
of hypoxic cells. However, 50 µM doxorubicin significantly decreased cell viability 
in normoxic cells and in hypoxic cells when compared to control (p = <0.001 and p = 
0.002 respectively, α/n = 0.01) (Figure 3.3 and Tables 3.8 and 3.9). Under hypoxic 
conditions, 10 µM doxorubicin was more effective at decreasing cell viability than 
25 µM (p = 0.007, α/n = 0.01) (Table 3.8 and 3.9).  
A 10 µM doxorubicin treatment was significantly more effective at decreasing cell 
viability in normoxic cells than in hypoxic cells (p = 0.014, α/n = 0.025) (Table 
3.10). 
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Figure 3.1 The Effects of 24 Hours Exposure to Doxorubicin on Viability of 
HepG2 Cells Cultured Under Normoxic and Hypoxic Conditions.  
1 x 10
4 
cells/200 µl were added to each well of a 96-well plate and incubated 
overnight at 37°C under normoxic conditions. The following day, the plates were 
removed to either normoxic or hypoxic conditions and exposed to doxorubicin, 6 
replicate wells for each concentration. The plates were incubated under normoxic or 
hypoxic conditions for 24 hours. Cell viability was measured using MTS assay and 
normalised to untreated control. Data points represent mean of 6 separate 
experiments ± standard error of the mean, except for 5 µM concentrations which 
represent a mean of 3 separate experiments ± standard error of the mean and 50 µM 
concentrations which represent a mean of 4 separate experiments ± standard error of 
the mean. * denotes significant decrease in cell viability compared to control, where 
p = < 0.01, α/n = 0.01. 
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Figure 3.2 The Effects of 48 Hours Exposure to Doxorubicin on Viability of 
HepG2 Cells Cultured under Normoxic and Hypoxic Conditions. 
1 x 10
4 
cells/200 µl were added to each well of a 96-well plate and incubated 
overnight at 37°C under normoxic conditions. The following day, the plates were 
removed to either normoxic or hypoxic conditions and exposed to doxorubicin, 6 
replicate wells for each concentration. The plates were incubated under normoxic or 
hypoxic conditions for 48 hours. Cell viability was measured using MTS assay and 
normalised to untreated control. Data points represent a mean of 6 separate 
experiments ± standard error of the mean for all doxorubicin concentrations, except 
for 5 µM concentrations which represent a mean of 3 separate experiments ± 
standard error of the mean and 50 µM concentrations which represent mean of 4 
separate experiments ± standard error of the mean. * denotes significant decrease in 
cell viability compared to control, where p = < 0.01, α/n = 0.01; ** denotes 
significant decrease in cell viability compared to control, where p = < 0.001, α/n = 
0.01; # denotes significant decrease in cell viability compared to control, where p = < 
0.025, α/n = 0.025. 
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Figure 3.3 The Effects of 72 Hours Exposure to Doxorubicin on Viability of 
HepG2 Cells Cultured Under Normoxic and Hypoxic Conditions.  
1x10
4 
cells/200 µl were added to each well of a 96-well plate and incubated 
overnight at 37°C under normoxic conditions. The following day, the plates were 
removed to either normoxic or hypoxic conditions and exposed to doxorubicin, 6 
replicate wells for each concentration. The plates were incubated under normoxic or 
hypoxic conditions for 72 hours. Cell viability was estimated using MTS assay and 
normalised to untreated control. Data points represent a mean of 6 separate 
experiments ± standard error of the mean, except for 5 µM concentrations which 
represent a mean of 3 separate experiments ± standard error of the mean and 50 µM 
concentrations which represent mean of 4 separate experiments ± standard error of 
the mean. * denotes significant decrease in cell viability compared to control, where 
p = < 0.01, α/n = 0.01.** denotes significant decrease in cell viability compared to 
control, where p = <  0.001, α/n = 0.01. # denotes significant decrease in cell 
viability compared to control, where p = < 0.025, α/n = 0.025. 
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Figure 3.4 Cell Proliferation in Normoxic Compared to Hypoxic Cells.  
1 x 10
4 
cells in 200 µl aliquots were added to each well of a 96-well plate and 
incubated overnight at 37°C under normoxic conditions. The following day, the 
plates were removed to either normoxic or hypoxic conditions and the media was 
replenished. The plates were incubated under normoxic or hypoxic conditions for 24, 
48 and 72 hours. Cell viability was measured using MTS assay and normalised to 
cell viability at 0 hours. Data points represent a mean of 6 separate experiments ± 
standard error of the mean. * denotes significant difference, p = < 0.05, using a two 
sample one tailed T test. 
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3.4.4 Statistical Analysis. 
 
 
Comparison 
p value 
normality 
 
N.D. 
 
Test used 
 
p value 
 
α/n 
 
Significant 
0 vs.  5 µM 0.109 Yes One sample T 0.019 0.0125 No 
0 vs. 10 µM 0.299 Yes One sample T 0.082 0.0125 No 
0 vs. 25 µM 0.606 Yes One sample T 0.009 0.0125 Yes 
0 vs. 50 µM 0.195 Yes One sample T 0.057 0.0125 No 
 
Table 3.1 Comparisons for Factor [drug] after 24 Hours of Treatment under 
Normoxic Culture Conditions.  
For each doxorubicin concentration, the mean % cell viability compared to control 
readings from each of the replicate experiments were subjected to a normality test. 
For normally distributed (N.D.) data, a one sample T test was carried out, using a one 
tailed comparison, 100 vs. < 100. The significance level was adjusted for multiple 
tests using the Bonferroni correction, whereby the significance level is equal to α/n, 
where n = the number of tests carried out.  
 
 
 
 
Comparison 
p value 
normality 
 
N.D. 
 
Test used 
 
p value 
 
α/n 
 
Significant 
0 vs.  5 µM 0.332 Yes One sample T 0.085 0.0125 No 
0 vs. 10 µM 0.948 Yes One sample T 0.124 0.0125 No 
0 vs. 25 µM 0.788 Yes One sample T 0.177 0.0125 No 
0 vs. 50 µM 0.029 No 
One sample 
Wilcoxon 0.100 0.0125 No 
 
Table 3.2 Comparisons for Factor [drug] after 24 Hours of Treatment under 
Hypoxic Culture Conditions. 
For each doxorubicin concentration, the mean % cell viability compared to control 
readings from each of the replicate experiments were subjected to a normality test. 
For normally distributed data, a one sample T test was carried out, using a one tailed 
comparison, 100 vs. < 100. For non-normally distributed data, a one sample 
Wilcoxon Rank test was carried out, using a one tailed comparison, 100 vs.<100. The 
significance level was adjusted for multiple tests using the Bonferroni correction, 
whereby the significance level is equal to α/n, where n = the number of tests carried 
out.  
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Comparison 
p value 
normality 
 
N.D. 
 
Test used 
 
p value 
 
α/n 
 
Significant 
0 vs.  5 µM 0.065 Yes One sample T 0.012 0.010 No 
0 vs. 10 µM 0.479 Yes One sample T <0.001 0.010 Yes 
0 vs. 25 µM 0.136 Yes One sample T <0.001 0.010 Yes 
0 vs. 50 µM 0.068 Yes One sample T <0.001 0.010 Yes 
10 vs. 25 µM 0.017 No 
One sample 
Wilcoxon 
One sample T 
 0.030 0.010 No 
 
Table 3.3 Comparisons for Factor [drug] after 48 Hours of Treatment under 
Normoxic Culture Conditions.  
For each doxorubicin concentration, the mean % cell viability compared to control 
readings from each of the replicate experiments were subjected to a normality test. 
For normally distributed data, a one sample T test was carried out, using a one tailed 
comparison, 100 vs. < 100. For comparisons between different doxorubicin 
concentrations, a normality test was carried out on the differences between the mean 
% cell viability readings (differences = 25 µM - 10 µM). For non-normally 
distributed data, a one sample Wilcoxon Rank test was carried out, using a one tailed 
comparison, 0 vs.>0. The significance level was adjusted for multiple tests using the 
Bonferroni correction, whereby the  significance level is equal to α/n, where n = the 
number of tests carried out.  
 
 
Comparison 
p value 
normality 
 
N.D. 
 
Test used 
 
p value 
 
α/n 
 
Significant 
0 vs.  5 µM 0.606 Yes One sample T 0.029 0.010 No 
0 vs. 10 µM 0.230 Yes One sample T <0.001 0.010 Yes 
0 vs. 25 µM 0.117 Yes One sample T 0.008 0.010 Yes 
0 vs. 50 µM 0.456 Yes One sample T 0.018 0.010 No 
10 vs. 25 µM 0.179 Yes One sample T <0.001 0.010 Yes 
 
Table 3.4 Comparisons for Factor [drug] after 48 Hours of Treatment under 
Hypoxic Culture Conditions.  
For each doxorubicin concentration, the mean % cell viability compared to control 
readings from each of the replicate experiments were subjected to a normality test. 
For normally distributed data, a one sample T test was carried out, using a one tailed 
comparison, 100 vs. < 100. For comparisons between different doxorubicin 
concentrations, a normality test was carried out on the differences between the mean 
% cell viability readings (differences = 25 µM - 10 µM). For normally distributed 
data, a one sample T test was carried out, using a one tailed comparison, 0 vs.>0. The 
significance level was adjusted for multiple tests using the Bonferroni correction, 
whereby the  significance level is equal to α/n, where n = the number of tests carried 
out. 
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Comparison 
p value 
normality 
 
N.D. 
 
Test used 
 
p value 
 
α/n 
 
Significant 
0 vs.  5 µM 0.591 Yes One sample T 0.010 0.010 Yes 
0 vs. 10 µM 0.429 Yes One sample T <0.001 0.010 Yes 
0 vs. 25 µM 0.380 Yes One sample T <0.001 0.010 Yes 
0 vs. 50 µM 0.520 Yes One sample T <0.001 0.010 Yes 
10 vs. 25 µM 0.177 Yes One sample T 0.029 0.010 No 
 
Table 3.5 Comparisons for Factor [drug] after 72 Hours of Treatment under 
Normoxic Culture Conditions.  
For each doxorubicin concentration, the mean % cell viability compared to control 
readings from each of the replicate experiments were subjected to a normality test. 
For normally distributed data, a one sample T test was carried out, using a one tailed 
comparison, 100 vs. < 100. For comparisons between different doxorubicin 
concentrations (differences = 25 µM – 10 µM), a normality test was carried out on 
the differences between the mean % cell viability readings. For normally distributed 
data, a one sample T test was carried out, using a one tailed comparison, 0 vs. > 0. 
The significance level was adjusted for multiple tests using the Bonferroni 
correction, whereby the  significance level is equal to α/n, where n = the number of 
tests carried out.  
 
 
Comparison 
p value 
normality 
 
N.D. 
 
Test used 
 
p value 
 
α 
 
Significant 
0 vs.  5 µM 0.067 Yes One sample T 0.106 0.010 No 
0 vs. 10 µM 0.059 Yes One sample T <0.001 0.010 Yes 
0 vs. 25 µM 0.035 No 
One sample 
Wilcoxon 
0.030 0.010 No 
0 vs. 50 µM 0.180 Yes One sample T 0.002 0.010 Yes 
10 vs. 25 µM 0.098 Yes One sample T 0.007 0.010 Yes 
 
Table 3.6 Comparisons for Factor [drug] after 72 Hours of Treatment under 
Hypoxic Culture Conditions.  
For each doxorubicin concentration, the mean % cell viability compared to control 
readings from each of the replicate experiments were subjected to a normality test. 
For normally distributed data, a one sample T test was carried out, using a one tailed 
comparison, 100 vs. <100. For non-normally distributed data, a one sample 
Wilcoxon Rank test was carried out, using a one tailed comparison, 100 vs. < 100. 
For comparisons between different doxorubicin concentrations, a normality test was 
carried out on the differences between the mean % cell viability readings (differences 
= 25 µM – 10 µM). For normally distributed data, a one sample T test was carried 
out, using a one tailed comparison, 0 vs.>0. The significance level was adjusted for 
multiple tests using the Bonferroni correction, whereby the  significance level is 
equal to α/n, where n = the number of tests carried out.  
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Comparison 
 
[Dox] 
p value 
normality 
 
N.D. 
 
Test used 
p 
value 
 
α 
 
Significant 
Normoxic 
vs. hypoxic 
 
10 µM 
 
0.619 
 
Yes 
 
One sample T 
 
0.019 
 
0.025 
 
Yes 
Normoxic 
vs. hypoxic 
 
25 µM 
 
0.679 
 
Yes 
 
One sample T 
 
0.005 
 
0.025 
 
Yes 
 
Table 3.7 Comparisons for Culture Conditions after 48 Hours Exposure to 
Doxorubicin.  
The differences between the mean % cell viability readings for normoxic and 
hypoxic culture conditions at the same doxorubicin concentration were calculated 
(hypoxic – normoxic), and these differences were then subjected to a normality test. 
For normally distributed data, a one sample T test was carried out, using a one tailed 
comparison, 0 vs. > 0. The significance level was adjusted for multiple tests using the 
Bonferroni correction, whereby the  significance level is equal to α/n, where n = the 
number of tests carried out.  
 
 
 
 
 
 
Comparison 
 
[Dox] 
p value 
normality 
 
N.D. 
 
Test used 
p 
value 
 
α 
 
Significant 
Normoxic 
vs. hypoxic 
 
10 µM 
 
0.841 
 
Yes 
 
One sample T 
 
 0.014 
 
0.025 
 
Yes 
Normoxic 
vs. hypoxic 
 
25 µM 
 
0.531 
 
Yes 
 
One sample T 
 
 0.031 
 
0.025 
 
No 
 
Table 3.8 Comparisons for Culture Conditions after 72 Hours Exposure to 
Doxorubicin.  
The differences between the mean % cell viability readings for normoxic and 
hypoxic culture conditions at the same doxorubicin concentration were calculated 
(differences = hypoxic – normoxic), and these differences were then subjected to a 
normality test. For normally distributed data, a one sample T test was carried out, 
using a one tailed comparison, 0 vs. > 0. The significance level was adjusted for 
multiple tests using the Bonferroni correction, whereby the  significance level is 
equal to α/n, where n = the number of tests carried out.  
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3.4.5 50 µM Doxorubicin Attenuates Hypoxia Stimulated HIF-1α Nuclear 
Accumulation. 
To determine the effect of doxorubicin treatment on hypoxia stimulated nuclear 
accumulation of HIF-1α, SDS-PAGE and Western Blotting was carried out on 
nuclear extracts from HepG2 cells cultured under normoxic and hypoxic conditions, 
and exposed to drug concentrations as shown, see Figure 3.8. The results confirmed 
that 24 hours incubation under hypoxic conditions resulted in a significant increase 
in the amount of HIF-1α in the nucleus of HepG2 cells (p = 0.013, α/n = 0.017), see 
Figure 3.5 (Lane 4). Doxorubicin treatment of 10 µM had no significant effect on the 
nuclear accumulation of HIF-1α in hypoxic cells; see Figure 3.5 (Lane 5).  However, 
the 50 µM treatment significantly reduced the amount of HIF-1α detected in the 
nucleus (p = 0.003), see Figure 3.5 (Lane 6). The 10 µM and 50 µM doxorubicin 
treatments had no effect on the amount of HIF-1α detected in the nucleus of 
normoxic cells.  
3.4.6 Doxorubicin Activates NFkB p50 in Normoxic Cells. Hypoxia Activates 
NFkB p50, and Doxorubicin has no Effect on Hypoxia Stimulated Activation of 
NFkB p50. 
To determine the effect of doxorubicin treatment on hypoxia stimulated nuclear 
accumulation of NFkB p50, SDS-PAGE and Western Blotting was carried out on 
nuclear extracts from HepG2 cells cultured under normoxic and hypoxic conditions, 
and exposed to drug concentrations as shown, see Figure 3.6. Doxorubicin treatment 
of normoxic HepG2 cells increased the amount of p50 NFkB in the nucleus (Lanes 1, 
2 and 3). However, the increase was not significant (10 µM doxorubicin, p = 0.087; 
50 µM doxorubicin, p = 0.034, α = 0.017). Hypoxia also increased the amount of p50 
NFkB in the nucleus of HepG2 cells (p = 0.049, α = 0.017) (Lane 4). However, 
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doxorubicin treatment of hypoxic cells did not increase the amount of NFkB 
compared to the effects of hypoxia alone (Lanes 5 and 6). 
3.4.7 Effects of Doxorubicin on p70 S6K and p70 S6K (phospho T389). 
To determine the effect of doxorubicin treatment on S6K and the phosphorylation of 
S6K, SDS-PAGE and Western Blotting was carried out on cytoplasmic extracts from 
HepG2 cells cultured under normoxic and hypoxic conditions, and exposed to drug 
concentrations as shown, see Figure 3.7. Hypoxia had no effect on the ratio of 
phosphorylated S6K to total S6K (Panel A and Lanes 1 and 4). Similarly, 
doxorubicin had no effect on the ratio of phosphorylated S6K to total S6K in cells 
cultured under normoxic or hypoxic conditions (Panel A, Lanes 1 – 3 and 4 - 6). 
Levels of total S6K remained the same in normoxia and hypoxia and for all 
treatments (Panel B, Lanes 1 – 3 and 4 - 6). 
3.4.8 Effects of Doxorubicin on Akt and Akt (phospho ser473). 
Akt was observed to be activated in normoxic and hypoxic cells, see Figure 3.8. 
Hypoxia was not observed to have any effect on Akt phosphorylation (Lanes 1 and 
3). Doxorubicin treatment was not observed to have any effect on Akt 
phosphorylation in either normoxic or hypoxic conditions (Lanes 1 – 3 and 4 – 6).  
The total amount of Akt did not change in either normoxic or hypoxic conditions or 
with application of doxorubicin.  
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Figure 3.5 Nuclear Accumulation of HIF-1α after Doxorubicin Treatment. 
HepG2 cells were seeded onto T75 tissue culture flasks and incubated under 
normoxic conditions until 60% confluent. The cells were exposed to doxorubicin in 
normoxic or hypoxic conditions and incubated for 24 hours. The cells were harvested 
and nuclear extracts were prepared. Equal quantities of protein were fractionated on a 
10% SDS-PAGE gel. The proteins were transferred to a PVDF membrane and 
probed with anti-HIF-1α antibodies. Proteins were visualised using 
chemiluminescent reagents. The membrane was stripped and reprobed using 
antibodies against the nuclear house-keeping protein Lamin B1. Protein levels were 
quantified using densitometry analysis. The amount of HIF-1α was normalised to 
Lamin. Fold change compared to untreated hypoxic cells was calculated. Data shown 
represents mean of 4 independent experiments ± standard error of the mean for 
hypoxic cells, and mean of 3 independent experiments ± standard error of the mean 
for normoxic cells.  Statistical analysis was carried out using a one sample one tailed 
T test, 1 vs. < 1. * denotes a statistically significant result, p = < 0.05; ** denotes a 
statistically significant result, p = < 0.01. 
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Figure 3.6  Nuclear Accumulation of NFkB p50 after Doxorubicin Treatment.  
HepG2 cells were seeded onto T75 tissue culture flasks and incubated under 
normoxic conditions until the cells reached 60% confluence. The cells were exposed 
to doxorubicin in normoxic or hypoxic conditions and incubated for 24 hours. The 
cells were harvested and nuclear extracts were prepared. Equal quantities of protein 
were fractionated on a 10% SDS-PAGE gel. The proteins were transferred to a 
PVDF membrane and probed with anti-NFkB p50 antibodies. Proteins were 
visualised using chemiluminescent reagents. The membrane was stripped and 
reprobed using antibodies against the nuclear house-keeping protein Lamin B1. 
Protein levels were quantified using densitometry analysis. The amount of NFkB p50 
was normalised to Lamin. Fold change compared to untreated normoxic cells was 
calculated. Data shown represents mean of 3 separate experiments ± standard error of 
the mean. 
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Figure 3.7 Cytoplasmic p70 S6K and p70 S6K (phospho T389) after 
Doxorubicin Treatment of Normoxic and Hypoxic Cells.  
Cells were treated as described in Figure 6.1. Cytoplasmic extracts were prepared 
and fractionated on a 10% SDS-PAGE gel. The proteins were transferred to a PVDF 
membrane and probed with anti- p70 S6K (phospho T389) antibodies. Proteins were 
visualised and the membrane was stripped and reprobed using antibodies against 
total S6K, and antibodies against B actin. Protein levels were quantified using 
densitometry analysis. Ratio of p70 S6K (phospho T389) to total S6K was 
calculated, as was the amount of p70 S6K normalised to B actin. Data shown 
represents mean of 3 separate experiments ± standard error of the mean. 
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Figure 3.8 Cytoplasmic Akt and Akt (phospho ser473) after Doxorubicin 
Treatment of Normoxic and Hypoxic Cells.  
Cells were treated as described in Figure 6.1. Cytoplasmic extracts were prepared 
and fractionated on a 10% SDS-PAGE gel. The proteins were transferred to a PVDF 
membrane and probed with anti- Akt (phospho ser473) antibodies. Proteins were 
visualised and the membrane was stripped and reprobed using antibodies against 
total Akt, and antibodies against B actin. Protein levels were quantified using 
densitometry analysis. Ratio of Akt (phospho ser473) to total Akt was calculated, as 
was the amount of Akt normalised to B actin. Data shown represents mean of 3 
separate experiments ± standard error of the mean. 
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3.5 Discussion. 
3.5.1 Poor Treatment Outcomes Observed in Clinic are Likely Due to Sub-
Clinical Concentrations of Doxorubicin Reaching Tumour Cells. 
It has been shown here that doxorubicin concentrations of < 5 µM do not exhibit 
cytotoxic effects against normoxic or hypoxic HepG2 cells (Chapter 3). 
One explanation for the resistance to doxorubicin in the treatment of HCC after 
systemic administration is almost certainly due to the fact that intratumoural 
concentrations of doxorubicin are sub-clinical. Bolus administration of doses 
between 15 and 90 mg/m
2 
give a maximal initial plasma concentration of 
approximately 5 µM (Brenner et al 1985; Greene et al 1983), with most initial 
plasma concentrations lying between 1 – 2 µM (Muller et al 1993; Speth et al 1987; 
Benjamin et al 1993; Creasey et al 1976). However, there is a rapid decline after 1 
hour to plasma concentrations between 25 – 250 nM, which is the same range as 
achieved when doxorubicin is administered by continuous infusion (Greene et al; 
Muller et al; Speth et al). Experiments using three different tumour types in a mouse 
model showed that even when potentially lethal intraperitoneal doses of doxorubicin 
were administered, intratumoural concentrations of doxorubicin declined 
exponentially with distance from tumour blood vessels, with little or no doxorubicin 
detectable in many of the tumour cells (Primeau et al., 2005). In vitro data suggests 
that concentrations of 0.1 – 5 µM (Fornari et al 1996); at least 2 µM (Meriwether et 
al 1972); and in some cases up to 100 µM (Momparler et al 1976) are necessary for 
inhibition of DNA and RNA synthesis. As discussed in the introduction, different 
mechanisms of action are likely to be involved at different drug concentrations.  
The delivery of doxorubicin to tumour cells is vastly improved when cTACE is used. 
Intratumoural drug concentration has been reported to be 60% of the injected dose 
(Raoul et al., 1992). Concentrations of doxorubicin within tumour tissue are 10 to 
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100 times higher after cTACE than after systemic application (Konno, 1990). 
Doxorubicin release from DC Bead after DEB-TACE has been reported as 52% at 
day 28, and 89% at day 90 (Namur et al., 2010). Low plasma concentrations after 
DEB-TACE compared to TACE suggest that tumour retention of doxorubicin is high 
(Hong et al., 2006). The loco-regional delivery of doxorubicin to HCCs therefore 
ensures that the tumour cells experience effective doses of chemotherapeutic. 
3.5.2 Relevance of Results to DEB-TACE. 
Here we have shown in vitro that there is a therapeutic window for doxorubicin of 10 
µM (= 5.8 µg/ml), where the drug is cytotoxic to both normoxic and hypoxic HepG2 
cells. Concentrations above 10 µM do not show increased cytotoxicity in normoxic 
cells. However, in hypoxic cells, concentrations above 10 µM have decreased 
cytotoxicity, even up to a concentration x 5 higher. 
So how does this in vitro finding translate to the clinical setting? Three studies have 
looked at the release and tissue penetration of doxorubicin from DEBDOX in 
embolised swine liver. In one, using radioopaque beads, MicroCT and epiflourescent 
microscopy demonstrated that the concentration of doxorubicin into liver tissue at 1 
to 4 hours post TACE reached a maximum of 150 µM within a distance of 10 μm 
from the bead. Doxorubicin concentration decreased with increasing distance from 
the bead and concentrations >10μM extended out to 250-350 μm from the bead 
surface. Necrosis was observed 24 hours post TACE and coincided with areas of 
high drug exposure (Reddy et al., 2010). Another study used fluorescence 
microscopy to image the distribution of doxorubicin in liver tissue after embolisation 
using DEBDOX 100 – 300 µm in diameter. Doxorubicin was detected up to 200 µm 
from the bead surface 2 hours after embolisation had taken place (Dreher et al., 
2009). In another study, livers were sampled at day 28 and day 90 post TACE. 
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Fourier transform IR spectroscopy/mass spectrometry (FTIR-MS) was then used to 
image the amount of doxorubicin left in the beads. Results showed that 52% of the 
doxorubicin had eluted from the bead at day 28, and that 89% of doxorubicin had 
eluted from the bead at day 90 (Namur et al., 2010). 
In fact, Namur et al (2008) had shown previously in an animal model that therapeutic 
doses of doxorubicin are released into liver tissue up to 90 days after application of 
DEBDOX (Namur et al., 2008a). Namur et al 2008 also looked at doxorubicin 
elution in liver explants from HCC patients who underwent TACE using DEBDOX 
prior to transplantation. Time between treatment and explantation ranged from one 
day to 36 days. For the 6 hour explant, doxorubicin was detected within the tumour 
up to a distance of 1.1 cm from the bead, with intratumoural concentrations of 6.4 
µM. No necrosis was evident in this explant. Doxorubicin was detected up to 600 µm 
from the beads in all explants. The concentration of doxorubicin decreased with 
distance, by up to 70% between 20 µm and 600 µm from the bead. Since the limit of 
oxygen diffusion in tissue is 100 – 200 µm from the capillary, it is clear that cells 
experiencing hypoxia which has not occurred as a result of the embolisation itself, 
are in contact with the drug (Namur et al., 2011). The concentration of doxorubicin 
decreased with time, from one day to 9 – 14 days, and from 9 -14 days to 32 – 36 
days after treatment in the Namur study. The tissue concentration of doxorubicin at 
day one was within the therapeutic window for both normoxic and hypoxic cells that 
we have identified in vitro, up to a distance of 600 µm from the bead. The extent of 
tumour necrosis correlated with penetration and concentration of doxorubicin, and 
necrotic/fibrotic tissue surrounded the beads at day 9 to day 36 explantation. 
Doxorubicin concentration in normal tissue in the Namur et al animal model was 
higher at time points and similar distances from the bead than doxorubicin 
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concentrations in HCCs. This is likely to be due to increased interstitial pressure in 
tumour compared to normal tissue. 
A retrospective study by Citron et al, (2008), looked at the distribution of drug and 
the extent of tumour necrosis following TACE using doxorubicin-loaded LC Bead™. 
Seven patients received one treatment, two patients received > one treatment. Doses 
were 150 mg doxorubicin per treatment. CT scan was used to assess treatment 
response prior to explantation, and further analysis investigated necrosis, drug 
diffusion and the relationship between the two. Histological analysis demonstrated 
cytostatic drug concentrations in tissue surrounding the beads up to several hundred 
microns away. Complete tumour necrosis was observed in all but one of the patients, 
who was transplanted 8 hours after treatment. Complete tumour necrosis was 
observed after histological assessment in all but two patients – the patient 
transplanted 8 hours after treatment and another patient where histology revealed a 
small residual focus. No tumour recurrence occurred during 15 months of follow up, 
although 2 patients died; one from Hepatitis C related liver failure and one from 
multi-organ failure after candidal infection (Citron et al., 2008). 
A recent study used contrast-enhanced ultrasonography (CEUS) to assess the 
efficacy of DEBDOX for the treatment of unresectable HCC. 10 patients were given 
a 4 ml dose of DEBs, preloaded with 25 mg doxorubicin/ml hydrated beads. After 2 
days, necrosis ranged from 21% to 70%, with a mean of 44%. After 35 to 40 days 
this had increased significantly (= 0.0012) to necrosis ranging between 24% and 
88%, with a mean of 52%. This suggests that during the first 2 days after treatment 
necrosis is evident, and that there is a sustained effect out to 40 days post TACE 
(Moschouris et al., 2010). 
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As discussed above, several clinical studies have now been published, citing 
improved treatment responses for DEB-TACE compared to cTACE (Lammer et al., 
2010, Dhanasekaran et al., 2010, Ferrer Puchol et al., 2011); and compared to bland 
embolisation using unloaded beads (Malagari et al., 2010). Other data, as cited 
above, demonstrates that doxorubicin elution from ionic exchange microspheres in 
vivo, in both animal models and HCC explants, provides tissue and intratumoural 
drug concentrations that result in necrosis (Reddy et al., 2010, Namur et al., 2010, 
Citron et al., 2008, Moschouris et al., 2010). The response of tumour cells to DEB-
TACE can be seen as soon as one day after embolisation and continues for at least 36 
days afterward (Moschouris et al., 2010). 
Here we have shown that concentrations above 5 µM are required for cell death in 
both normoxic and hypoxic cells. The reported intratumoural concentration of 
doxorubicin at distances up to 600 µm from the beads fits the therapeutic window 
that we have identified for both normoxic and hypoxic tumour cells. Viable hypoxic 
cells have been observed at distances of 50 – 250 µm from the nearest blood vessel 
(Sutherland, 1988). The drug is diffusing out to distances where cells are hypoxic, 
whether this hypoxia is due to distance from the nearest blood vessel or due to the 
embolisation procedure itself. Effects are time and dose dependent, and so the 
prolonged and sustained release of drug into the tumour associated with DEB-TACE 
is likely to provide optimal exposure of tumour cells to the drug. 
3.5.3 Increased Doxorubicin Resistance in Hypoxic Cells. 
The data here shows that hypoxia protects HepG2 cells from doxorubicin-induced 
cytotoxicity. This effect is seen at the 48 and 72 hour time points, at doxorubicin 
concentrations of 10, 25 and 50 µM (Figures 3.5 and 3.6). Hypoxia-induced 
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resistance to chemotherapeutics is well documented (Gupta and Costanzi, 1987, 
Kalra et al., 1993, Kennedy et al., 1983, Luk et al., 1990, Martin and McNally, 1980, 
Sakata et al., 1991, Sanna and Rofstad, 1994, Song et al., 2006, Tomida and Tsuruo, 
1999, Wilson et al., 1989, Yamagata et al., 1992, Yamauchi et al., 1987, Sullivan et 
al., 2008, Unruh et al., 2003, Liu et al., 2008b, Jung et al., 2010, Rohwer et al., 
2010) and interference with HIF-1α has been reported to reverse this (Chang et al., 
2006, Liu et al., 2008a, Wang and Minko, 2004, Song et al., 2006, Nardinocchi et 
al., 2009a, Daskalow et al., 2010). 
No data has been published to date on resistance to doxorubicin in HepG2 cells 
cultured in vitro under hypoxic conditions. However, a recent publication has shown 
that the unfolded protein response (UPR), which is activated in hypoxia, is activated 
in HCCs and protects against doxorubicin cytotoxicity to HepG2 cells in vitro (Al-
Rawashdeh et al., 2010). Another study has shown that hypoxia protects against 
doxorubicin cytotoxicity in Huh-7 HCC cells (Jung et al., 2010). 
As discussed in the introduction, the cytotoxicity of doxorubicin is due to a number 
of different mechanisms. Resistance to chemotherapies in hypoxic tumour cells is 
therefore likely to be multi-factorial. Oxygen is thought to be involved both directly 
and indirectly in mechanisms of action of doxorubicin (Teicher et al., 1981). 
3.5.3.1 Reduced Drug Accumulation in Hypoxia - Influence of the Extracellular 
Milieu. 
 
The interstitial fluid within solid tumours has increased acidity when compared to 
that of normal tissue, with a further increase in acidosis in hypoxic compartments 
(Vaupel et al., 1989; Chiche et al., 2010). Both glucose consumption and lactate 
production have been shown to increase by a factor of three in HepG2 cells exposed 
to severe hypoxia (Chevrollier et al., 2005). Doxorubicin is a weak base, and the 
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local pH affects the ionisation state of the drug. Increased acidity reduces the 
proportion of doxorubicin in the non-ionised, membrane-permeable form. As a 
consequence, there is a reduction in the accumulation of doxorubicin in hypoxic 
tumour cells (Mellor and Callaghan, 2011, Gerweck et al., 1999; De Milito and Fais, 
2005, Raghunand et al., 1999). 
3.5.3.2 Enhanced Drug Efflux Under Hypoxic Conditions. 
 
Drug efflux has long been recognised as a major contributor to chemoresistance. Pgp 
is a transmembrane glycoprotein which functions as an efflux pump for a wide range 
of xenobiotics and is widely expressed in hepatocytes (Thiebaut et al., 1987). 
Hypoxia has been shown to increase the expression of Pgp in HepG2 cells and in 
other cell lines (Comerford et al., 2002, Zhu et al., 2005, Wartenberg et al., 2003).  
3.5.3.3 Oxygen-Dependent Cytotoxicity. Free Radical Formation. 
 
Doxorubicin-induced free radical DNA damage occurs at doxorubicin concentrations 
> 10 µM (Ubezio and Civoli, 1994; Benchekroun et al., 1993a, Benchekroun et al., 
1993b). However, in hypoxic conditions, tumour cells may not be capable of 
carrying out these reductive reactions (Teicher et al., 1981). If this mechanism of 
cytotoxicity comes into effect above a threshold concentration, but is only seen in 
cells where the oxygen concentration is sufficiently high, this would explain the 
decrease in the cytotoxicity of doxorubicin towards hypoxic cells at higher drug 
concentrations.  
3.5.3.4 Reduced Levels of Topoisomerase II in Hypoxic Cells. 
 
Drug sensitivity correlates with cellular TOP2 levels and drug resistant cancer cells 
have been shown to have reduced activity and/or decreased levels of TOP2 (Beck et 
al., 1993, Hofmann and Mattern, 1993). Hypoxia has been shown to reduce 
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intracellular topoisomerase II levels and so reduce the cytotoxicity of TOP2 poisons 
(Sullivan and Graham, 2009). 
3.5.3.5 Hypoxia and Apoptosis. 
 
Hypoxia can induce both pro- and anti-apoptotic responses, depending on the 
severity and duration of oxygen depletion. The apoptotic cascade in hypoxia is to 
some extent directly regulated by HIF. (Goda et al., 2003, Sowter et al., 2001, Piret 
et al., 2005, Dong et al., 2003, Erler et al., 2004, Baek et al., 2000). In HepG2 cells 
hypoxia has been shown to protect from apoptosis (Sermeus et al., 2008; Piret et al., 
2005). 
3.5.4 The Nuclear Accumulation of HIF-1α in Response to Hypoxia and 
Doxorubicin. 
This study investigated the effect of doxorubicin, an anthracycline and 
Topoisomerase II poison, on the amount of HIF-1α in the nucleus of HepG2 cells 
cultured under normoxic and hypoxic conditions, and found that a doxorubicin dose 
of 50 µM significantly attenuated nuclear HIF-1α found in cells cultured under 
hypoxic conditions. A dose of 10 µM however, had no significant effect. 
Analysis of doxorubicin elution from embolisation particles following TACE 
demonstrates that concentrations of the drug may be as high as 150 µM up to 10 μm 
from the beads, whilst concentrations >10μM extend out to 250-350 μm from the 
beads (Reddy et al., 2010). Consequently, the high concentrations of doxorubicin 
which are found in cancer tissue close to the embolised blood vessel may be 
sufficient to block HIF-1 signalling in cells which experience hypoxia as a result of 
embolisation therapy itself, and inhibit the activation of hypoxia-induced survival 
pathways. Without the activation of compensatory mechanisms which enable a cell 
to adapt to hypoxia, the cells will undergo necrosis. 
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The investigations undertaken in this thesis have identified a therapeutic window of 
10 µM doxorubicin, where the drug is more toxic to hypoxic HepG2 cells than a 50 
µM dose. Hypoxic cells were found to be significantly more resistant to doxorubicin 
than normoxic cells at all effective concentrations. Whilst 50 µM doxorubicin 
attenuates the hypoxia stimulated nuclear accumulation of HIF-1α, a 10 µM 
application has no significant effect. It seems that the cytotoxicity of this critical 10 
µM dose is not connected to the ability of doxorubicin to inhibit HIF-1α 
accumulation in the nucleus. However, it may well be connected to the ability of 
doxorubicin to inhibit HIF-1 transcriptional activity, and block hypoxia-induced 
survival pathways. 
So why does a dose of 50 µM reduce HIF-1α levels? There are at least three possible 
explanations – firstly, doxorubicin increases the degradation of HIF-1α; secondly, 
doxorubicin decreases the translocation of HIF-1α to the cell nucleus; and thirdly, 
doxorubicin decreases the rate of transcription or translation of HIF-1α.  
The degradation of HIF-1α is dependent on oxygen and intracellular iron in the form 
of Fe
2+
. Under anaerobic conditions, the semiquinone free radical forms of 
doxorubicin catalyze the rapid release of iron from the intracellular iron storage 
molecule ferritin (Thomas and Aust, 1986). Free intracellular iron contributes to 
ROS formation and to the cytotoxic effects of doxorubicin via catalysation of the 
Fenton reaction. However, the degradation of HIF-1α depends not only on the 
presence of iron, but also on the presence of oxygen. Whether or not increased iron 
availability reduces the threshold oxygen concentration below which HIF-1α is 
stabilised has not yet been explored.  
Levels of cytoplasmic HIF-1α were undetectable both before and after doxorubicin 
treatment (data not shown), so it would seem that the reduction in nuclear 
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accumulation of HIF-1α is not a result of a decrease in the translocation of the 
protein from the cytoplasm to the nucleus. The rate of transcription of hif 1α could be 
reduced due to a stalling of transcriptional machinery as a result of the formation of 
doxorubicin/DNA complexes (Sinha and Chignell, 1979).  GL331 is a plant toxin 
derivative and Topoisomerase II poison (Lee and Huang, 2001) that has been shown 
to downregulate expression of HIF-1α mRNA by interfering with the binding of 
cellular components to the promoter region of the HIF-1α gene and so repressing its 
transcription (Chang et al., 2003). 
Doxorubicin is known to inhibit global protein synthesis at the elongation step of 
translation (White et al., 2007). Topotecan is a topoisomerase I poison that inhibits 
the translation of HIF-1α mRNA (Rapisarda et al., 2004a, Puppo et al., 2008). 
Metronomic doses of Topotecan inhibit angiogenesis and tumour growth in glioma 
xenograft models (Rapisarda et al., 2004b) and topotecan can also block the 
expression of IGF-1 induced HIF-1α in normoxic cancer cells (Beppu et al., 2005). 
The topoismerase II poison NSC 644221 inhibits the translation of HIF-1α and 
expression of HIF target genes in cancer cells (Creighton-Gutteridge et al., 2007). 
Yamazaki’s laboratory failed to observe any decrease in HIF-1α in HepG2 cells after 
doxorubicin treatment, although it should be noted that their group only tested 
concentrations of doxorubicin up to 0.5 µM (Yamazaki et al., 2006). Similarly, Lee’s 
group (Lee et al., 2009a) failed to observe any decrease of HIF-1α in Hep3B cells 
treated with doxorubicin, but only tested concentrations up to 10 uM. However, 
Lee’s group reported a downregulation of HIF-1 target genes after administration of 
10 uM doxorubicin. 
Further work is needed to elucidate the mechanism of HIF-1α inhibition by the 
higher dose of doxorubicin that we have observed here. Further work is also needed 
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to ascertain whether the lower dose of doxorubicin inhibits the transcriptional 
activity of HIF-1 on downstream genes in hypoxic HepG2 cells. 
3.5.5 Activation of the Transcription Factor NFkB. 
Activation of NF-kB is, in general, associated with upregulation of anti-apoptotic 
proteins, particularly in cancer cells. NF-kB is upregulated in HCC, probably as a 
result of hypoxia, and is associated with both pathogenesis and chemoresistance 
(Arsura and Cavin, 2005, He and Karin, 2011, Luedde and Schwabe, 2011). 
In this study doxorubicin treatment of normoxic cells induced nuclear localisation of 
p50 NFkB. Doxorubicin treatment of normoxic cells induces p50 NFkB activation 
(Figure 3.6). Anthracyclines have been widely reported to activate NFkB, and 
doxorubicin-induced NFkB activation is associated with chemoresistance (Wang et 
al., 2003, Gruber et al., 2008), and inhibition of NFkB sensitises cells to doxorubicin  
(Wang et al., 2003, Chiao et al., 2002, Gangadharan et al., 2009, Bednarski et al., 
2008, Ahn et al., 2008, Mi et al., 2008). Doxorubicin appears to activate NFkB via 
the canonical pathway and the degradation of IkB (Bednarski et al., 2008, Tapia et 
al., 2007). 
This study also found that hypoxia induced nuclear translocation of NFkB (Figure 
3.6). The mechanism of hypoxia-induced NFkB is not well described as yet. There 
are reports that hypoxia causes the activation of NFkB in an IKK-independent way 
(Koong et al., 1994a, Koong et al., 1994b) and also reports that it activates NFkB in 
an IKK-dependent way (Romano et al., 2004). Interestingly, hypoxic cells appeared 
to be protected from doxorubicin induced NFkB activation (Figure 3.6). 
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3.5.6 The Effects of Hypoxia and Doxorubicin on phosphorylation of p70 S6K. 
The phosphorylation of p70S6K was not affected by culture conditions or 
doxorubicin treatments. Levels of total S6K remained the same across all 
experimental conditions (Figure 3.7).  
3.5.7 The Effects of Hypoxia and Doxorubicin on phosphorylation of Akt. 
The phosphorylation of Akt was not affected by culture conditions or doxorubicin 
treatments. Levels of Akt remained the same across all treatments and culture 
conditions. Phosphorylated Akt was observed across all experimental conditions. 
Phosphorylation at this site is known to be mediated by mTORC2.  
3.6 Conclusions. 
We have here identified a doxorubicin concentration of 10 µM that is effective 
against normoxic and hypoxic HCC cells. This concentration is commensurate with 
reported tissue and intratumoural concentrations of doxorubicin released by drug-
eluting beads from both human and animal studies (Namur et al., 2008b, Namur et 
al., 2010, Reddy et al., 2010, Citron et al., 2008). The cytotoxicity of doxorubicin in 
vitro was also observed to be time and dose dependent, and this implies that the 
prolonged and sustained release of drug associated with DEB-TACE in vivo provides 
an effective method of drug delivery.  
50 µM doxorubicin, but not 10 µM doxorubicin, attenuated the stabilisation of HIF-
1α under hypoxic conditions. This suggests that the effectiveness of the 10 µM dose 
of doxorubicin towards hypoxic cells is not due to its activity preventing the 
stabilisation of HIF-1α. Doxorubicin induced nuclear localisation of NFkB in 
normoxic cells. Hypoxia alone also induced nuclear localisation of NFkB, with no 
further localisation observed after application of doxorubicin.  
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Recently there has been a great deal of interest in the use of the mTOR inhibitor 
rapamycin, and a number of rapalogs, in the treatment of HCC (Treiber, 2009). This 
came about after the observation that patients who were prescribed rapamycin as an 
immunosuppressant after liver transplantation had much lower rates of tumour 
recurrence than patients who were prescribed other immunosuppressants 
(Castroagudin et al., 2011). Rapamycin inhibits the mTOR pathway. mTOR is a 
central regulator of cell growth and angiogenesis, and the mTOR pathway is 
activated in 40-50% of patients with HCC (Sieghart et al., 2007). The following 
chapter will report on investigations into the effects of rapamycin on HepG2 cells 
cultured under normoxic and hypoxic conditions. 
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Chapter 4  
 
The Effect of Rapamycin on the Viability of HepG2 Cells Cultured In Vitro 
under Normoxic and Hypoxic Conditions. 
 
4.1 Introduction. 
 
As the understanding of the molecular mechanisms and pathways involved in the 
initiation and progression of cancers increases, so opportunities have arisen to 
identify novel molecular targeted therapies in the fight against them. Pathways that 
are deregulated in cancer cells, and which may be essential for the survival of those 
cells, can be blocked or disrupted using agents that often have very specific targets. 
The PI3K/Akt/mTOR pathway is deregulated in many cancers and hyperactivity is 
implicated in tumourigenesis (Liu et al., 2009, Treiber, 2009, Zhou et al., 2009, 
Villanueva et al., 2008). Tumours with hyperactive mTOR tend to be highly 
vascularised and the mTOR signalling pathway has been shown to be deregulated in 
40-50 % of HCCs, and this is associated with a poor prognosis (Sahin et al., 2004, 
Zhou et al., 2009, Sieghart et al., 2007). If tumour cells are dependent on mTOR 
signalling for survival, there is a potential role for mTOR inhibitors in the treatment 
of cancers with deregulated PI3K/Akt/mTOR signalling (Tsang et al., 2007). 
Hypoxia is a negative regulator of mTOR in many cell lines (Arsham et al., 2003). 
However, cells which carry mutations to the PTEN/PI3K/Akt pathway have been 
shown to retain mTOR activity even under hypoxic conditions (Kaper et al., 2006). 
HepG2 cells and human hepatocarcinoma tissues have reduced levels of PTEN 
(Zhang et al., 2004, Tian et al., 2010a).  
4.1.1 Rapamycin. 
Recently there has been a great deal of interest in the use of rapamycin and other 
mTOR inhibitors in the treatment of HCC. This came about after the observation that 
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patients who were prescribed rapamycin as an immunosuppressant after liver 
transplantation had much lower rates of tumour recurrence than patients who were 
prescribed other immunosuppressant drugs (Toso et al., 2010, Vivarelli et al., 2010b, 
Zhou et al., 2008, Zimmerman et al., 2008). Rapamycin is a bacteria-derived 
macrolide which has antifungal, immunosuppressant and anti proliferative properties. 
Although the anticancer activity of rapamycin was first recognised by the National 
Cancer Institute in the 1970s, it was not extensively investigated until the late 90s. 
Rapamycin has been shown to have anti-tumoural effects in vitro and in vivo (Semela 
et al., 2007, Zhang et al., 2007, Huynh et al., 2009a, Huynh et al., 2008b, Huynh et 
al., 2009b, Rizell et al., 2008, Wang et al., 2008b, Wang et al., 2009b, Wang et al., 
2008c, Wang et al., 2009c, Heuer et al., 2009). The biological activity of rapamycin 
is due to inhibition of mTORC1. Results from pilot studies using rapamycin or its 
derivatives as a single agent for the treatment of HCC patients show promising 
results (Vivarelli et al., 2010a, Rizell et al., 2008, Zhu et al., 2011, Schoniger-Hekele 
and Muller, 2010, Hui et al., 2010). Clinical trials using rapamycin and rapalogs 
against a wide range of malignancies are currently underway (O'Donnell et al., 2008, 
Okamoto et al., 2010, Hudes et al., 2009, Slomovitz et al., 2010, Yao et al., 2008, 
Hess, 2009, Motzer et al., 2010, Lu et al., 2008). 
4.1.2 Rapamycin and HIF-1α. 
Some of the anticancer activity of appears to be due to inhibition of survival 
pathways induced by hypoxia. Rapamycin has been demonstrated to inhibit HIF-1α 
in a number of cancer cell types (Arsham et al., 2003, Wang et al., 2008b, Hudson et 
al., 2002, Jiang and Feng, 2004). mTOR activation enhances the rate of translation of 
HIF-1α (Land and Tee 2007), and mTOR is aberrantly activated in 40 – 50% of 
HCCs (Sieghart et al., 2007). Inhibition of mTOR using rapamycin inhibits tumour 
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growth and progression in HCC in vivo and in vitro (Heuer et al., 2009, Huynh et al., 
2008a, Jimenez et al., 2009, Ong et al., 2009, Shirouzu et al., 2010, Varma and 
Khandelwal, 2007, Wang et al., 2008b, Wang et al., 2009b, Wang et al., 2006, Wang 
et al., 2008c, Zhang et al., 2007). There is therefore a need to investigate the 
cytotoxicity of rapamycin to tumour cells cultured under hypoxic conditions in vitro.  
4.1.3 Rapamycin and S6K. 
Rapamycin inhibits the formation of mTORC1 and blocks downstream signalling, 
thus reducing cell growth and proliferation. S6K is directly regulated by mTORC1 
via phosphorylation of thr
389
. Rapamycin therefore reduces the phosphorylation of 
S6K at this residue. 
4.2 Aims. 
• To study the effects of rapamycin in a time and concentration dependent manner on 
the viability of HepG2 cells under normoxic and hypoxic conditions, and identify the 
minimum effective concentration. 
• To evaluate the response of HIF-1α and S6K expression in HepG2 cells under 
normoxic and hypoxic conditions.  
4.3 Objectives. 
 
Here the chemosensitivity of HepG2 cells cultured under normoxic and hypoxic 
conditions to the application of clinically relevant concentrations of rapamycin was 
investigated. Cell viability was estimated using the CellTiter 96
® 
Aqueous One 
Solution Proliferation Assay. Hypoxic culture conditions (oxygen = 1%) were 
established using the Coy Hypoxic Glove box, as described in the Methods section. 
SDS-PAGE and Western Blotting were used to quantify the nuclear accumulation of 
HIF-1α and the phosphorylation status of p70 S6K. 
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4.4 Results. 
4.4.1 Cell Viability at 24 Hours. 
At the 24 hour time point, 100 nM rapamycin was found to be the lowest effective 
concentration for decreasing cell viability in normoxic cells (p = 0.011). Hypoxic 
cells were resistant up to 500 nM rapamycin (Figure 4.1). 
4.4.2 Cell Viability at 48 Hours. 
At the 48 hour time point, 10 nM rapamycin was found to be the lowest effective 
concentration for decreasing cell viability in normoxic cells (p = 0.047), and 100 nM 
rapamycin was found to be the lowest effective concentration for decreasing cell 
viability in hypoxic cells (p = 0.023) (Figure 4.2). 
4.4.3 Cell Viability at 72 Hours. 
At the 72 hour time point no decrease in cell viability was observed at any rapamycin 
concentration in either of the culture conditions (Figure 4.3). Cell proliferation was 
significantly less at 72 hours in hypoxic cells compared to normoxic cells (p = 0.001) 
(Figure 4.4). 
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Figure 4.1 The Effects of 24 Hours Exposure to Rapamycin on the Viability of 
HepG2 Cells Cultured under Normoxic and Hypoxic Conditions.  
1x10
4 
cells/200 µl were added to each well of a 96-well plate and incubated 
overnight at 37°C under normoxic conditions. The following day, the plates were 
removed to either normoxic or hypoxic conditions and exposed to rapamycin, 6 
replicate wells for each concentration. The plates were incubated under normoxic or 
hypoxic conditions for 24 hours. Cell viability was estimated using MTS assay and 
normalised to untreated control. Data points for normoxic conditions represents the 
mean of 6 separate experiments ± standard error of the mean for all rapamycin 
concentrations, except for 100 nM and 500 nM concentrations which represents the 
mean of 4 separate experiments ± standard error of the mean. Data points for hypoxic 
conditions represents the mean of 7 separate experiments ± standard error of the 
mean for all rapamycin concentrations, except for 100 nM and 500 nM 
concentrations which represents the mean of 5 separate experiments ± standard error 
of the mean. * denotes lowest effective rapamycin concentration that resulted in a 
significant decrease in cell viability compared to untreated control under same 
culture conditions using a one sample T test carried out using a one tailed 
comparison, 100 vs. < 100, p = < 0.05. 
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Figure 4.2 The Effects of 48 Hours Exposure to Rapamycin on the Viability of 
HepG2 Cells Cultured under Normoxic and Hypoxic Conditions.  
1x10
4 
cells/200 µl were added to each well of a 96-well plate and incubated 
overnight at 37°C under normoxic conditions. The following day, the plates were 
removed to either normoxic or hypoxic conditions and exposed to rapamycin, 6 
replicate wells for each concentration. The plates were incubated under normoxic or 
hypoxic conditions for 48 hours. Cell viability was estimated using MTS assay and 
normalised to untreated control. Data points for normoxic conditions represents the 
mean of 6 separate experiments ± standard error of the mean for all rapamycin 
concentrations, except for 100 nM and 500 nM concentrations which represents the 
mean of 4 separate experiments ± standard error of the mean. Data points for hypoxic 
conditions represents the mean of 7 separate experiments ± standard error of the 
mean for all rapamycin concentrations, except for 100 nM and 500 nM 
concentrations which represents the mean of 5 separate experiments ± standard error 
of the mean. * denotes lowest effective rapamycin concentration that resulted in a 
significant decrease in cell viability compared to untreated control under same 
culture conditions using a one sample T test carried out using a one tailed 
comparison, 100 vs. < 100, p = < 0.05. 
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Figure 4.3 The Effects of 72 Hours Exposure to Rapamycin on the Viability of 
HepG2 Cells Cultured under Normoxic and Hypoxic Conditions.  
1x104 cells/200 µl were added to each well of a 96-well plate and incubated 
overnight at 37°C under normoxic conditions. The following day, the plates were 
removed to either normoxic or hypoxic conditions and exposed to rapamycin, 6 
replicate wells for each concentration. The plates were incubated under normoxic or 
hypoxic conditions for 72 hours. Cell viability was estimated using MTS assay and 
normalised to untreated control. Data points for normoxic conditions represents the 
mean of 6 separate experiments ± standard error of the mean for all rapamycin 
concentrations, except for 100 nM and 500 nM concentrations which represents the 
mean of 4 separate experiments ± standard error of the mean. Data points for hypoxic 
conditions represents the mean of 7 separate experiments ± standard error of the 
mean for all rapamycin concentrations, except for 100 nM and 500 nM 
concentrations which represents the mean of 5 separate experiments ± standard error 
of the mean.  
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Figure 4.4 Cell Proliferation in Normoxic Compared to Hypoxic Cells. 
1 x 10
4 
cells/200 µl were added to each well of a 96-well plate and incubated 
overnight at 37°C under normoxic conditions. The following day, the plates were 
removed to either normoxic or hypoxic conditions and the media was replenished. 
The plates were incubated under normoxic or hypoxic conditions for 24, 48 and 72 
hours. Cell viability was measured using MTS assay and normalised to cell viability 
at 0 hours. Data points represents the mean of 6 separate experiments ± standard 
error of the mean for normoxic cells and 7 separate experiments ± standard error of 
the mean for hypoxic cells. *denotes a significant difference, using a two sample one 
tailed T test, p = 0.001. 
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4.4.4 Rapamycin Attenuates Hypoxia Stimulated HIF-1α Nuclear 
Accumulation. 
To determine the effect of rapamycin treatment on hypoxia stimulated nuclear 
accumulation of HIF-1α, SDS-PAGE and Western Blotting was carried out on 
nuclear extracts from HepG2 cells cultured under normoxic and hypoxic conditions, 
and exposed to drug concentrations as shown, see Figure 4.5. After 24 hours, both 10 
nM rapamycin and 100 nM rapamycin treatments significantly reduced the amount 
of HIF-1α detected in the cell nucleus (p = 0.021 and p = 0.005 respectively), (Lanes 
4, 5 and 6). The 10 nM and 100 nM rapamycin treatments had no effect on levels of 
HIF-1α detected in the nucleus of normoxic cells (Lanes 1, 2 and 3).  
4.4.5 Effects of Rapamycin on Phosphorylation of S6K. 
To determine the effect of rapamycin treatment on S6K and the phosphorylation of 
S6K, SDS-PAGE and Western Blotting was carried out on cytoplasmic extracts from 
HepG2 cells cultured under normoxic and hypoxic conditions, and exposed to drug 
concentrations as shown, see Figure 4.6. Again, hypoxia had no effect on 
phosphorylation of p70 S6K (Lanes 1 and 4). Rapamycin was observed to decrease 
the ratio of phosphorylated S6K to total S6K in both hypoxia and normoxia, although 
the results were not significant (Lanes 1 – 3 and 4 – 6). Levels of total S6K 
compared to B actin remained the same across all treatments in culture conditions.
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Figure 4.5 Nuclear Accumulation of HIF-1α after Rapamycin Treatment.  
HepG2 cells were seeded onto T75 tissue culture flasks and incubated under 
normoxic conditions until 60% confluent. The cells were exposed to rapamycin in 
normoxic or hypoxic conditions and incubated for 24 hours. The cells were harvested 
and nuclear extracts were prepared. Equal quantities of protein were fractionated on a 
10% SDS-PAGE gel. The proteins were transferred to a PVDF membrane and 
probed with anti-HIF-1α antibodies. Proteins were visualised using 
chemiluminescent reagents. The membrane was stripped and reprobed using 
antibodies against the nuclear house-keeping protein Lamin B1. Protein levels were 
quantified using densitometry analysis. The amount of HIF-1α was normalised to 
Lamin. Fold change compared to untreated hypoxic cells was calculated. Data shown 
represents mean of 4 independent experiments ± standard error of the mean for 
hypoxic cells, and mean of 3 independent experiments ± standard error of the mean. 
for normoxic cells. Statistical analysis was carried out using a one sample one tailed 
T test, 1 vs. < 1. * denotes a statistically significant result, p = < 0.05; ** denotes a 
statistically significant result, p = < 0.01. 
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Figure 4.6 Cytoplasmic p70 S6K and p70 S6K (phospho T389) after Rapamycin 
Treatment of Normoxic and Hypoxic Cells.  
Cells were treated as described in Figure 6.2. Cytoplasmic extracts were prepared 
and fractionated on a 10% SDS-PAGE gel. The proteins were transferred to a PVDF 
membrane and probed with anti- p70 S6K (phospho T389) antibodies. Proteins were 
visualised and the membrane was stripped and reprobed using antibodies against 
total S6K, and antibodies against B actin. Protein levels were quantified using 
densitometry analysis. Ratio of p70 S6K (phospho T389) to total S6K was 
calculated, as was the amount of p70 S6K normalised to B actin. Data shown 
represents mean of 3 separate experiments ± standard error of the mean. 
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4.4.6 Statistical Analysis. 
 
Comparison 
Test statistic 
for normality 
 
N.D. 
 
Test used 
Test 
statistic 
 
p value 
 
Significant? 
 
Untreated vs. 100 nM 
 
0.647 
 
Yes 
 
One sample T 
 
0.011 
 
0.050 
 
Yes 
 
            Table 4.1 Comparisons for Factor [drug] after 24 Hours of Treatment under Normoxic Culture Conditions.  
To determine the lowest effective concentration of rapamycin, a one sample T test was carried out, using a one tailed 
comparison, 100 vs. < 100. 
 
 
Comparison 
Test statistic 
for normality 
 
N.D. 
 
Test used 
Test 
statistic 
 
p value 
 
Significant? 
 
Untreated vs. 10 nM 
 
0.596 
 
Yes 
 
One sample T 
 
0.047 
 
0.050 
 
Yes 
 
Table 4.2 Comparisons for Factor [drug] after 48 Hours of Treatment under Normoxic Culture Conditions.  
To determine the lowest effective concentration of rapamycin, a one sample T test was carried out, using a one  
tailed comparison, 100 vs. < 100. 
 
 
Comparison 
Test statistic 
for normality 
 
N.D. 
 
Test used 
Test 
statistic 
 
p value 
 
Significant? 
 
Untreated vs. 100 nM 
 
0.373 
 
Yes 
 
One sample T 
 
0.023 
 
0.050 
 
Yes 
 
Table 4.3 Comparisons for Factor [drug] after 48 Hours of Treatment under Hypoxic Culture Conditions.  
To determine the lowest effective concentration of rapamycin, a one sample T test was carried out, using a one  
tailed comparison, 100 vs. < 100. 
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4.5 Discussion. 
4.5.1 Cell Viability after Rapamycin Treatment. 
After 24 hours of treatment in normoxia, 100 nM rapamycin significantly inhibited 
the cell viability of HepG2 cells, and was observed to be more effective than 500 
nM. Rapamycin had no significant effect on hypoxic cells. 
After 48 hours, a rapamycin dose of 10 nM significantly inhibited the viability of 
HepG2 cells cultured under normoxic conditions (Figure 4.3). 10 nM rapamycin 
represents a clinically relevant dose, where clinical serum levels are between 5 – 10 
nM after a 5 mg daily oral dose (McAlister et al., 2000, Kneteman et al., 2004). 
However, a 100 nM dose was required for significant inhibition of viability in 
hypoxic cells. 
The findings for the normoxic cells are in line with other studies, as discussed below. 
A 2009 in vitro study demonstrated that low-dose rapamycin inhibited the growth of 
HepG2 cells at doses of 1, 5 and 10 nM.  Cell growth was reduced by 15% to 35% at 
48 and 72 hour time points. By 96 hours the growth inhibition was declining. There 
was a cut off dose of 20 nM, above which a decrease in growth inhibition was seen 
(Heuer et al., 2009). Heuer et al, 2009, hypothesised that there exists a rapamycin 
dose that reverses the mechanisms of action in treated cells, and above which 
increased dose results in a decreased inhibition of tumour cell growth. 
A study by Schumacker et al 2002 found that a 5 nM application of rapamycin for 5 
days caused G1 arrest in Hep3B and SKHep1 cells but not apoptosis (Schumacher et 
al., 2002). Similarly, when MHCC97H cells (highly metastatic) were treated with 10 
nM rapamycin, growth arrest at occurred at G0/G1 stage, but no apoptosis was seen 
(Wang et al., 2006). A 2007 in vitro study found that rapamycin between 30 nM and 
50 nM had a significant inhibitory effect on the growth of HepG2 cells via the 
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induction of apoptosis. The response was dose and time dependant up to 4 days 
(Zhang et al., 2007). The effect of rapamycin in the Zhang et al 2007 study was 
much more marked than our own and other findings, and interestingly, this was the 
only study which detected apoptosis. 
After 72 hours, the inhibitory effect of the drug towards normoxic cells is no longer 
seen (Figure 4.4). Continuous low dose rapamycin has been shown to be more 
effective than higher dose bolus application in vivo (Guba et al., 2005). In one in 
vitro study, rapamycin was renewed every 48 hours, rather than a single application 
at the start of the experiment, and rapamycin induced a dose dependent inhibition of 
tumour cell proliferation in the HCC cell lines PLC5 and HuH for seven days 
(Shirouzu et al., 2010). 
In the cells cultured under hypoxia, rapamycin appeared to have a stimulatory effect, 
although this was not statistically significant. Inhibition of mTORC1 can result in 
mTORC2 mediated phosphorylation and activation of Akt (Huang and Manning, 
2009), although prolonged exposure to rapamycin is thought to attenuate this effect 
by inhibiting the assembly of mTORC2 (Sarbassov et al., 2006). This may be one 
reason why metronomic administration of rapamycin is more effective than higher 
intermittent doses, although the low concentrations used and the short half life (60 
hours) of rapamycin may have an influence. Furthermore, the HepG2 cell line has 
little or no detectable PTEN protein (Zhang et al., 2004, Ma et al., 2005). PTEN 
functions by negatively counteracting PI3K signalling, and low PTEN expression is 
associated with liver malignancies (Peyrou et al., 2010). Hypoxia-induced mTOR 
inhibition is attenuated in cells lacking TSC2 or PTEN and cells retain mTOR 
activity and increased translation and protein synthesis under hypoxic conditions 
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(Kaper et al., 2006). Loss of PTEN facilitates the expression of HIF-1 gene 
expression via activation of Akt (Zundel et al., 2000). 
Rapamycin is known to be a substrate for Pgp (Arceci et al., 1992), and hypoxia-
induced overexpression of Pgp could potentially result in rapamycin resistance 
(Thews et al., 2008). 
The intrinsic anti-tumour activity of rapamycin towards normoxic HepG2 cells due 
to the inhibition of mTORC1 is not apparent in the cells cultured under hypoxic 
conditions. Is this because the drug isn’t getting into the cells, or because the 
pathway is different due to the cell responses to hypoxia? There is clearly a need to 
investigate the phosphorylation of proteins downstream of mTOR, and this will be 
addressed in Chapter 6. 
4.5.2 The Nuclear Accumulation of HIF-1α in Response to Rapamycin. 
Rapamycin significantly reduced the amount of HIF-1α detected in the nucleus of 
hypoxic HepG2 cells. 10 nM rapamycin and 100 nM rapamycin treatments both 
significantly inhibited the accumulation of HIF-1α in the nucleus of hypoxic cells, 
although the 10 nM treatment was not significantly more effective than the 100 nM 
treatment. This is in accordance with other studies. Wang et al (2009) found that 10 
nM rapamycin decreased the expression of cobalt chloride-induced HIF-1α in a 
metastatic HCC cell line. Rapamycin was found to inhibit expression of HIF-1α in 
human embryonic kidney cells (Arsham et al., 2003), and in in vivo models of 
ovarian cancer and pancreatic cancer, which also showed a concomitant increase in 
tumour apoptosis and decreased tumour growth (Hudson et al., 2002, Jiang and 
Feng, 2004). 
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4.5.3 Hypoxia, Rapamycin and phosphorylation of p70 S6K. 
In this study the effect of hypoxia on mTOR activity was investigated by analysing 
the phosphorylation status of the mTORC1 target S6K. Cell stressors, such as low 
oxygen, nutrient or iron availability, typically result in the downregulation of 
mTORC1 activity and inhibition of protein synthesis in order to conserve energy 
(Ellisen, 2005). Regulation of mTORC1 activity by hypoxia requires REDD1 and 
TSC2 (Brugarolas et al., 2004). However, the ability of cancer cells to survive in 
unfavourable environments is often due to mutation(s) to the PI3K/Akt/mTOR 
pathway, so that cells retain mTOR activity even under hypoxic conditions (Kaper et 
al., 2006). This investigation found that hypoxia had no effect on the ratio of S6K 
(phospho Thr389) to total S6K when compared to normoxia. This investigation also 
found that Akt was hyperphosphorylated in both normoxic and hypoxic cells. 
Activation of Akt was not affected by treatment with doxorubicin. Akt activation in 
HepG2 cells can be due to loss of  PTEN which results in constitutive activation of 
the PI3K/Akt/mTOR pathway, and is associated with mTOR dependent HIF-1α 
translation (Zundel et al., 2000). In HepG2 cells PTEN is barely detectable (Ma et 
al., 2005, Zhang et al., 2004). In conclusion, hypoxia does not inhibit the mTOR 
pathway downstream of mTOR itself. 
Next, the effect of rapamycin on mTORC1 activity was investigated by analysing the 
phosphorylation status of S6K. 10 nM and 100 nM rapamycin treatments inhibited 
phosphorylation of S6K in a dose dependent manner in both normoxic and hypoxic 
cells, although no significance was observed. Levels of total S6K remained the same 
under all conditions and treatments. Rapamycin appears to be inhibiting mTORC1 
activity under both normoxic and hypoxic conditions. However, comparing the 
pattern of mTOR inhibition with the cell proliferation data (Chapter 4), we can see 
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that the inhibition of phosphorylation of S6K does not necessarily go hand-in-hand 
with a decrease in cell proliferation. A 2009 study interrogated a panel of 
tumorigenic hepatic cell lines, some of which were rapamycin resistant. They found 
that rapamycin was effective at blocking mTORC1 signalling via S6K in all the cell 
lines, and concluded that ‘mechanisms of rapamycin resistance are not dependent on 
alterations in the direct actions of mTOR on its targets, but may be related to 
deregulation of the cell cycle’ (Jimenez et al., 2009). Hypoxia is known to affect cell 
cycling, and the effects of hypoxia on cell cycling in HepG2 cells are complex 
(Koshiji and Huang, 2004). 
Rapamycin was initially thought to inhibit mTORC1 exclusively (Jacinto et al., 
2004), although recent research suggests that this is dependent on the duration and 
dosage (Sarbassov et al., 2006, Foster and Toschi, 2009). mTORC2 positively feeds 
back to Akt via phosphorylation of Akt at Ser
473 
(Sarbassov et al., 2005). In this 
study we observed that Akt was phosphorylated at this residue, but phosphorylation 
was not increased by the application of rapamycin (data not shown). 
4.6 Conclusions. 
 
This study has shown that treatment with rapamycin can inhibit the cell proliferation 
of both normoxic and hypoxic HepG2 cells, although hypoxic cells are less 
susceptible to mTOR inhibition. The lowest effective concentration against normoxic 
cells was 100 nM, and the lowest effective concentration against hypoxic cells was 
100 nM. Using a single dose of rapamycin at time 0 leads to attenuation of the effect 
beyond 48 hours. Repeated administration every 24 hours warrants investigation. 
Rapamycin inhibited phosphorylation of S6K in a dose dependent manner in both 
normoxic and hypoxic cells, although not significantly. Rapamycin attenuated the 
stabilisation of HIF-1α under hypoxic conditions.  
120 
 
The effectiveness of chemotherapy can be improved by the administration of 
antitumour drugs in combination rather than as single agents (Forster, 2009). The use 
of molecular inhibitors in combination with traditional chemotherapeutics may 
facilitate the modulation of biochemical pathways in order to overcome 
chemoresistance in HCC (Boulin et al., 2011, Ferrer Puchol et al., 2011). In the 
following chapter, the activity of rapamycin and doxorubicin combinations against 
HepG2 cells cultured under normoxic and hypoxic conditions will be investigated.  
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Chapter 5  
 
The Effects of Doxorubicin in Combination with Low Dose Rapamycin on the 
Viability of HepG2 Cells Cultured In Vitro under Normoxic and Hypoxic 
Conditions. 
 
5.1 Introduction. 
 
The combination of standard chemotherapeutic agents with one (or more) of the 
recently identified molecular targeted therapies in the treatment of HCC presents 
opportunities to improve patient outcome.  
There have been quite a number of in vitro investigations into the effects of 
combinations of rapamycin (and rapamycin analogues) with other agents towards 
cancer cells. Doxorubicin and rapamycin combinations have been investigated in 
vitro and found to have synergistic or additive effects against leukaemias (Batista et 
al., 2011, Avellino et al., 2005); breast cancers (Mondesire et al., 2004, Steelman et 
al., 2008, Sokolosky et al., 2011a); T cell lymphoma (Huang et al., 2010); thyroid 
cancer (Lin et al., 2010); colon cancer (Sun et al., 2008, O'Reilly et al., 2011); 
mantle cell lymphoma (Haritunians et al., 2007); melanoma (Romano et al., 2004); 
cervical cancer (O'Reilly et al., 2011), lung cancer (O'Reilly et al., 2011), prostate 
cancer (Grunwald et al., 2002) and HCC (Piguet et al., 2008).  
5.1.1 Rapamycin and Doxorubicin Combinations. 
It has been shown in vitro that known clinical concentrations of doxorubicin in liver 
tumours post DEB-TACE may be effective against hypoxic as well as normoxic cells 
(Chapter 3), and that low dose rapamycin inhibited cell viability in normoxic cells, 
although doses tenfold higher were required to inhibit cell viability in hypoxic cells 
(Chapter 4). Combination therapies, where targeted therapies are administered in 
combination with standard chemotherapeutics, offer more of an opportunity to 
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interfere with activated signalling cascades which contribute to drug resistance, 
including pathways activated by hypoxia. 
5.1.2 Rapamycin and Doxorubicin Combinations and HIF-1α. 
Targeting HIF-1 in combination with doxorubicin has been to enhance the 
cytotoxicity of doxorubicin in a range of cancer types (Liang et al., 2010c, Liu et al., 
2008a, Wang et al., 2010, Nardinocchi et al., 2009b, Du et al., 2010, Chen et al., 
2009b). Doxorubicin and rapamycin combinations have been shown to be effective 
in an HCC model (Piguet et al., 2008), although the effects of the drug combination 
on HIF-1α were not investigated. 
Using a combination of localised and sustained delivery of doxorubicin with 
metronomic low dose orally administered rapamycin in vivo may result in decreased 
activation of hypoxia-induced survival pathways and improved treatment responses. 
There is also scope for loading rapamycin onto DEBs (Forster, 2009). Locoregional 
delivery of rapamycin may show some of the same pharmacokinetic advantages as 
the locoregional delivery of doxorubicin. There is clearly a need to investigate the 
activity of doxorubicin/rapamycin combinations at clinically relevant concentrations 
towards HCC cell lines cultured in vitro under normoxic and hypoxic conditions. 
5.2 Aims. 
 
• To assess the cell viability of HepG2 cells cultured under normoxic and hypoxic        
   conditions to rapamycin and doxorubicin in combination. 
• To investigate the nuclear accumulation of HIF-1α in response to this combination.  
• To investigate the nuclear accumulation of NFkB in response to this combination. 
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5.3 Objectives. 
 
Here the chemosensitivity of HepG2 cells cultured under normoxic and hypoxic 
conditions to the application of clinically relevant concentrations of doxorubicin and 
rapamycin in combination was investigated. Cell viability was estimated using the 
CellTiter 96
® 
Aqueous One Solution Proliferation Assay. Hypoxic culture conditions 
(oxygen = 1%) were established using the Coy Hypoxic Glove box, as described in 
the Methods section. SDS-PAGE and Western Blotting were used to quantify the 
nuclear accumulation of HIF-1α and NFkB. 
5.3 Results. 
5.3.1 Rapamycin and Doxorubicin Combination Treatments and Cell Viability.  
To investigate the effects of combinations of doxorubicin and rapamycin against 
HCC, HepG2 cells were incubated with a range of doxorubicin concentrations with 
or without the addition of 10 nM rapamycin. Cell viability was measured after 24, 48 
and 72 hours using the MTS assay.  
After 24 hours (Figures 5.1 and 5.4), cell viability was observed to be less with the 
addition of rapamycin compared to doxorubicin alone, and this was consistent for all 
concentrations investigated. The decrease in cell viability was significantly more for 
the combinations where doxorubicin concentrations were 1 µM (p = 0.006) and 25 
µM (p = 0.008) for normoxic cells, and 1 µM for hypoxic cells (p = 0.043). After 48 
hours (Figures 5.2 and 5.5), cell viability was observed to be less with the addition of 
rapamycin compared to doxorubicin alone, and this was consistent for all 
concentrations investigated except 0.1 µM doxorubicin in hypoxic cells. The 
decrease in cell viability was significantly more for the combinations where 
doxorubicin concentrations were 1 µM (p = 0.036) for normoxic cells, but there was 
no significant effect for any of the hypoxic cells. After 72 hours, (Figures 5.3 and 
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5.6), cell viability was observed to be less with the addition of rapamycin compared 
to doxorubicin alone, and this was consistent for all concentrations investigated 
except 25 µM doxorubicin in normoxic cells. The decrease in cell viability was 
significantly more for the combinations where doxorubicin concentrations were 10 
µM (p = 0.004) for hypoxic cells, but there was no significant effect for any of the 
normoxic cells. The additive effects of rapamycin were more pronounced at the 24 
hour time point than at either of the other time points, and more pronounced in the 
normoxic cells than in the hypoxic cells. 
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Figure 5.1 The Effects of 24 Hours Exposure to Varying Concentrations of 
Doxorubicin + 10 nM Rapamycin on the Viability of HepG2 Cells Cultured 
under Normoxic Conditions.  
1x10
4 
cells/200 µl were added to each well of a 96-well plate and incubated 
overnight at 37°C under normoxic conditions. The media was removed and replaced 
with a range of doxorubicin concentrations + 10 nM rapamycin. 6 replicate wells for 
each concentration. The plates were incubated under normoxic conditions for 24 
hours. Cell viability was measured using MTS assay and normalised to untreated 
control. Data points represent mean of 3 separate experiments ± standard error of the 
mean. Statistical analysis was carried out using a one tailed paired t test. ** denotes a 
significant difference, p = < 0.01. 
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Figure 5.2 The Effects of 48 Hours Exposure to Varying Concentrations of 
Doxorubicin + 10 nM Rapamycin on the Viability of HepG2 Cells Cultured 
under Normoxic Conditions.  
1x10
4 
cells/200 µl were added to each well of a 96-well plate and incubated 
overnight at 37°C under normoxic conditions. The media was removed and replaced 
with a range of doxorubicin concentrations + 10 nM rapamycin. 6 replicate wells for 
each concentration. The plates were incubated under normoxic conditions for 48 
hours. Cell viability was measured using MTS assay and normalised to untreated 
control. Data points represent mean of 3 separate experiments ± standard error of the 
mean. Statistical analysis was carried out using a one tailed paired t test. * denotes a 
significant difference, p = < 0.05. 
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Figure 5.3 The Effects of 72 Hours Exposure to Varying Concentrations of 
Doxorubicin + 10 nM Rapamycin on the Viability of HepG2 Cells Cultured 
under Normoxic Conditions.  
1x10
4 
cells/200 µl were added to each well of a 96-well plate and incubated 
overnight at 37°C under normoxic conditions. The media was removed and replaced 
with a range of doxorubicin concentrations + 10 nM rapamycin. 6 replicate wells for 
each concentration. The plates were incubated under normoxic conditions for 72 
hours. Cell viability was measured using MTS assay and normalised to untreated 
control. Data points represent mean of 3 separate experiments ± standard error of the 
mean. 
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Figure 5.4 The Effects of 24 Hours Exposure to Varying Concentrations of 
Doxorubicin + 10 nM Rapamycin on the Viability of HepG2 Cells Cultured 
under Hypoxic Conditions.  
1x10
4 
cells/200 µl were added to each well of a 96-well plate and incubated 
overnight at 37°C under normoxic conditions. The plates were removed to hypoxic 
conditions and the media was removed and replaced with a range of doxorubicin 
concentrations + 10 nM rapamycin. 6 replicate wells for each concentration. The 
plates were incubated under hypoxic conditions for 24 hours. Cell viability was 
measured using MTS assay and normalised to untreated control. Data points 
represent mean of 3 separate experiments ± standard error of the mean. Statistical 
analysis was carried out using a one tailed paired t test. * denotes a significant 
difference, p = < 0.05. 
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Figure 5.5 The Effects of 48 Hours Exposure to Varying Concentrations of 
Doxorubicin + 10 nM Rapamycin on the Viability of HepG2 Cells Cultured 
under Hypoxic Conditions.  
1x10
4 
cells/200 µl were added to each well of a 96-well plate and incubated 
overnight at 37°C under normoxic conditions. The plates were removed to hypoxic 
conditions and the media was removed and replaced with a range of doxorubicin 
concentrations + 10 nM rapamycin. 6 replicate wells for each concentration. The 
plates were incubated under hypoxic conditions for 48 hours. Cell viability was 
measured using MTS assay and normalised to untreated control. Data points 
represent mean of 3 separate experiments ± standard error of the mean. 
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Figure 5.6 The Effects of 72 Hours Exposure to Varying Concentrations of 
Doxorubicin + 10 nM Rapamycin on the Viability of HepG2 Cells Cultured 
under Hypoxic Conditions.  
1x10
4 
cells/200 µl were added to each well of a 96-well plate and incubated 
overnight at 37°C under normoxic conditions. The plates were removed to hypoxic 
conditions and the media was removed and replaced with a range of doxorubicin 
concentrations + 10 nM rapamycin. 6 replicate wells for each concentration. The 
plates were incubated under hypoxic conditions for 72 hours. Cell viability was 
measured using MTS assay and normalised to untreated control. Data points 
represent mean of 3 separate experiments ± standard error of the mean. Statistical 
analysis was carried out using a one tailed paired t test. * denotes a significant 
difference, p = < 0.05. 
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5.3.2 There is No Additive Effect on the Attenuation of Hypoxia Stimulated 
HIF-1α Nuclear Accumulation after Combination Treatments. 
To determine the effect of rapamycin and doxorubicin combination treatments on 
hypoxia stimulated nuclear accumulation of HIF-1α, SDS-PAGE and Western 
Blotting was carried out on nuclear extracts from HepG2 cells cultured under 
hypoxic conditions, and exposed to drug concentrations as shown, see Figure 5.7. 
Whilst the application of 10 nM rapamycin alone reduced the amount of  nuclear 
HIF-1α (p = 0.060) (Lanes 1 and 2), the addition of either 10 nM rapamycin or 100 
nM rapamycin to 10 µM doxorubicin did not result in increased reduction of HIF-1α 
when compared to 10 µM doxorubicin alone (Lanes 3, 4, and 5). The application of 
50 µM doxorubicin alone caused a reduction in HIF-1α, although the small sample 
size precluded statistical analysis (Lane 6). Again, the addition of either 10 nM 
rapamycin or 100 nM rapamycin to 50 µM doxorubicin did not result in increased 
reduction of HIF-1α when compared to 50 µM doxorubicin alone (Lanes 7 and 8). 
5.3.3 Nuclear Accumulation of NFkB p50 after Combination Treatments of 
Hypoxic Cells. 
To determine the effect of rapamycin alone, and rapamycin and doxorubicin 
combinations on hypoxia stimulated nuclear accumulation of NFkB p50, SDS-PAGE 
and Western Blotting was carried out on nuclear extracts from HepG2 cells cultured 
under hypoxic conditions, see Figure 5.8. Although there appeared to be some 
reduction in the amount of nuclear NFkB p50 after rapamycin treatment, no 
significant effect was observed (Lanes 1, 2 and 3). No other significant effects were 
observed, although the addition of rapamycin to doxorubicin treatments suggested 
increased NFkB activity compared to doxorubicin alone. 
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Figure 5.7 Nuclear Accumulation of HIF-1α after Rapamycin and Doxorubicin 
Combination Treatments.  
HepG2 cells were seeded into T75 tissue culture flasks and incubated under 
normoxic conditions until the cells reached 60% confluence. The flasks were 
removed to hypoxic conditions and the cells exposed to different concentrations of 
rapamycin, doxorubicin and both in combination in growth medium. The flasks were 
incubated under hypoxic conditions for 24 hours, and the cells were harvested. 
Nuclear extracts were prepared and equal quantities of protein were fractionated on a 
10% SDS-PAGE gel. The proteins were transferred to a PVDF membrane and 
probed with anti-HIF-1α antibodies. Proteins were visualised using 
chemiluminescent reagents. The membrane was stripped and reprobed using 
antibodies against the nuclear house-keeping protein Lamin B1. Protein levels were 
quantified using densitometry analysis. The amount of HIF-1α was normalised to 
Lamin. Fold change compared to untreated hypoxic cells was calculated. Data shown 
represents mean of 3 independent experiments ± standard error of the mean, unless 
indicated otherwise. 
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Figure 5.8 Nuclear Accumulation of NFkB p50 after Combination Treatments 
of Hypoxic Cells.  
HepG2 cells were seeded into T75 tissue culture flasks and incubated under 
normoxic conditions until the cells reached 60% confluence. The flasks were 
removed to hypoxic conditions and the cells exposed to different concentrations of 
rapamycin, doxorubicin and both in combination in growth medium. The flasks were 
incubated under hypoxic conditions for 24 hours, and the cells were harvested. 
Nuclear extracts were prepared and equal quantities of protein were fractionated on a 
10% SDS-PAGE gel. The proteins were transferred to a PVDF membrane and 
probed with anti-NFkB p50 antibodies. Proteins were visualised using 
chemiluminescent reagents. The membrane was stripped and reprobed using 
antibodies against the nuclear house-keeping protein Lamin B1. Protein levels were 
quantified using densitometry analysis. The amount of NFkB p50 was normalised to 
Lamin. Fold change compared to untreated hypoxic cells was calculated. Data shown 
represents mean of 3 separate experiments ± standard error of the mean. 
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5.4 Discussion. 
5.4.1 Combination Treatments and Cell Viability. 
This study has shown that the addition of the mTOR inhibitor rapamycin to the 
standard chemotherapeutic agent doxorubicin significantly decreases cell viability 
compared to doxorubicin treatment alone in both normoxic and hypoxic cells. The 
effects of rapamycin were more pronounced at 24 hours than at later time points and 
this is consistent with reports from in vitro and in vivo studies that metronomic 
applications of rapamycin appear to more effective than single applications (Guba et 
al., 2005, Tabernero et al., 2008). 
It has been suggested that pre-incubating cells with rapamycin before the addition of 
doxorubicin may be more effective than adding both the drugs at the same time. 
Semela and co-workers (2008) investigated doxorubicin and temsirolimus 
combinations on the viability of Morris Hepatoma (MH) cells (isogenic rat liver 
cancer cells) and rat endothelial cells. They used 1 nM and 10 nM temsirolimus in 
combination with 15 nM or 150 nM doxorubicin. In concordance with the data 
shown here, 150 nM doxorubicin monotherapy had only a weak effect on cell 
proliferation, and the addition of temsirolimus had no further effect. However, when 
the same regimen was tested on rat endothelial cells the minimum effective dose of 
doxorubicin as a monotherapy was found to be 15 nM, and the addition of rapamycin 
at both 1 nM and 10 nM increased the cytotoxic effects. Interestingly, the addition of 
temsirolimus to the higher dose of doxorubicin had no additive effect. 
As mentioned previously, one of the mechanisms contributing to drug resistance is 
the upregulation of P-glycoprotein MDR1 (Roninson, 1992). Rapamycin has been 
reported to improve the uptake of chemotherapeutics in multidrug-resistant cell lines 
due to competitive inhibition because of a direct interaction of rapamycin with Pgp 
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(Hoof et al., 1993, Arceci et al., 1992, Pawarode et al., 2007). In one study, 
rapamycin bound with high affinity to Pgp and enhanced growth inhibitory effects of 
doxorubicin in Chinese hamster ovary cells (Hoof et al., 1993). 1 uM rapamycin 
reduced the IC50 of doxorubicin from 18 ng/ml to 9 ng/ml in the parent cell line, and 
from 280 ng/ml to 200 ng/ml in a multi-drug resistant mutant (Hoof et al., 1993). 
Another study demonstrated a similar reversal of multi drug resistance by rapamycin, 
but only at µM concentrations that would not therefore be suitable in vivo (Arceci et 
al., 1992). Pawarode et al (2007) showed that rapamycin enhanced the cellular 
uptake of drugs in cells overexpressing Pgp and MDR-1. The optimal rapamycin 
concentration was 2.5 µM, but they showed an effect with 250 nM rapamycin if the 
cells were pre-incubated for 30 minutes prior to drug exposure, where the rapamycin 
saturated the MDR-1 binding sites before the application of doxorubicin (Pawarode 
et al., 2007). In this study there was less of an additive effect with rapamycin in 
hypoxic cells compared to normoxic cells. Hypoxic cells are likely to have 
upregulated drug resistance mechanisms as a consequence of HIF activation, and if 
rapamycin prevents some of the Pgp regulated doxorubicin resistance and therefore 
increases its cytotoxicity, would that be more apparent in hypoxic than in normoxic 
cells? Pre-incubation of the cells with rapamycin before the addition of doxorubicin 
may increase the additive effects, and this should be explored further. 
As discussed previously, the PI3K/Akt/mTOR pathway is constitutively active in 
many cancers, and this is often due to mutations or deletions in the tumour 
suppressor phosphatase protein PTEN. A 10 nM dose of rapamycin was shown to 
increase the sensitivity of the PTEN deleted cell line PC-3 to doxorubicin, as did 
transfection with a PTEN construct (Grunwald et al., 2002). Akt activation confers 
resistance to doxorubicin treatment (Tanaka et al., 2000, Tanaka et al., 2005), and 
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this may be due to protection from apoptosis (Huang et al., 2001). One study looked 
at the rapalog everolimus in combination with cisplatin in HCC cell lines with 
different p53 status (HepG2, He3p3B and PLC) and found that everolimus sensitised 
all the cell lines to cisplatin cytotoxicity. Whilst this was independent of p53, it 
appeared to be related to p21-induced apoptosis in response to DNA damage (Tam et 
al., 2009). This then raises the question of whether inhibition of mTOR using 
rapamycin sensitises PTEN deficient cells to doxorubicin induced apoptosis. 
5.4.2 Combination Treatments. 
There was no evidence of any complimentary inhibition of HIF-1α after combination 
treatments. Indeed, the results suggested that the addition of rapamycin led to an 
attenuation of the effect on HIF-1α of either drug alone. 
5.4.3 Activation of the Transcription Factor NFkB. 
There was a suggestion that 100 nM rapamycin inhibited the hypoxia stimulated 
activation of NFkB, although the result was not statistically significant (Figure 5.8, 
Lanes 1 and 3). It has been reported that rapamycin can prevent the translocation of 
NFkB to the nucleus. Rapamycin binds to FKBP51, which is an important co-factor 
of the IKK complex, inhibits IKK kinase activity and prevents degradation of IkB 
(Giordano et al., 2006, Romano et al., 2004). Furthermore, rapamycin has been 
shown to inhibit doxorubicin-induced NFkB activation and enhance apoptosis in 
melanoma cells (Romano et al., 2004). However, in this study rapamycin failed to 
inhibit p50 NFkB in doxorubicin-treated hypoxic cells (Figure 5.8, Lanes 4 – 9). This 
study did not investigate the effect of rapamycin on p50 NFkB in doxorubicin-treated 
normoxic cells, and this is work that clearly needs to be done. 
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5.5 Conclusions. 
 
A combination of low dose rapamycin and doxorubicin appears to have improved 
cytotoxicity towards both normoxic and hypoxic HepG2 cells than either treatment 
alone.  
Whilst 50 µM doxorubicin and 10 nM and 100 nM rapamycin attenuated the 
stabilisation of HIF-1α under hypoxic conditions, doxorubicin and rapamycin 
combinations showed no evidence of complimentary effects. Doxorubicin induced 
nuclear localisation of NFkB in normoxic cells. Hypoxia alone also induced nuclear 
localisation of NFkB, with no further localisation observed after application of 
doxorubicin. The results presented here suggest that rapamycin may inhibit the 
extent of NFkB activation. 
Consequent to the findings described above, the anti-tumour effects of doxorubicin 
and rapamycin both as monotherapies and in combination in vivo, were evaluated in 
a murine model of HCC. 
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Chapter 6  
 
In Vivo Investigations into the Effects of Doxorubicin-eluting Beads and 
Rapamycin as Monotherapies and in Combination on Tumour Burden in an 
Ectopic Xenograft Mouse Model of Hepatocellular Carcinoma. 
 
6.1 Introduction 
 
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide 
(Parkin et al., 2005). Treatment options for HCC are limited due to tumour stage at 
diagnosis, and treatment outcomes are often poor (Colombo and Sangiovanni, 2003, 
Raoul, 2008). The standard of care for patients unsuitable for the potentially curative 
therapies of ablation, resection or transplantation is TACE (Lencioni, 2010). DEB-
TACE using doxorubicin-loaded microspheres is a treatment regime which has been 
shown to have improved response rates when compared with conventional TACE 
(Dhanasekaran et al., 2010, Lammer et al., 2010). For patients with more advanced 
disease, sorafenib is the standard of care (Lencioni, 2010).     
Targeting signalling pathways that are aberrantly activated in HCC can potentially 
inhibit tumour growth (Whittaker et al., 2010). mTOR has a critical role in the 
pathogenesis of HCC and is associated with a poor prognosis (Villanueva et al., 2008, 
Chen et al., 2009a, Whittaker et al., 2010, Zhou et al., 2010b). Activated mTOR has 
been reported in 40% of explanted HCCs (Sieghart et al., 2007). Pre-clinical 
investigations of rapamycin and its analogues have shown anti-tumoural effects in 
mouse models of HCC (Guba et al., 2002, Huynh et al., 2008a, Huynh et al., 2008b, 
Ong et al., 2009, Wang et al., 2008b, Wang et al., 2008c, Semela et al., 2007, Piguet 
et al., 2011, O'Reilly et al., 2011).  
Since rapamycin demonstrates both immunosuppressive and anti-cancer effects, it is 
increasingly being utilised as the immunosuppressant of choice for HCC patients 
undergoing liver transplantation (Castroagudin et al., 2011, Sanchez Antolin et al., 
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2011). Fourteen clinical studies have been published which suggest improved 
survival times and anti-tumour effects of mTOR inhibition after liver transplantation 
for HCC (Schnitzbauer et al., 2011). However, no randomized trials evaluating 
immunosuppressive drugs and HCC recurrence after liver transplantation have so far 
been published, although a prospective randomised clinical trial is now underway 
(Schnitzbauer et al., 2010). One pilot study assessing rapamycin as a single agent for 
the treatment of advanced HCC found that, although the drug was well tolerated, it 
was only minimally effective (Schoniger-Hekele and Muller, 2010). However, 
another pilot study showed that the drug was well tolerated in cirrhotic patients with 
advanced HCC, and had a significant impact on tumour growth in 40% of the cohort 
(Decaens, 2009). A phase 1/2 study of everolimus for advanced HCC has shown 
preliminary evidence of anti-tumour activity (Zhu et al., 2011).  
In vivo animal research indicates that rapamycin may have additive or synergistic 
effects when used in combination with other chemotherapeutics or other molecular 
inhibitors (Huynh et al., 2008b, LoPiccolo et al., 2008, Wang et al., 2008c, Piguet et 
al., 2008, Piguet et al., 2011, Newell et al., 2009, Ong et al., 2009, Jasinghe et al., 
2008, Ribatti et al., 2007, Ahn et al., 2008). Rapamycin and doxorubicin have been 
demonstrated to have additive effects in vivo in murine models of liver, prostate, 
cervical and lung cancer (Piguet et al., 2008, O'Reilly et al., 2011, Grunwald et al., 
2002).  
It has recently been shown that rapamycin can be loaded onto drug-eluting beads 
either alone or in combination with doxorubicin, without compromising the loading 
or release kinetics of doxorubicin (Forster 2009). This fact, together with the 
evidence cited above, warrants further investigations into rapamycin and doxorubicin 
combinations towards HCC in vivo. 
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6.2 Aims. 
 
To evaluate the anti-cancer effects of rapamycin and doxorubicin monotherapies and 
combinations in HepG2 tumour-bearing mice treated with doxorubicin-loaded beads 
(DOXDEB); rapamycin-loaded beads (RAPADEB); rapamycin and doxorubicin co-
loaded beads (RAPADOXDEB); oral rapamycin (rapa p.o.); and DOXDEB in 
combination with oral rapamycin.  
6.3 Results. 
 
Using a mouse model of HCC we investigated the effects of DOXDEB; RAPADEB; 
RAPADOXDEB; rapamycin p.o.; and DOXDEB in combination with rapamycin p.o. 
HepG2 cells were implanted subcutaneously and tumour growth was monitored 
regularly. When tumours reached palpable size, at day 23, treatment regimes 
commenced.  Tumour burden was evaluated by measuring tumour volume (length x 
width x width x π/6) at days 23, 25, 28, 30, 32, 35, 42 and 45. Anti-tumour activity 
was assessed by comparing tumour volumes, comparing final tumour volume/control 
and comparing tumour weight post mortem. Toxicity was assessed using mouse body 
weight and behavioural and physiological observations. The sample size for each 
treatment was n = 3.  
6.3.1 Untreated Control. 
Unfortunately, the tumour transplantation was unsuccessful in one of the control 
animals, thus reducing the sample size of the control group to n = 2. The mean 
increase in tumour size in the successful transplants was > 700% between day 23 and 
day 45. 
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Figure 6.1 Anti-tumoural Activity of Doxorubicin and Rapamycin Treatments 
in a Mouse Model of HCC.  
5 x 10
6
 HepG2 cells were subcutaneously implanted in NMRI: nu/nu mice at day 0. 
Tumour volume was palpable at day 23 after implantation and treatment was 
initiated. Rapamycin was administered by gavage at a dose of 1 mg/kg/day. 100 ul of 
beads loaded as specified was injected adjacent to the tumour at day 23. Tumour 
volume was measured at days 23, 25, 28, 30, 32, 35, 37, 42 and 45. Data shown 
represents the mean value of 3 replicates per group ± standard error of the mean, 
apart from the control group where data represents mean of 2 replicates ± standard 
error of the mean. Data was found to be normally distributed with equal variance. 
Multivariate ANOVA (general linear model) data analysis showed a significant 
difference between the groups at day 45, p = < 0.01. Post hoc Bonferroni pairwise 
comparisons at day 45 identified significant differences between control vs. 
DOXDEB, p = < 0.05; control vs. RAPADOXDEB, p = < 0.01; and control vs. 
rapamycin p.o. + DOXDEB, p = < 0.05. * denotes a significant difference, p = < 
0.05; ** denotes a significant difference, p = < 0.01. 
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Figure 6.2 Anti-tumoural Activity of Doxorubicin and Rapamycin Treatments 
in a Mouse Model of HCC.  
5 x 10
6
 HepG2 cells were subcutaneously implanted in NMRI: nu/nu mice at day 0. 
Tumour volume was palpable at day 23 after implantation and treatment was 
initiated. Rapamycin was administered by gavage at a dose of 1 mg/kg/day. 100 ul of 
beads loaded as specified was injected adjacent to the tumour at day 23. Tumour 
volume was measured at days 23, 25, 28, 30, 32, 35, 37, 42 and 45. The difference 
(Δ) in tumour volume compared to day 23 was calculated for each treatment at each 
time point by subtraction. Data shown represents the mean value of 3 replicates per 
group ± standard error of the mean, apart from the control group where data 
represents mean of 2 replicates ± standard error of the mean. Data was found to be 
normally distributed with equal variance. Multivariate ANOVA (general linear 
model) data analysis showed a significant difference between the groups at day 28, p 
= < 0.05; day 30, p = < 0.05; and day 45, p = < 0.01. Post hoc Bonferroni pairwise 
comparisons at day 28 identified significant differences between rapamycin p.o. vs. 
RAPADOXDEB, p = < 0.05. Post hoc Bonferroni pairwise comparisons at day 30 
identified significant differences between control vs. rapamycin p.o. + DOXDEB, p 
= < 0.05.  Post hoc Bonferroni pairwise comparisons at day 45 identified significant 
differences between control vs. DOXDEB, p = < 0.05; control vs. RAPADEB, p = < 
0.05; control vs. RAPADOXDEB, p = < 0.01; control vs. rapamycin p.o., p = < 0.05; 
and control vs. rapamycin p.o. + DOXDEB, p = < 0.01. * denotes a significant 
difference, p = < 0.05; ** denotes a significant difference, p = < 0.01. 
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Figure 6.3 Box Plots of Tumour Volumes and delta Tumour Volumes at Day 45.  
HepG2 cells were subcutaneously implanted in NMRI: nu/nu mice at day 0. Tumour 
volume was palpable at day 23 after implantation and treatment was initiated. 
Rapamycin was administered by gavage at a dose of 1 mg/kg/day. 100 ul of beads 
loaded as specified was injected adjacent to the tumour at day 23. Tumour volume 
was measured at day 45. Delta tumour volume was calculated by subtracting volume 
at day 23 from volume at day 45. Data shown represents 3 replicates per group ± 
standard error of the mean, apart from the control group where data represents 2 
replicates.  
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Figure 6.4 Box Plots of AUC Day 23 – 45 for Tumour Volumes and delta 
Tumour Volumes.  
HepG2 cells were subcutaneously implanted in NMRI: nu/nu mice at day 0. Tumour 
volume was palpable at day 23 after implantation and treatment was initiated. 
Rapamycin was administered by gavage at a dose of 1 mg/kg/day. 100 ul of beads 
loaded as specified was injected adjacent to the tumour at day 23. Tumour volume 
was measured at day 45. Delta tumour volume was calculated by subtracting volume 
at day 23 from volume at day 45. AUC between day 23 and day 45 was calculated 
for tumour volume and delta tumour volume. Data shown represents 3 replicates per 
group ± standard error of the mean, apart from the control group where data 
represents 2 replicates. 
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Figure 6.5 Effects of Doxorubicin and Rapamycin Treatments on Body Weight 
between Day 23 and Day 45 in a Mouse Model of HCC.  
Mice were weighed at days 23, 25, 28, 30, 32, 35, 37, 42 and 45. Data shown 
represents the mean value of 3 replicates per group ± standard error of the mean, 
apart from the control group where data represents mean of 2 replicates. Data was 
found to be normally distributed with equal variance. Multivariate ANOVA (general 
linear model) data analysis showed no significant differences in body weight 
between treatment groups, and no significant differences in body weight between 
days within each treatment group. 
 
 
Figure 6.6 % Change in Body Weight after Doxorubicin and Rapamycin 
Treatments in a Mouse Model of HCC.  
Data was found to be normally distributed with equal variance. Multivariate 
ANOVA (general linear model) data analysis showed a significant difference 
between the treatments at day 28 (p = 0.016). Post hoc Bonferroni pairwise 
comparisons identified this as a significant difference between the RAPADOX DEB 
vs. oral rapamycin + DOXDEB treated animals (p = 0.017). No significant 
differences were found between days within each treatment group. 
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Figure 6.7 Effects of Doxorubicin and Rapamycin Treatments on Tumour 
Weight at Day 45 in a Mouse Model of HCC.  
Mice were euthanized at day 45, and the tumours excised and weighed. Data 
represents mean ± standard error of the mean. Because of the small sample sizes, 
statistical analysis was not carried out. 
 
Treatment  Observations 
Control 1 No tumour growth 
Control 2 OK 
Control 3 OK 
DOXDEB 1 From day 42 ulceration  
DOXDEB 2 From day 37 ulceration 
DOXDEB 3 OK 
RAPADEB 1 OK 
RAPADEB 2 OK 
RAPADEB 3 OK 
RAPADOXDEB 1 From day 30 ulceration 
RAPADOXDEB 2 From day 35 ulceration 
RAPADOXDEB 3 From day 37 ulceration 
Rapamycin p.o. 1 OK 
Rapamycin p.o. 2 OK 
Rapamycin p.o. 3 OK 
Rapamycin p.o. + DOXDEB 1 OK 
Rapamycin p.o. + DOXDEB 2 From day 28 ulceration 
Rapamycin p.o. + DOXDEB 3 From day 28 ulceration 
 
Table 6. 1 Physiological Examination of Tumour-bearing Animals.  
HepG2 cells were subcutaneously implanted in NMRI: nu/nu mice at day 0. Tumour 
volume was palpable at day 23 when treatment was initiated. Rapamycin was 
administered by gavage at a dose of 1 mg/kg/day. 100 ul of beads loaded as specified 
was injected adjacent to the tumour at day 23. Gross physiological examination was 
made at days 23, 25, 28, 30, 32, 35, 37, 42 and 45. No behavioural changes were 
reported, and no mice were euthanized due to toxic effects or to tumour load being ≥ 
10% of body size. 
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Table 6.2 Anti-tumour Effects of Doxorubicin and Rapamycin Treatments in a Mouse Model of HCC at Day 45.  
HepG2 cells were subcutaneously implanted in NMRI: nu/nu mice at day 0. Tumour volume was palpable at day 23 after implantation 
and treatment was initiated. Rapamycin was administered by gavage at a dose of 1 mg/kg/day. 100 ul of beads loaded as specified was 
injected adjacent to the tumour at day 23. Tumour volume, mouse body weight and tumour weight of excised tumour were measured at 
day 45. Tumour volume and body weight data shown represents the mean value of 3 replicates per group ± standard error of the mean, 
apart from the control group where data represents mean of 2 replicates ± standard error of the mean. Statistical analysis of treatment vs. 
control was determined using a multivariate ANOVA with post hoc Bonferroni comparisons. Anti-tumour effect was expressed as T/C. 
Δ tumour volume = difference in tumour volume between day 23 and day 45 (subtracted). SEM, standard error of the mean; CI, 
Confidence Interval.  
 
 
 
Treatment 
 
Tumour volume   
(cm
3
) ± SEM 
 
Δ tumour volume   
(cm
3
) ± SEM 
Tumour 
volume T/C  
(95% CI) 
Δ tumour 
volume T/C  
(95% CI) 
 
Tumour 
weight T/C 
 
Body weight  
T/C  (95% CI) 
AUC Δ tumour 
volume  T/C  
(95% CI) 
 
Control 
 
0.871 ± 0.318  
 
0.753 ± 0.080 
 
1.00 (0.72) 1.00 (0.21) 1.00 (0.68) 1.00 (0.02) 
 
1.00 (1.03) 
 
DOXDEB 
 
0.118 ± 0.073 (p = 0.012) 
 
0.067 ± 0.070 (p = 0.005) 
 
0.14 (0.16) 0.09 (0.18) 0.25 (0.22) 1.03 (0.07) 
 
0.41 (0.38) 
 
RAPADEB 
 
0.310 ± 0.077 (p = 0.089) 
 
0.239 ± 0.038 (p = 0.045) 
 
0.36 (0.17) 0.32 (0.10) 0.35 (0.16) 1.01 (0.06) 
 
0.40 (0.14) 
 
RAPADOXDEB 
 
0.091 ± 0.090 (p = 0.009) 
 
0.033 ± 0.073 (p = 0.004) 
 
0.10 (0.20) 0.04 (0.19) 0.24 ( - ) 1.00 (0.17) 
 
0.57 (0.85) 
 
Rapamycin p.o. 
 
0.290 ± 0.030 (p = 0.072) 
 
0.238 ± 0.280 (p = 0.044) 
 
0.33 (0.07) 0.32 (0.73) 0.31 (0.07) 0.95 (0.05) 
 
0.31 (0.05) 
 
Rapamycin p.o. + DOXDEB 
 
0.152 ± 0.077 (p = 0.017) 
 
0.085 ± 0.069 (p = 0.007) 
 
0.17 (0.17) 0.11 (0.18) 0.26 (0.18) 0.98 (0.05) 
 
0.12 (0.16) 
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Figure 6.8 Tumour Volumes, Raw Data for each Mouse in a Treatment Group. 
NMRI: nu/nu mice were randomly assigned to one of six treatment groups, three 
mice per group. HepG2 cells were subcutaneously implanted and treatments were 
initiated at day 23. Tumours were measured at day 23, 25, 28, 30, 32, 35, 38, 42 and 
45. Tumour volume was calculated as length x width x width x π/2. 
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6.3.2 In Vivo Activity of DOXDEB. 
DOXDEB demonstrated sustained inhibition of tumour growth compared to control, 
with tumour regression from day 32. Tumour regression was more pronounced from 
day 42. At day 45, DOXDEB showed significant anti-tumour activity compared to 
untreated control (p = 0.12 for tumour volume, p = 0.05 for Δ tumour volume). The 
mean tumour weight at day 45 was 25% that of control (95% CI, 22) (Table 6.2). 
Final tumour volume was 14% of control (95% CI, 16); final Δ tumour volume was 
9% of control (95% CI, 18). Δ tumour volume over the time course of the experiment 
(as calculated using AUC day 23 - 45) was 41% that of control. There was no 
significant body weight loss compared to any of the other groups and no significant 
differences in body weight over time (Figure 6.5 and 6.6). Two of the mice in this 
group suffered ulceration at the tumour injection site; one from day 37 and one from 
day 42 (Table 6.1). 
6.3.3 In Vivo Activity of RAPADEB. 
RAPADEB demonstrated sustained inhibition of tumour growth compared to 
control, although no tumour regression was apparent. At day 45, RAPADEB showed 
significant anti-tumour activity compared to untreated control (p = 0.045 for Δ 
tumour volume). The mean tumour weight at day 45 was 35% (95% CI, 16) that of 
control (Table 6.2). Mean tumour volume at day 45 was 36% of control (95% CI, 
17), and mean Δ tumour volume at day 45 was 32% of control (95% CI, 10) (Figures 
6.1 and 6.2). Δ tumour volume over the time course of the experiment (as calculated 
using AUC day 23 - 45) was 40% that of control.  There was no significant body 
weight loss compared to any of the other groups and no significant difference in 
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body weight between days of treatment (Figures 6.5 and 6.6). None of the mice in 
this group suffered ulceration at the tumour injection site (Table 6.1). 
6.3.4 In Vivo Activity of RAPADOXDEB. 
RAPADOXDEB demonstrated inhibition of tumour growth up to day 30, and then 
tumour regression from day 32. Rapid tumour growth was reported between days 30 
and 32. At day 45, RAPADOXDEB showed significant anti-tumour activity 
compared to untreated control (p = 0.009 for tumour volume, p = 0.004 for Δ tumour 
volume). The mean tumour weight at day 45 was 24% that of control (one sample 
only) (see Table 6.2). Mean tumour volume at day 45 was 10% of control (95% CI, 
20), and mean Δ tumour volume at day 45 was 4% of control (95% CI, 19) (Table 
6.2). Δ tumour volume over the time course of the experiment (as calculated using 
AUC day 23 - 45) was 57% that of control.  At day 28 the % body weight loss was 
significantly more in this group compared to the group treated with rapamycin p.o. + 
DOXDEB (p = 0.017). There was no significant difference in body weight between 
days of treatment (Figures 6.5 and 6.6). Two of the mice in this group suffered 
ulceration at the tumour injection site; one from day 30, one from day 35 and one 
from day 37 (Table 6.1). 
6.3.5 In Vivo Activity of Rapamycin p.o. 
Monotherapy with oral rapamycin showed sustained inhibition of tumour growth 
across the time course of the experiment, with complete inhibition of tumour growth 
to day 28. At day 28, rapamycin p.o. showed significant anti-tumour activity 
compared to RAPADOXDEB (p = 0.033 for Δ tumour volume). The p value for 
rapamycin p.o.  vs. control was 0.051. At day 45, rapamycin p.o. showed significant 
anti-tumour activity compared to untreated control (p = 0.044 for Δ tumour volume). 
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The mean tumour weight at day 45 was 31% (95% CI, 7) that of control (see Table 
6.2). Mean tumour volume at day 45 was 33% of control (95% CI, 7), and mean Δ 
tumour volume at day 45 was 32% of control (95% CI, 73) (see Table 6.2). Δ tumour 
volume over the time course of the experiment (as calculated using AUC day 23 - 
45) was 31% that of control.  There was no significant body weight loss compared to 
any of the other groups and no significant difference in body weight between days of 
treatment (Figures 6.5 and 6.6). None of the mice in this group suffered ulceration at 
the tumour injection site (Table 6.1).  
6.3.6 In Vivo Activity Rapamycin p.o. in Combination with DOXDEB. 
The most effective treatment across the time course of the experiment was the 
combination of oral rapamycin with DOXDEB (Figure 6.4). Tumour growth was 
inhibited from day 23 to day 28, with evidence of tumour regression between days 28 
and 30, followed by complete inhibition between days 30 to 35. At day 30 rapamycin 
p.o. + DOXDEB showed significant anti-tumour activity compared to untreated 
control (p = 0.035 for Δ tumour volume). At day 45, rapamycin p.o. + DOXDEB 
showed significant anti-tumour activity compared to untreated control (p = 0.017 for 
tumour volume, p = 0.007 for Δ tumour volume). The mean tumour weight at day 45 
was 26% (95% CI, 18) of control (Table 6.2). Mean tumour volume at day 45 was 
17% of control (95% CI, 17), and mean Δ tumour volume at day 45 was 11% of 
control (95% CI, 18) (see Table 6.2). Δ tumour volume over the time course of the 
experiment (as calculated using AUC day 23 - 45) was 12% that of control.  There 
was a significant difference in % body weight loss at day 28 when compared with 
RAPADOXDEB, with weight loss being more in the RAPADOXDEB group (p = 
0.017) (Figure 6.6). There was no significant body weight loss compared to any of 
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the other groups and no significant difference in body weight between days of 
treatment (Figure 6.5). Two of the mice in this group suffered ulceration at the 
tumour injection site. In both cases the ulceration started at day 28 (Table 6.1). At 
day 45 complete tumour regression was reported in one of the mice. The tumour 
volume measurements for one of the mice in this group were unusual; with an 
increase in tumour size > 400% between day 30 and day 32, and this has skewed the 
data for the group. 
6.4 Discussion. 
6.4.1 DOXDEB as Monotherapy. 
We have shown that monotherapy using DOXDEB is an effective treatment for 
human HCC tumours growing as subcutaneous xenografts in immunocompromised 
mice. Tumour regression was observed, with a mean decrease in Δ tumour volume at 
day 45 of 90% compared to control, with a decrease in AUC for Δ tumour volume of 
59%. One of the mice showed tumour shrinkage of > 98% between days 32 and 45, 
by which point the tumour was barely palpable at 0.001 cm
3
. Another tumour from 
this treatment group weighed only 0.056 g at day 45. The treatment was well 
tolerated, as assessed using loss of body weight as a parameter for toxicity, although 
ulceration of the injection site was observed in two out of three animals.  
There is no other data on the effect of doxorubicin-eluting microspheres in this type 
of model with which to compare these results. There have been a few animal studies 
investigating doxorubicin-eluting beads for liver cancer. Three of these employed the 
Vx-2 rabbit tumour model. Vx-2 tumours are carcinomas derived from a virus-
induced rabbit papilloma, and are characterised by rapid growth (Kidd and Rous, 
1940). Vx-2 tumour cells can successfully be implanted into the liver of rabbits, 
resulting in the growth of a tumour with a hypervascular blood supply, similar to that 
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of human liver tumours. The size of the animal enables embolisation therapy to the 
established tumour and so provides a good animal model for investigating the effects 
of TACE and DEB-TACE (Lee et al., 2009b). One study used DOXDEB of 100 – 
300 µm diameters, and a doxorubicin dose of 2.6 – 3.2 mg/kg. Intratumoural 
doxorubicin concentration was 414 nM/g, 116 nM/g and 42 nM/g at 3, 7 and 14 days 
after treatment respectively. Necrosis was greatest at 7 days after treatment (Hong et 
al., 2006). Another study used Contour SE (Contour SE, Boston Scientific, Natick, 
Massachusetts) and two different prototype PVA microspheres (diameters 100 – 300 
µm) and a doxorubicin dose of 1 mg/kg. Two days after treatment the intratumoural 
concentration of doxorubicin was 160 nM/g (Lee et al., 2008). More recently, a study 
using doxorubicin-loaded Quadraspheres (QuadraSphere
s
 microspheres; BioSphere 
Medical, Inc., Rockland, MA, USA) resulted in intratumoural concentrations of 50 
nM/g at day 3 and 23 nM/g at day 7; in accordance with the DOXDEB study, 
necrosis was greatest 7 days after treatment (Lee et al., 2010). 
Here tumour regression was observed from 9 days after treatment in the DOXDEB 
and RAPADOXDEB groups, which continued out to day 45. The observations from 
this thesis and the other studies mentioned suggest that it takes some days for 
doxorubicin to elute from the beads and concentrate in sufficient amounts for 
necrosis to occur. It is interesting to note that at day 37 there is increased cell 
proliferation in the untreated control group, and that this occurs 5 days prior to 
increased tumour regression in the doxorubicin-treated groups. Several of the 
mechanisms of cytotoxicity of doxorubicin are known to be dependent on cell 
division (Aubel-Sadron and Londos-Gagliardi, 1984), perhaps explaining the 
connection between these two events. 
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6.4.2 Rapamycin Monotherapies. 
Monotherapy using RAPADEB was also shown to be an effective treatment using 
this model. Here, the observation was of a pattern of sustained inhibition of tumour 
growth, rather than tumour regression, with a mean decreases in tumour volume and 
tumour weight at day 45 of > 60% when compared to control; and a decrease in AUC 
for Δ tumour volume of 60%. The treatment was well tolerated and no ulceration was 
observed. Again, there is no comparable data from other studies available. 
Monotherapy using low dose metronomic orally administered rapamycin 
demonstrated anti-tumoural activity across the time course of the experiment, and 
complete inhibition of tumour growth to day 28. As was the case with RAPADEB 
we observed a pattern of sustained inhibition of tumour growth rather than tumour 
regression, with a mean decrease in tumour volume and tumour weight at day 45 of 
almost 70% when compared to control, and a decrease in AUC for Δ tumour volume 
of 69%. The treatment was well tolerated. These findings are in accordance with 
several other published studies on mTOR inhibition for HCC. 2 mg/kg/day of oral 
rapamycin for 4 weeks was found to significantly reduce HCC growth and improve 
survival in an orthotopic allograft rat model, primarily via antiangiogenesis (Semela 
et al., 2007). 1 mg/kg/day oral rapamycin inhibited tumour growth in an orthotopic 
intraportal HepG2 mouse model in mice (Ong et al., 2009). This group used Micro-
PET imaging and histological analysis to assess HCC inhibition, and concluded that 
rapamycin has anti-angiogenic activity towards both tumour and normal hepatocytes. 
Other studies using orthotopic highly metastatic mouse models of HCC found that 2 
mg/kg/day of oral rapamycin for five weeks prevented growth and metastatic 
progression and downregulated the expression of HIF-1α (Wang et al., 2009c). 
Another group used a chemically-induced HCC model in rats, and found that 
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rapamycin at doses 1.5 mg/kg/day and 4.5 mg/kg/day “repressed the expression of 
HIF-1α and VEGF…. and significantly inhibited the growth and metastasis of HCC” 
and that there was no significant difference between these two doses (Wang et al., 
2008b). Everolimus is a derivative of rapamycin which has improved aqueous 
solubility and bioavailability (Schuler et al., 1997), and suppresses tumour growth in 
subcutaneous HCC xenografts in mice (Tam et al., 2009, Huynh et al., 2008a). 
In this experiment oral rapamycin inhibited the growth of HCC more effectively than 
RAPADOX. The elution kinetics of rapamycin from the microspheres has not been 
extensively investigated, although we know that the theoretical maximum possible 
eluted dose is 0.67 mg in total. Several studies have suggested that a continuous low 
dose rapamycin therapy is the most effective regimen for inhibiting tumour growth 
(Guba et al., 2005, Heuer et al., 2009, Wang et al., 2008b, O'Reilly et al., 2011). It 
has also been established that the anti-angiogenic activity of rapamycin is due to 
interference with signalling pathways outside of the tumour itself (Wang et al., 
2008b, Semela et al., 2007). Rapamycin has a relatively long half-life of around 72 
hours (Yatscoff et al., 1995), and there is some evidence from animal models and 
phase I clinical trials that weekly doses are as effective as daily doses although daily 
dosing regimens seem to be the most effective (Boulay et al., 2004, Tabernero et al., 
2008, O'Donnell et al., 2008, Guba et al., 2005, Rizell et al., 2008). The optimal 
dosing regime is one that results in an effective and sustained inhibition of S6K. 
Higher doses may be less effective at S6K inhibition than lower doses (Guba et al., 
2002, Heuer et al., 2009). Lower doses of rapamycin are obviously advantageous in 
terms of minimising adverse side effects associated with rapamycin. Phase I/II 
clinical trials investigating everolimus for unresectable HCC are underway 
(NCT00390195, NCT01374750, NCT00516165, NCT01035229), as are Phase II/III 
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clinical trials investigating sirolimus after liver transplant for HCC (NCT01374750, 
NCT00328770). 
6.4.3 Combination Therapies. 
Here we have shown that combination therapy using RAPADOXDEB had anti-
tumoural activity against HCC tumours growing as subcutaneous xenografts in 
immunocompromised mice. Tumour inhibition was apparent from the start of 
treatment, and tumour regression was observed from day 32, with a mean decrease in 
Δ tumour volume at day 45 of > 90% compared to control, and a decrease in AUC 
for Δ tumour volume of 43%. Two of the mice in this group showed tumour 
reduction of > 99% between days 28 and 45, by which point the tumour was barely 
palpable at 0.001 cm
3
. This treatment had a noticeable, though not significant, impact 
on mouse body weight. Ulceration of the injection site was observed in all three 
animals. There is no other data on rapamycin/doxorubicin co-loaded microspheres 
with which to compare these results.  
Interestingly, the data for the individual mice treated with RAPADOXDEB shows 
wide inter-individual variability, with a noticeable increase in tumour volume 
between day 30 and day 32 in one animal. This may be due to Akt activation. 
Both rapamycin and everolimus inhibit mTORC1 but not mTORC2 (Jacinto et al., 
2004), although this is not clear cut and specific effects vary with cell type, 
mutations to cell signalling pathways, and dosing regimens (Foster and Toschi, 2009, 
Huang and Manning, 2009, Zhou et al., 2010a, Wander et al., 2011). There is a 
concern that positive feedback from mTORC2 to Akt may improve tumour cell 
survival. It has been demonstrated that endothelial cell proliferation in hypoxia 
depends on both mTORC1 and mTORC2, so that rapamycin does not fully block 
angiogenesis, although reports are not consensual (Li et al., 2007, Barilli et al., 
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2008). Akt takes centre stage in the PI3K/Akt/mTOR pathway, with a vast array of 
effectors under its control (Foster and Fingar, 2010). The outcomes of Akt activation 
are anti-apoptotic and pro-proliferative cell survival strategies (Jiang and Liu, 
2008a). There is some evidence to suggest that activation of Akt only occurs when 
higher doses of rapamycin/everolimus are used (Tabernero et al., 2008). We don’t 
know what the intratumoural concentration of rapamycin is after the administration 
of rapamycin-loaded beads, but it is likely to be higher than after oral administration, 
possibly leading to Akt activation in tumour cells. However, whilst we saw increased 
tumour volume in the RAPADOXDEB group, the same effect was not seen in the 
RAPADEB group. Akt activation potentially has more than one impact on cell 
survival in this model, since it protects against doxorubicin-induced apoptosis in 
HepG2 cells (Alexia et al., 2006). Of course, the rapid increase in tumour volume 
was only observed in one of the mice and more work needs to be done before we can 
draw any conclusions. 
The final combination treatment investigated was oral rapamycin and DOXDEB, 
which demonstrated the best anti-tumour activity over the time course of the 
experiment (Figure 6.4), with near-stable disease, and transient tumour regression. 
Tumour inhibition was apparent from the start of treatment. Tumour regression was 
observed at day 28, and complete inhibition of tumour growth from day 30 to day 35. 
However, from day 35 there was an increase in tumour volume. There was a mean 
decrease in Δ tumour volume at day 30 of > 60% compared to control, and a mean 
decrease in Δ tumour volume at day 45 of almost 90% compared to control. The 
decrease in AUC for Δ tumour volume was 88%. Ulceration of the injection site was 
observed in two animals. There was no significant body weight loss compared to any 
of the other groups and no significant difference in body weight between days of 
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treatment (Figure 6.5 and 6.6). At day 45 tumour cure was reported in one of the 
mice. There is no other data on oral rapamycin combined with doxorubicin-loaded 
microspheres with which to compare these results. 
A few other groups have looked at doxorubicin in combination with mTOR 
inhibition. In accordance with our findings, combination treatments were found to be 
more successful at tumour inhibition than monotherapies. Piguet et al (2008) 
reported additive effects in an orthotopic syngeneic rat HCC model. Pegylated 
liposomal doxorubicin was injected intravenously every four days, with a starting 
dose of 4.5 mg/kg and subsequent doses of 1 mg/kg. Rapamycin was administered in 
drinking water at a dose of 2 mg/kg/day. Treatments were well tolerated. T/C after 
30 days of treatment was reported as 52%, 56% and 27% for doxorubicin, rapamycin 
and both in combination respectively. Grunwald and colleagues (2002) reported 
additive effects in an ectopic xenograft mouse model of prostate cancer. Doxorubicin 
was administered i.v. as a single dose of 10 mg/kg and the rapamycin analogue CCI-
779 was administered i.p. for 5 days at a dose of 10 mg/kg. T/C after 33 days of 
treatment was reported as 61%, 30% and 23% for doxorubicin, rapamycin and both 
in combination respectively. Recently, O’Reilly and co-workers (2011) investigated 
everolimus in combination with doxorubicin for the treatment of ectopic xenograft 
mouse models of lung and cervical cancers. For the cervical cancer model they 
reported a synergistic effect when 5 mg/kg/week doxorubicin i.v. was administered 
alongside 2.5 mg/kg/day everolimus p.o., and for the lung cancer model they 
reported an additive effect for the same doses. T/C after 16 days of treatment for the 
cervical cancer model was 6%, 43% and 1% for doxorubicin, rapamycin and both in 
combination respectively. T/C after 16 days of treatment for the lung cancer model 
was 31%, 17% and 7% for doxorubicin, rapamycin and both in combination 
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respectively. Body weight loss was reported after doxorubicin monotherapies, and 
was more pronounced in the lung cancer model, but was not exacerbated by 
everolimus – indeed, in the lung cancer model everolimus protected against body 
weight loss. Continuing everolimus treatment after a one off doxorubicin treatment 
inhibited tumour outgrowth in the cervical cancer model. The inhibitory effect of 
DOXDEB in combination with rapamycin p.o. over the 22 day treatment period is 
striking.  
6.4.4 Tolerability. 
An important aspect to a pre-clinical study is an initial assessment of drug toxicity. 
Drug combinations may have additive or synergistic effects with regard to side 
effects and toxicity, rendering them unsuitable for clinical use. Here we monitored 
change in mouse body weight as a parameter for toxicity, with measurements taken 
twice weekly. Regular observations were also made to ascertain any gross 
physiological or behavioural changes. We used this data to assess the tolerability of 
the drugs in combination compared to either drug alone.  
6.4.4.1 Mouse Body Weight. 
Comparisons between the control and treatment showed no significant differences in 
mouse body weight for any of the treatments at any time point (Figure 6.3), and no 
significant differences in % change in mouse body weight compared to weight at day 
23 (Figure 6.4). Comparisons between the different time points within each treatment 
also showed no significant differences (multivariate ANOVA analysis, data not 
shown). Reduction in body weight was most pronounced in the mice treated with 
RAPADOXDEB. All the mice in this group were observed to have ulceration of the 
tumour injection site, and the weight loss may be connected to loss of appetite due to 
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general discomfort. We can conclude that body weight losses for all the treatments are 
within a tolerable range. However, it should be noted that tolerability data may not be 
accurate since the metabolism of the drug by the liver is not compromised by the 
presence of any underlying liver disease.  
6.4.4.2 Ulceration. 
Gross examination of the tumour injection site showed up localised ulceration, which 
in some cases was quite extensive. The ulceration was only associated with the 
application of beads loaded with doxorubicin, and is presumably due to its well 
recognised activity as a vesicant (causing blistering, ulceration and skin damage) if 
and when extravasation occurs (Schrijvers, 2003). Rapamycin-loaded microspheres 
did not cause ulceration, and it is therefore unlikely that either the bead itself or the 
alginate suspension were the cause. The fact that the beads are positioned 
subcutaneously and adjacent to the tumour means that extravasation is at least 
possible, or even likely. Ulceration after application of DOXDEB was reported in two 
mice, starting at day 37 and day 42 respectively. Ulceration after application of 
RAPADOXDEB was reported in all three mice starting at day 30, day 35 and day 37 
respectively. Ulceration after application of DOXDEB in combination with oral 
rapamycin was reported in two mice, starting at day 28 and day 28 respectively. The 
ulceration seems to start earlier and occur more frequently when doxorubicin is used in 
combination with rapamycin. The ulceration amongst the mice in the RAPADOXDEB 
group was reported as being the most severe. The local concentration of rapamycin as 
eluted from the microsphere is likely to be much higher than from an oral dose. 
Rapamycin is known to impair wound healing by a number of different mechanisms 
(Ekici et al., 2007, Weinreich et al., 2011), and may well be exacerbating the effects of 
the vesicant activity of the doxorubicin.  
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6.4.5 Limitations of the Mouse Model. 
There a several limitations regarding the use of this mouse model. Firstly, the 
tumours are implanted ectopically. This facilitates tumour measurement, but the 
tumour microenvironment is not accurately modelled, since the subcutaneous 
microenvironment is very different from the liver microenvironment. Interactions 
between the tumour cells and the graft site will affect the cell phenotype, the 
availability of growth factors and nutrients, microcirculation, angiogenesis and 
motility and invasiveness (Kubota, 1994, Fukumura et al., 1997, Cespedes et al., 
2006, Kerbel, 2003). The sensitivity and responses of cancer cells to 
chemotherapeutics can therefore be altered according to the site of implantation 
(Fidler et al., 1994, Cespedes et al., 2006). However, for early pre-clinical studies 
where budgets are limited, ectopic mouse models are useful predictors of outcome. 
Interesting or promising results can then be investigated further using a more suitable 
animal model.  
Secondly, the dose of doxorubicin delivered does not reflect the dose used in clinic. 
Here we used DEBs loaded with 25 mg/ml doxorubicin. 1 ml of DEB was then 
mixed with 3 ml of alginate solution, giving a final doxorubicin concentration of 6.25 
mg/ml. 100 µl of DEB was injected for each treatment, equivalent to 0.625 mg 
doxorubicin/mouse. This represents a theoretical maximum dose of 30 mg/kg. The 
maximum recommended clinical dosage of doxorubicin in one procedure is 150 mg. 
For DEB-TACE 4 ml of 37.5 mg/ml doxorubicin DOXDEB are injected per 
embolisation. This represents a dose of 2 – 3 mg/kg, and no systemic doxorubicin-
related toxicities at this dosage of DEB-TACE have been reported (Malagari, 2008). 
Animal studies have found that hepatic intra-arterial delivery of 3-4 mg 
doxorubicin/kg loaded into DEBs proves cytotoxic to cells at a locoregional site, and 
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is well tolerated by the animal (Lewis et al., 2006, Hong et al., 2006, Eyol et al., 
2008). However, doses in the range 15 – 60 mg/kg ‘were efficacious…..but induced 
significant hepato-toxicity, often leading to the death of the animal’ (Eyol et al., 
2008). We have delivered a theoretical maximum dose of 30 mg/kg. In vivo studies 
estimate that 43% of the drug is eluted from the bead 28 days after embolisation 
(Namur et al., 2010). The time course of our model ran out to 22 days, at which point 
we could expect < 50% of the drug, equivalent to < 15 mg/kg, to have eluted from 
the bead. Note that delivery was subcutaneous, so that the concentrations within the 
liver would not be as high as in the Eyol et al (2008) experiment; and that liver 
function in our experiment was not compromised by the presence of disease. So, 
whilst the delivered dose exceeds that used in the clinic, there is no evidence from 
the body weight data that it impacts on the general well-being of the mouse.  
Thirdly, and perhaps most importantly, the delivery of DOXDEB is not intra-arterial 
or embolic. DEBs were injected as close to the tumour as possible, and delivered in 
an alginate solution in an attempt to stop the DEBS drifting away from the tumour. 
Regions of hypoxia will be present in the subcutaneous tumours once they reach a 
palpable size, and the presence of the beads may well disrupt the supply of blood to 
the tumour, but the mode of delivery does not model DEB-TACE and the resulting 
intra-tumoural anoxia or hypoxia. Since we are interested in the effects of 
chemotherapeutics on hypoxia-induced survival pathways, we would ideally use an 
animal model which allows DEB-TACE. As discussed above, the rabbit Vx-2 
tumour model enables embolisation therapy to the established tumour. Previous 
experiments using this model demonstrate the existence of intrinsic intratumoural 
hypoxia (Rhee et al., 2007, Virmani et al., 2008), and show that TAE results in 
further increases in HIF-1α expression compared to control (Rhee et al., 2007), and 
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that post-TAE biopsy specimens have significantly higher HIF-1α levels than pre-
TAE specimens from the same rabbit (Virmani et al., 2008). This model has been 
used to study DEB-TACE using doxorubicin-eluting microspheres (Hong et al., 
2006, Lee et al., 2008, Lee et al., 2010). However, no investigations into mTOR 
inhibition in combination with DEB-TACE have yet been carried out using this 
model.  
6.5 Conclusions. 
 
In this study we evaluated tumour burden in a mouse model of HCC. Rapamycin 
monotherapies inhibited tumour growth for the duration of the experiment, and oral 
rapamycin inhibited tumour growth more effectively than RAPADEB, although the 
pattern of growth inhibition was the same for both treatments. DOXDEB inhibited 
tumour growth in a similar manner to RAPADEB up to day 32. We found that 
doxorubicin was necessary and sufficient for tumour regression, which occurred from 
day 32 in the DOXDEB and RAPADOXDEB groups. The most effective treatment 
overall was the combination of DOXDEB and oral rapamycin, which resulted in 
almost total inhibition of tumour growth to day 35; tumour regression day 28 to 30 and 
day 42 to 45; and complete tumour destruction reported in one animal by day 45. 
There was evidence of increased anti-tumoural activity with combination therapies 
compared to either treatment alone, and all treatments were well tolerated.  
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Chapter 7 
Discussion.  
Molecular oxygen is an essential substrate for eukaryotic cell respiration, and 
organisms have evolved a range of adaptive and protective mechanisms to survive 
episodes of decreased oxygen supply. The transcription factor HIF-1 regulates the 
expression of most of the genes involved in adaptations to hypoxia. The protein 
products of genes regulated by HIF-1 are involved in increasing oxygen availability 
and in regulating essential metabolic alterations that allow the cell and the organism 
to survive hypoxic conditions (Semenza, 2000a).  
Intratumoural hypoxia is a feature of solid tumours, and hypoxia-derived 
angiogenesis is a requirement for tumour growth (Harris, 2002). Cellular adaptations 
to hypoxia potentially increases the malignancy of the cancer, since HIF-1 
upregulates genes associated with increased survival, invasiveness, metastases and 
tumour growth; and radio- and chemo-therapy resistance (Huynh et al., 2009a, 
Maxwell et al., 2001; Unruh et al., 2003).  
Hepatocellular carcinoma is a major cause of cancer-related mortality. Treatment 
options are limited by disease stage at diagnosis, and overall survival rates for 
inoperable HCC are poor (Sapra et al., 2011b). The current standard of care for 
intermediate HCC combines locoregional delivery of the chemotherapeutic 
doxorubicin with trans-arterial embolisation. Embolisation therapies result in the 
necrosis of cells exposed to severe hypoxia or anoxia, but also result in the escape 
and proliferation of those cells which adapt to hypoxia and display a hypoxia-
resistant phenotype. Targeting HIF-1 presents an opportunity to improve treatment 
outcome for patients with HCC.  
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The majority of in vitro investigations are carried out at ambient (21%) oxygen, and 
do not properly model in vivo intratumoural physiology, wherein oxygen 
concentrations are likely to be much lower. The phenotypic alterations which occur 
as a result of hypoxia reduces the chemosensitivity of cancer cells via a number of 
different mechanisms (Dong et al., 2003, Tak et al., 2011, Erler et al., 2004, Baek et 
al., 2000; Comerford et al., 2002, Ding et al., 2010, Zhu et al., 2005). Toxic effects 
which are oxygen-dependent, as is the case with some of the anthracyclines, are also 
reduced in hypoxia (Gewirtz, 1999). 
In this thesis in vitro investigations were carried out under both normoxic and 
hypoxic culture conditions. The HepG2 cell line was used as a model for HCC. Two 
drugs – doxorubicin and rapamycin - were investigated, both as monotherapies and 
in combination. Doxorubicin is the current standard of care for TACE and there is 
some evidence that doxorubicin inhibits the activity of HIF-1 in cancer cells. 
Rapamycin is currently under investigation as a treatment for HCC, and 
downregulates HIF-1α expression via suppression of mTOR (Land and Tee, 2007).  
In addition to the potential for either one of these drugs to be used against HCC, 
there is also potential for using both in combination. The use of traditional 
chemotherapeutics in combination with therapies that target signalling pathways has 
been the subject of much recent investigation, and results from pre-clinical and 
clinical trials are encouraging. Whilst the cytotoxicity of the more traditional 
chemotherapeutic drugs depends on cell division, which has implications for other 
non-cancerous dividing cells in the body, drugs which target molecular pathways 
exert their effects on stromal tissues and cells and the processes which support 
tumour growth, as well as on tumour cells themselves. Rapamycin interferes with the 
PI3K/Akt/mTOR signalling pathway, a pathway that is known to play an important 
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role in cancer progression and is known to be dysregulated in around half of all 
HCCs (Sokolosky et al., 2011b). Rapamycin and doxorubicin have been 
demonstrated to have additive effects in vivo in murine models of liver, prostate, 
cervical and lung cancer (Piguet et al., 2008, O'Reilly et al., 2011, Grunwald et al., 
2002).  
The results from Chapter 3 demonstrate two important findings – that hypoxia 
protects cells from the cytotoxic effects of doxorubicin at doses of 5 µM and above; 
and that there is a biphasic effect where higher doses are significantly less effective 
against hypoxic HepG2 cells than the 10 µM treatment. 10 µM is as effective as 
higher doses in normoxic cells and so this study has identified a therapeutic window 
of 10 µM where doxorubicin inhibits cell proliferation of normoxic cells by ≈ 70% at 
48 hours and ≈ 90% at 72 hours, and hypoxic cells by ≈ 60% at 48 hours and ≈ 80% 
at 72 hours (Figures 3.2 and 3.3). The differences in cell viability between normoxic 
and hypoxic cells are significant for 10 µM treatment at both these time points. 
The results from Chapter 3 (Figure 3.5) clearly demonstrate that only the 50 µM dose 
of doxorubicin inhibits the hypoxia stimulated nuclear accumulation of HIF-1α. 
There are important experiments that need to be carried out for further elucidation of 
doxorubicin activity in hypoxic conditions. The first is to block the VHL pathway 
using the proteasome inhibitor MG132. The accumulation of HIF-1α after 
proteosome inhibition reflects the rate of synthesis of the protein and so it is possible 
to determine whether the abrogation of HIF-1α following 50 µM treatment is due to 
a reduction in the expression of the protein itself at the transcriptional or translational 
level, or if this concentration of doxorubicin stimulates the degradation of HIF-1α 
even in the absence of oxygen. It would also be interesting to observe the effects of 
doxorubicin on HIF-1α that has been stabilised in normoxia using a hypoxia mimetic 
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such as cobalt chloride or desferrioxamine. Experiments could then be carried out to 
determine the effects of doxorubicin on the expression of HIF-1α mRNA, and the 
effects of inhibiting translation using actinomycin D, a compound that inhibits 
protein synthesis (Wang et al., 2009a). The data presented here indicates that the 
mechanism by which doxorubicin exerts its cytotoxic effect is distinct from the 
mechanism by which it inhibits HIF-1α. 
An important next step will be to determine what effect 10 µM doxorubicin has on 
the expression of genes downstream of HIF-1, and whether doxorubicin interferes 
with the transcriptional activity of HIF-1, as has been reported in Hep3B cells (Lee et 
al., 2009a). 
Hypoxia-induced mechanisms of resistance to doxorubicin include reduced drug 
accumulation and increased drug efflux (Comerford et al., 2002, Ding et al., 2010, 
Zhu et al., 2005); resistance to apoptosis (Dong et al., 2003, Erler et al., 2004, 
Lechanteur et al., 2005, Piret et al., 2002a); decreased levels of topoisomerase II 
(Tomida and Tsuruo, 1999, Ogiso et al., 2000); and a reduction in free radical-
dependant DNA damage (Potmesil et al., 1983, Smith et al., 1980, Tannock, 1982, 
Rharass et al., 2008). 
NFkB activation and post-translational modification and the consequent effects of 
NFkB activation on apoptosis, seems to vary with cell type and with the NFkB 
inducer (Cho et al., 2008, Perkins, 2006). Looking at Figure 3.6, there would appear 
to be a difference in post translational modification of NFkB under hypoxia when 
compared to doxorubicin treatment. Doxorubicin-activated NFkB has been reported 
to be both anti-apoptotic (Bednarski et al., 2008, Chiao et al., 2002) and pro-
apoptotic (Wang et al., 2011). Basal levels of NFkB have been reported to increase 
resistance to doxorubicin (Gangadharan et al., 2009) and overexpression of VHL 
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protein increased the sensitivity of cells to doxorubicin in a mouse model of HCC 
(Wang et al., 2010). In this study doxorubicin was found to activate NFkB in 
normoxic cells. However, hypoxia was also observed to activate NFkB, and after 
doxorubicin treatment of hypoxic cells no further activation was observed (Figure 
3.6). It would be interesting to explore whether activation of NFkB by doxorubicin 
has pro-apoptotic consequences, and activation of NFkB by hypoxia has anti-
apoptotic consequences in HepG2 cells. 
However, the key finding from these investigations into doxorubicin and cell 
viability is the identification of 10 µM as a dose which is efficacious against both 
normoxic and hypoxic cells. This 10 µM dose is commensurate with concentrations 
of doxorubicin that are eluted from DC Beads at distances of up to 350 µm and 600 
µm in animal models, and where tissue necrosis was associated with penetration and 
concentration of doxorubicin (Reddy et al., 2010, Namur et al., 2008a). Evidence 
from the clinic suggests that effective concentrations of doxorubicin are eluted for up 
to 40 days post DEB-TACE (Moschouris et al., 2010). This is in accordance with the 
findings from the in vivo study presented in this thesis, where the application of 
doxorubicin-eluting microspheres significantly inhibited the growth of an ectopic 
xenograft tumour in a mouse model of HCC (Figure 6.1 and 6.2). It should be noted, 
however, that in this animal study, the tumour xenografts are subcutaneous and 
ectopic, so embolisation is not accurately modelled, and this will have an impact on 
intratumoural hypoxia. 
Following on from investigations into the effects of doxorubicin on normoxic and 
hypoxic HepG2 cells, the next stage of this thesis was concerned with the impact of 
rapamycin treatment. The effect of rapamycin on cell viability in normoxic and 
hypoxic cells was most noticeable after 48 hours (Figure 4.2). The minimum 
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concentration of rapamycin effective against normoxic cells was 10 nM, whilst for 
hypoxic cells the minimum effective concentration was 100 nM (Figure 4.2). After 
72 hours, the single dose of rapamycin had ceased to have an effect (Figure 4.3). 
Again, hypoxia protected the cells against the effects of rapamycin on cell viability. 
Both 10 nM and 100 nM rapamycin inhibited the hypoxia stimulated nuclear 
accumulation of HIF-1α, although 100 nM was more effective (Figure 4.5). Hypoxia 
did not result in a reduction in phosphorylation of p70 S6K, but rapamycin inhibited 
phosphorylation of p70 S6K in both normoxic and hypoxic cells. This suggests that 
the mechanism by which rapamycin inhibits cell viability is due to a reduction in cell 
growth and proliferation, being cytostatic rather than cytotoxic. This is supported by 
the fact that at 72 hours, the inhibitory effects of rapamycin were abolished. 
The effects of rapamycin as a monotherapy in the in vivo studies presented here are 
quite striking. Oral rapamycin appears to be more effective than rapamycin delivered 
loco-regionally and this may reflect the effects of rapamycin on inhibition of 
angiogenic signalling pathways in stromal cells (Figure 6.1 and 6.2). 
Finally, the effects of combined doxorubicin and rapamycin treatments were 
investigated. The addition of rapamycin to doxorubicin consistently led to a further 
decrease in cell viability (Figures 5.1 – 5.6). Spiking the cells with rapamycin every 
24 hours, or pre-treatment with rapamycin before the addition of doxorubicin should 
be investigated, as this may increase the additive effects that were observed after a 
single application of rapamycin. 
Paradoxically, the addition of rapamycin to doxorubicin treated cells appeared to 
abrogate any inhibitory effects of either drug as monotherapy on the nuclear 
accumulation of hypoxia stimulated HIF-1α, although these results were not 
statistically significant (Figure 5.7). Doxorubicin had no effect on the 
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phosphorylation of p70 S6K, which suggests that the inhibition of HIF-1α occurs by 
a different pathway or mechanism than inhibition of HIF-1α by rapamycin (Figure 
3.7). 
In vivo, the combination of oral rapamycin and loco-regional delivery of doxorubicin 
was the most effective of all the treatment regimens investigated. The combined 
loco-regional delivery was as effective at day 45, but the disease control across the 
time course of the experiment was not seen Figure 6.1). 
Little is yet know about the effect of doxorubicin/rapamycin combinations on the 
health of cardiomyocytes. The role of mTOR signalling in the survival of both cancer 
cells and cardiomyocytes could lead to off-target effects which potentially increase 
doxorubicin-induced cardiotoxicity (Xiang et al., 2011), or inhibit wound healing 
(Ekici et al., 2007, Weinreich et al., 2011). 
Further studies are needed on the anti-tumoural activity of combinations of 
doxorubicin DEB-TACE and low dose oral rapamycin, preferably using an animal 
model that allows true embolisation of an orthotopic HCC. Immunohistochemical 
analysis of post mortem tumour samples could improve the understanding of the 
molecular mechanisms involved. 
Clinical trials using DEBDOX in combination with oral administration of everolimus 
have recently begun. In Switzerland, the ‘Phase I Open Label/Phase II Randomized, 
Double Blind, Multicentre Trial investigating the combination of Everolimus and 
Transarterial Chemoembolization with Doxorubicin Versus Transarterial 
Chemoembolization with Doxorubicin Alone in Patients With Hepatocellular 
Carcinoma’ (NCT01009801) is currently recruiting participants. This study is chaired 
by Jean-Francois Dufour, MD (University Hospital Inselspital, Berne), for the Swiss 
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Group for Clinical Cancer Research. Phase I will determine the recommended dose of 
everolimus in patients with HCC treated with DEBDOX TACE, and Phase II will 
determine the efficacy and tolerability of everolimus in patients with HCC treated with 
TACE as compared to TACE alone. Entry criteria include confirmed HCC at 
Intermediate stage B (according to BCLC classification), a Child Pugh score < 8, and 
no tumour involvement in > 50% of the liver. Patients with advanced disease, presence 
or history of metastatic spread, or those awaiting OLT will not be included. The 
expected enrolment is 98 patients, from eight clinics in Switzerland. Phase I is a dose 
escalation study, where patients receive oral everolimus once daily, followed by 
DEBDOX TACE seven days later. After one month an MRI scan will be carried out. If 
a viable tumour is detected then patients will undergo TACE treatment monthly for up 
to five treatments. Phase II is a randomised two arm study. Arm I patients will receive 
an oral placebo once daily for up to 12 months, and undergo DEBDOX TACE as in 
phase I at the maximum tolerated dose (MTD). Arm II patients will receive oral 
everolimus once daily for up to 12 months, and undergo DEBDOX TACE as in phase 
I at the maximum tolerated dose (MTD). Primary Outcomes are dose limiting toxicity 
(Phase I), and time to progression (Phase II). Secondary Outcomes include adverse 
events, tumour response, progression-free survival at 12 months and overall survival. 
The start date was February 2010, and the estimated primary completion date is 
September 2012.  
The second clinical trial is based in Asia. The ‘Phase II Randomized, Double-blind, 
Multicenter Asian Study Investigating the Combination of Transcatheter Arterial 
Chemoembolization (TACE) and Oral Everolimus (RAD001, Afinitor®) in Localised 
Unresectable Hepatocellular Carcinoma (HCC) - The TRACER Study’ 
(NCT01379521), chaired by Professor Ronnie Poon and Novartis Pharmaceuticals, 
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started in June 2011 and is not yet recruiting participants. The Primary Outcome is 
time to progression, and Secondary Outcomes include overall response rate, disease 
control rate, overall survival, tumour response and adverse events. The estimated 
enrolment is 80 patients, recruited from Hong Kong, Taiwan, Thailand and the 
Republic of Korea. This is a two arm study, where one arm will receive everolimus 
with DEBDOX TACE, and the other will receive everolimus placebo with DEBDOX 
TACE. Entry criteria, as in the Swiss study, include confirmed HCC at Intermediate 
stage B. The estimated primary completion date is January 2013.  
If cancer cells with a hypoxic phenotype, as well as cancer cells with a normoxic 
phenotype, can be successfully targeted by specific drug regimens, as has been 
indicated by the data presented in this thesis, there is the possibility of improving the 
outcome of patients suffering from primary liver cancer, a disease which at present 
has a dismal prognosis. 
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